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Abstract 
Growth factor mediated phosphatidylinositol 3 kinase/Akt/mechanistic target of rapamycin 
complex 1 (PI3K/Akt/mTORC1) signalling pathway regulates a variety of cellular activities, 
including protein translation, cell metabolism and cell growth. PI3K/Akt signalling pathway is 
frequently dysregulated in prostate cancer due to inactivation of the tumour suppressor 
phosphatase and tensin homolog (PTEN), and is responsible for tumour formation and 
development. Their downstream effector mTORC1 can integrate cellular signals as well as 
nutrient levels, such as leucine, to coordinate cellular activities. Leucine is an essential amino 
acid that participates in protein synthesis and provides metabolic intermediates, and it also 
serves as an mTORC1 signalling regulator. In prostate cancer cells, intracellular leucine levels 
are regulated by L-type amino acid transporter 3 (LAT3/SLC43A1). Therefore, we hypothesise 
that PI3K/Akt may regulate intracellular leucine concentration through LAT3. We have found 
that LAT3 is required for PI3K/Akt regulated leucine transport, and inhibition of PI3K/Akt 
signalling significantly reduced leucine transport in LNCaP and PC-3 human prostate cancer 
cell lines. With stimulation by EGF, leucine uptake increased significantly along with the 
activation of the PI3K/Akt signalling pathway. Knockdown of LAT3 effectively blocks leucine 
uptake, and this phenomenon cannot be rescued by growth factor addition or further inhibited 
by signalling pathway inhibition. Moreover, epidermal growth factor (EGF) significantly 
increases LAT3 protein levels when Akt is phosphorylated, and induces co-localisation of Akt 
and LAT3 on the plasma membrane in LNCaP cells. These effects are likely due to stabilisation 
of LAT3 protein levels on the plasma membrane, with EGF treatment preventing ubiquitin-
mediated LAT3 degradation.  
We next set out to understand how LAT3 might be regulated by binding partners. To do this, 
we used a genetic code expansion method to incorporate unnatural amino acid (Uaa) into target 
proteins. This method has been widely used to study protein structure and dynamics in protein-
xv 
 
protein interactions, as Uaas contain distinct chemical or physical properties compared to 
natural amino acids. We employed a photo-crosslinking Uaa, AzF, coupled with mass 
spectrometry to investigate the potential interactors of LAT3. We generated a series of LAT3 
mutants, and successfully incorporated AzF into specific residues. With UV induction, we 
observed migration of protein bands on western blots, indicating the formation of protein 
complex by AzF contained LAT3. We further investigated this complex by 
immunoprecipitation or in-gel enzymatic digestion, coupled with mass spectrometry study. We 
have generated many candidate proteins by comparing different conditions and different sites. 
Although we haven’t been able to confirm particular interactor(s) of LAT3, this work has 
expanded our understanding of probing protein-protein interactions, and has laid the foundation 
for future investigations. 
Finally, we set out to further understand the role of the essential amino acid leucine, one of the 
main LAT3 substrates, in cellular metabolism. Using radio-labelled leucine, we have observed 
the incorporation pattern of leucine under inhibition of PI3K/Akt signalling pathway or 
inhibition of transporter in prostate cancer cells. Leucine can be converted into glutamate and 
α-ketoglutarate through transamination, and participates in tricarboxylic acid (TCA) cycle, thus 
being incorporated into different cellular fractions. LNCaP cells exhibit decrease in most 
fractions under inhibition, however, PC-3 cells show increased incorporation into protein 
fraction under transporter inhibition.  
This work has expanded our knowledge and understanding of LAT3, and its regulation by 
growth factor and PI3K/Akt signalling pathway in prostate cancer. The establishment of 
genetic code expansion method and mass spectrometry analysis provides new approaches to 
study membrane proteins like amino acid transporters and protein-protein interactions. In 
addition, the study of leucine metabolism in prostate cancer cells has provided insights into the 
utilisation of leucine and the adaptation of metabolism by prostate cancer cells. Future work 
xvi 
 
will be needed to elucidate these aspects in more detail, and to identify vulnerability in 
metabolic pathway of leucine and to develop suitable therapeutic strategy targeting leucine 
metabolic pathway and/or LAT3 to improve prostate cancer treatment. 
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Chapter 1. Introduction 
1.1. Current status of prostate cancer  
Cancer is the second leading cause of death worldwide (Bray et al., 2018). In comparison to 
normal cells, cancer cells undergo uncontrolled growth and proliferation, and could potentially 
invade and spread into other organs and cause tissue damage, leading to malignant metastases 
which are a major cause of death from cancer (Seyfried and Huysentruyt, 2013). 
According to GLOBOCAN 2018 produced by the International Agency for Research on 
Cancer (IARC), it is estimated to have 18.1 million new cases of cancer being diagnosed, and 
9.6 million cancer deaths worldwide in 2018 (Ferlay et al., 2019, Bray et al., 2018). In terms 
of cancer type, lung cancer and breast cancer are the most common type, each accounting for 
11.6% of total incidence for both men and women, followed by prostate cancer which is 
estimated to have 1,276,106 new incidences, accounting for 7.1% (Bray et al., 2018). The 
mortality of prostate cancer is predicted to be 358,989, accounting for 3.8% worldwide (Ferlay 
et al., 2019, Bray et al., 2018). For males, lung cancer remains the most frequently diagnosed 
cancer and the number one cause of cancer death, followed by prostate and colorectal cancer 
for incidence, and liver and stomach cancer for mortality (Ferlay et al., 2019, Bray et al., 2018). 
For females, breast cancer is the most common cancer and the leading cause of cancer death, 
followed by colorectal and lung cancer for incidence, and lung and colorectal cancer for 
mortality (Ferlay et al., 2019, Bray et al., 2018). 
According to Australia Institute of Health and Welfare (AIHW), it is estimated that 138,300 
new cases of cancer (excluding basal and squamous cell carcinoma of the skin) will be 
diagnosed in Australia in 2018, an average of 380 diagnoses each day (AIHW, 2018). Similar 
to the global data, breast cancer in females is expected to be the most common cancer, followed 
by colorectal cancer, prostate cancer and melanoma of the skin (AIHW, 2017b). In terms of 
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mortality rate, lung cancer is expected to be the leading cause of cancer death, followed by 
colorectal cancer, prostate cancer, breast cancer in females and pancreatic cancer (AIHW, 
2017b, OECD/WHO, 2018).  
For men, prostate cancer is the most commonly diagnosed cancer in Australia since 2013, and 
the third most commonly diagnosed cancer in Australia in 2017 (AIHW, 2017b). According to 
AIHW, there would be 17,729 new male patients being diagnosed with prostate cancer, 
accounting for 23.8% of the total new diagnosed cases of male cancer patients in 2018 (AIHW, 
2017a). And an estimation of 3,500 men would die from prostate cancer in 2018 in Australia, 
accounting for 12.7% among all male deaths from cancer in 2018 (AIHW, 2017a). Even though 
the total number of cases dropped from 19,233 in 2013 to 17,729 in 2018, and the incidence 
rate has decreased from 151 cases per 100,000 males in 2013 to 115 cases per 100,000 males 
in 2017 (AIHW, 2017a), the risk of men being diagnosed with prostate cancer remains high 
and the burden of disease remains a severe issue for public health. There were 94,114 males 
living with prostate cancer at the end of 2012 (diagnosed in the 5-year period 2008 to 2012) 
(AIHW, 2017a), and 191,896 males who had been diagnosed with prostate cancer in the 
previous 31 years (from 1982 to 2012) (AIHW, 2017a).  
Prostate cancer is an age-dependent disease, and the highest incidence happens to age group 
65-69 and over 85. Recently, the incidence rate of prostate cancer among males increases from 
age group 35–39 until age group 65–69 and decreases until age group 80–84 before increasing 
for aged 85+ again (AIHW, 2017a). The estimated risk of male being diagnosed with prostate 
cancer by his 85th birthday will be 1 in 7. The mortality of prostate cancer has increased 
dramatically since 1968, from 963 to more than 3,000 (AIHW, 2016). However, the 5-year 
survival of prostate cancer patients increased from 58% to 95% from 1983-1987 to 2009-2013 
(AIHW, 2017a). It suggests that the advancement in early detection and diagnosis of prostate 
cancer as well as the ongoing improvement of treatment towards prostate cancer has greatly 
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enhanced the quality of patients’ life. The death rate of prostate cancer has slightly decreased 
from 4.3% in 2006 to 4% in 2016, but it still remains a leading cause of cancer-related death 
in men (AIHW, 2018). 
Since the early stage prostate cancer is highly dependent on androgen for its progression, the 
hormone therapy has been widely used in clinical practice in addition to surgery, radiotherapy, 
chemotherapy (Litwin and Tan, 2017). But prostate cancer could develop into a castration-
resistant status that cancer cells progress without androgen, thus becoming lethal. Systematic 
therapy has been developed well since 2004, including docetaxel, a microtubule inhibitor 
(Petrylak et al., 2004, Tannock et al., 2004); cabazitaxel, a tubulin-binding drug for docetaxel-
resistant cancers (de Bono et al., 2010); abiraterone acetate, inhibitor of cytochrome P (CYP) 
17 (Attard et al., 2009a, Attard et al., 2008); Enzalutamide, a targeted androgen receptor 
inhibitor (Tran et al., 2009); Olaparib, a poly(ADP–ribose) polymerase (PARP) inhibitor 
(Mateo et al., 2015); Pembrolizumab, an immune checkpoint inhibitor (Topalian et al., 2012, 
Patnaik et al., 2015), etc. The development of these drugs and many new drugs is attributed to 
better understanding of underlying mechanism and progression of advanced prostate cancer 
(Teo et al., 2019). Furthermore, continuous efforts are needed to identify new therapeutic 
targets in new aspects and to develop effective therapies. It is imperative to further improve the 
treatment of drug-resistant prostate cancer and metastatic prostate cancer, so that to reduce the 
burden of prostate cancer in Australia and world. 
1.2. Androgen and androgen receptor in prostate cancer 
1.2.1. AR signalling pathway 
Androgen exhibits its biological effects through androgen receptor (AR), which is a  ligand-
mediated transcriptional factor and a member of the nuclear receptor superfamily (Gao et al., 
2005). The AR signalling pathway is outlined in Figure 1.1. Without hormone ligand, the AR 
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is located at cytoplasm and forms a complex with heat shock proteins HSP90, HSP70 and other 
co-chaperones. This complex protects the AR from proteolysis and ensures AR remains in the 
right conformation ready for ligand-binding (Georget et al., 2002, Prescott and Coetzee, 2006). 
Binding with hormone ligand dihydrotestosterone (DHT) dissociates AR from HSP90 complex 
and induces a conformational change to yield a hydrophobic coactivator binding pocket that 
functions as a platform for interaction with coactivators (van de Wijngaart et al., 2012) and 
facilitates the interaction between N-terminal domain and ligand-binding domain (Askew et al., 
2012, Schaufele et al., 2005, van Royen et al., 2007). This interaction reduces the rate of 
dissociation with ligand and stabilises AR for optimal transcriptional reactions (He et al., 2000). 
AR then translocates into nucleus and binds to the 15-bp palindromic androgen response 
element (ARE) on target genes through a highly conserved DNA-binding domain (Heemers 
and Tindall, 2007). It then recruits co-regulators to form a pre-initiation complex and along 
with the basal transcriptional machinery initiates transcription of specific AR target genes 
(Ferraldeschi et al., 2015).  
In prostate cancer, AR is able to initiate the expression of multiple oncogenes by chromosomal 
gene rearrangement, including the androgen-regulated gene TMPRSS2 (transmembrane 
protease serine 2) fused to the ETS (E26 transformation-specific) transcription factors, such as 
ERG (ETS-related gene), ETV1 (ETS translocation variant 1), and ETV4 (ETS translocation 
variant 4) (Tomlins et al., 2005, Palanisamy et al., 2010, Soller et al., 2006). TMPRSS2-ERG 
gene fusions are the predominant molecular subtype of prostate cancer, and these fusions have 
been identified in 40-60% of prostate cancer, making them the most common chromosomal 
aberrance (Tomlins et al., 2005, Attard et al., 2010, Attard et al., 2009b, Clark et al., 2007, 
Hermans et al., 2006). This gene rearrangement happens during cancer initiation and is also 
detected during tumour progression. The fusion happens at the 3’ region of ERG with the 5’ 
region (containing the promoter/enhancer region) of TMPRSS2 gene. Since TMPRSS2 is 
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highly regulated by androgen receptor, the fusion TMPRSS: ERG becomes androgen-
dependent, and the androgen responsive regulatory elements of TMPRSS2 induces ERG over-
expression in fusion-positive cases (Tomlins et al., 2008). Since ERG is an oncogene, the 
overexpression of ERG increases cell invasion and causes prostate cancer precursor-like lesion 
in mice model (Klezovitch et al., 2008), while knockdown of ERG in VCaP cells (TMPRSS2-
ERG positive) blocks cell growth, cell invasion and xenograft tumour growth (Wang et al., 
2008, Tomlins et al., 2008).  
The androgen-regulated TMPRSS2-ERG fusion actually has a complicated role in prostate 
cancer progression. It has been found that this fusion disrupts AR signalling by inhibiting AR 
expression and attenuates AR activity by binding to gene-specific loci (Yu et al., 2010). 
Furthermore, TMPRSS2-ERG induces repressive epigenetic modification via direct activation 
of the H3K27 methyltransferase EZH2 (Enhancer of Zeste Homolog 2, a Polycomb group 
protein), which affects normal prostate differentiation. Thus, it acts as a malignant regulatory 
switch in prostate cancer (Yu et al., 2010). The expression of TMPRSS2-ERG and AR showed 
a negative correlation in localised prostate cancer, but exhibited a positive correlation in 
metastatic prostate cancer (Yu et al., 2010). This provides more insights into the mechanism of 
resistance observed in antiandrogen therapy (Yu et al., 2010, Tomlins et al., 2005).  
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Figure 1.1. Signalling network of the androgen receptor. Testosterone is reduced to DHT by 
5α-reductase when enters into cells. Androgen receptor binds to DHT and translocates to the 
nucleus, where it binds to its target genes and regulates their expression. Androgen receptor 
can also be activated by several signalling pathways, including IL-6 receptor-mediated 
JAK1/STAT3/p300 pathway, or growth factor-stimulated PI3K/Akt signalling pathway, or 
Ras/MEK/ERK1/2 pathway regulated by both extrinsic stimuli. AR: androgen receptor; DHT: 
dihydrotestosterone; HSP: heat shock protein; ARE: androgen response element; IL-6R: 
Interleukin-6 receptor; JAK1: Janus kinas 1; STAT3: signal transducer and activator of 
transcription 3; MEK: MAPK extracellular kinase; ERK1/2: extracellular signal-regulated 
kinases ½; PI3K: phosphatidylinositol 3 kinase; PIP2: phosphatidylinositol-3,4-bisphosphate; 
PIP3: phosphatidylinositol-3,4,5-trisphosphate; PTEN: phosphatase and tensin homolog;  
PDK1: 3-phosphoinositide dependent kinase 1. Adapted from (Lonergan and Tindall, 2011).  
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1.2.2. Dysregulation of AR activity 
1.2.2.1. AR mutation 
Many preclinical studies and analysis of castration-resistant prostate cancer (CRPC) tumour 
samples have uncovered a number of molecular mechanisms where AR signalling pathway can 
be activated or maintained after androgen deprivation therapy (ADT). There are over 100 
somatic mutations that have been identified in AR, and most of them happen within the N-
terminal domain (NTD) or the ligand-binding domain (LBD) (Ferraldeschi et al., 2015). They 
are involved in critical ligand receptor and protein-receptor interaction, and the mutations cause 
sporadic activation of the AR signalling pathway by either weak adrenal androgens or other 
steroid hormones. In addition, other mutations could turn AR antagonists (such as first 
generation of antiandrogen flutamide and bicalutamide) into potent agonists (Brooke and 
Bevan, 2009, Bergerat and Ceraline, 2009). 
AR mutation is rare in early stage prostate cancer, but shows significantly elevated occurrence 
in CRPC, indicating AR mutations plays a critical role in driving tumour progression (Taplin 
et al., 1995, Marcelli et al., 2000). One study investigated the activity of 44 AR mutations and 
observed that 20 showed a gain of function - greater activity than wild type AR- under the 
stimulation of dehydroepiandrosterone (Shi et al., 2002). Cells that harbour these mutations are 
prone to grow favourably in the androgen-depleted environment. Further studies have indicated 
that prostate cancer cells showed selective pressures for maintaining AR signalling to promote 
cancer progression (Garraway and Sellers, 2006), as treatment with specific AR antagonists 
actually selects for tumours expressing AR mutants induced by the therapeutic agent 
(Steinkamp et al., 2009). This therapy-induced selection of AR mutants could probably explain 
the withdrawal syndrome in which tumours regress on antiandrogen discontinuation (Scher and 
Kelly, 1993, Hara et al., 2003), and also explains why tumours resistant to a first-generation 
antagonist may still respond favourably to second-generation antiandrogens (Choi et al., 2011, 
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Okegawa et al., 2010). A new missense mutation F876L in the LBD has been identified, which 
can turn second-generation antiandrogens, enzalutamide and ARN-509, into AR agonist and 
lead to resistance in preclinical models (Korpal et al., 2013, Balbas et al., 2013, Joseph et al., 
2013). All these evidences indicate that such mutations provide a growth advantage due to 
alterations in cofactor recruitment or by reducing ligand specificity depending on the location 
of mutant occurrence and which ligand is present. 
1.2.2.2. AR overexpression 
The mRNA and protein level of AR showed significant increase in almost 80% of CRPC 
(Bubendorf et al., 1999, Linja et al., 2001, Haapala et al., 2007, Taylor et al., 2010). After 
castration or antiandrogen therapies, about one-third of patients showed tumour progression 
along with AR overexpression as a result of AR gene amplification (Bubendorf et al., 1999, 
Haapala et al., 2007, Koivisto et al., 1997, Visakorpi et al., 1995, Miyoshi et al., 2000). On the 
contrary, non-treated patients rarely contained AR gene amplification (Bubendorf et al., 1999). 
In 80% of cases where patients developed castration resistance, AR gene amplification was 
associated with AR overexpression. However, about 35% of cases where AR showed 
overexpression didn’t exhibit AR gene amplification (Edwards et al., 2003). The underlying 
mechanisms are not fully understood, but it may be because of increased transcription rates, 
decreased protein degradation or stabilisation of the mRNA or protein of AR (Edwards et al., 
2003, Zhang et al., 2009, Sharma et al., 2010, Lin et al., 2013). AR overexpression renders 
cells sensitive to low levels of androgens, thus allowing sustained tumour growth even in 
minimal androgen concentrations (Visakorpi et al., 1995, Waltering et al., 2009). Since AR 
overexpression could only partially explain the development of hormone resistance in a 
subgroup of prostate cancer group, alternative mechanisms, such as AR stimulation by other 
signalling pathways or activation of AR responsive genes that are not AR-dependent (Edwards 
et al., 2003).  
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1.2.2.3. AR crosstalk with other signalling pathways 
Other signalling pathways and their interactions with AR also play a critical role in regulating 
prostate cancer progression and development. PI3K/Akt signalling pathway (refer to 1.3.2 for 
more details) is one of the most commonly altered pathways in prostate cancer. Studies have 
demonstrated that inhibition of PI3K/Akt with selective inhibitors would promote AR 
transactivation (Yang et al., 2003a, Yang et al., 2005, Lin et al., 2001, Kaarbo et al., 2010, 
Carver et al., 2011). Akt phosphorylates and inactivates FOXO3 (Forkhead box O3)(Accili and 
Arden, 2004), resulting in deactivation of AR transcriptional activity and suppression of AR-
mediated genes (Yang et al., 2005). Other evidence showed that Akt directly interacts with AR 
and suppresses AR activity (Yang et al., 2003a, Yang et al., 2003b, Lin et al., 2002). Therefore, 
PI3K/Akt signalling pathway negatively regulates AR signalling through multiple mechanisms.  
MAPK signalling pathway is another major signalling pathway that regulates cell proliferation, 
differentiation, apoptosis and survival (Gregory et al., 2004). Evidence has shown that 
androgen-activated AR is able to switch on MAPK (Peterziel et al., 1999), but EGF-activated 
MAPK signalling affects AR function and the androgen response. The inhibition of MAPK 
extracellular kinase (MEK) reverses the EGF-mediated AR down regulation in differentiated 
cells. Therefore, it indicates the reverse correlation between EGF-mediated MAPK and 
androgen signalling in non-tumour epithelial cells (Leotoing et al., 2007, Gregory et al., 2004). 
The JAK (Janus kinase)/STAT3 (Signal transducer and activator of transcription 3) signalling 
pathway is highly involved in numerous cellular processes, including cell division, cell death, 
and tumour formation. STAT3 has been shown to enhance AR-mediated prostate specific 
antigen (PSA) expression and AR transcriptional activity in prostate cancer cells (Ueda et al., 
2002, Chen et al., 2000, DeMiguel et al., 2002). Increased levels of STAT3 lead to STAT3-AR 
complex formation in response to EGF and IL-6 (Lonergan and Tindall, 2011), whereas 
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inhibition of STAT3 blocks its transcriptional activity, thus affecting AR-mediated gene 
expression (Junicho et al., 2000, Yamamoto et al., 2003). In addition, AR has been found to be 
able to bind to another transcription factors Sp1 and act as a coactivator to induce p21 
transcription (Lu et al., 2000). 
1.2.2.4. Post-translational modification of AR 
Multiple post-translational modification (PTM) sites of AR have been identified to be able to 
modulate AR activity, including stability, transcriptional activity, and cellular localisation (van 
der Steen et al., 2013). AR is subjected to various PTMs, such as phosphorylation, acetylation, 
sumoylation, ubiquitination and methylation (Coffey and Robson, 2012).  
There are at least 16 phosphorylation sites being identified in AR, and they are regulated by 
various serine/threonine or tyrosine kinases, including PI3K/Akt (Lin et al., 2001, Lin et al., 
2003), cyclin-dependent kinases (CDKs) (Hsu et al., 2011a, Chen et al., 2012), 
serine/threonine-protein kinase pim-1 (PIM1) (Ha et al., 2013), proto-oncogene tyrosine-
protein kinase Src (SRC) (Liu et al., 2010, Guo et al., 2006) and activated cdc42-associated 
kinase 1 (ACK1) (Mahajan et al., 2007, Liu et al., 2010). The phosphorylation by androgen or 
antiandrogen, growth factors, and cytokines causes AR conformational change and functional 
alteration, thus regulating AR transactivation, translocation, protein turnover, cell growth, cell 
survival, and the development of CRPC (Coffey and Robson, 2012). 
Acetylation has been found at 3 lysine residues in the hinge area of AR. All of these residues 
are critical for the ligand-dependent activation of AR, and it has been observed that the 
acetylation level of AR is increased by DHT stimulation (Fu et al., 2004). Mutation of lysine 
residues to the non-acetylation-mimic arginine enhances cellular localisation of AR in the 
cytoplasm and reduces AR transcriptional activity in PC-3 cells (van der Steen et al., 2013). In 
addition, acetylation-mimic mutations in prostate cancer cells increases cell growth in vitro and 
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tumour growth in vivo, and these tumours exhibit resistance to the AR antagonist, flutamide 
(Fu et al., 2003).  
Small ubiquitin-like modifier (SUMO) proteins are similar to ubiquitin, which covalently 
attach to and detach from target proteins to modify their functions. Sumoylation is regulated 
by an E1 activating enzyme, an E2 conjugating enzyme and an E3 ligating enzyme (Gareau 
and Lima, 2010, Wilkinson and Henley, 2010). Sumoylation of AR happens mainly within the 
N-terminal domain at Lys386 and Lys520 (Poukka et al., 2000). The presence of ligand 
promotes sumoylation, and it has been demonstrated that sumoylation of the AR impedes the 
intramolecular interaction with the ligand-binding domain, which is critical for efficient 
transcriptional activation (Kaikkonen et al., 2009). Mutational analysis of the SUMO-accepting 
sites within the AR exhibited increased transcriptional activity, suggesting that sumoylation 
negatively mediates AR function (Kaikkonen et al., 2009). 
Ubiquitination is an important cellular regulatory mechanism of protein degradation and 
turnover. Ubiquitin molecules can also function as a signalling indicator to regulate other 
cellular activities such as cellular localisation, protein-protein interaction, through 
monoubiquitination or polyubiquitination (Kerscher et al., 2006, Ande et al., 2009). The 
ubiquitination status of AR alters its transcriptional activity and localisation. Mass 
spectrometric studies have revealed K845 and K847 are ubiquitination residues in the ligand-
binding domain of the AR, which is mediated by RING domain-containing E3 ligase (RNF6) 
(Xu et al., 2009). Once RNF6 is knocked down, the transcriptional activity of AR is decreased 
because RNF6 is able to promote transcriptional activity by inducing polyubiquitination (Xu 
et al., 2009). In addition, ubiquitination is commonly associated with phosphorylation. 
Evidence showed that phosphorylation of AR is required for an E3 ubiquitin-protein ligase 
MDM2-mediated ubiquitination, as activation/phosphorylation of MDM-2 by Akt coincides 
with the phosphorylation of AR (Lin et al., 2002). MDM-2 and CHIP (Carboxyl-terminus of 
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Hsc70-Interacting Protein) are E3 ligases for AR polyubiquitination that promotes proteasomal 
degradation (Lin et al., 2002, Rees et al., 2006, He et al., 2004).  
AR can be methylated at K632 within the hinge region. An H3 lysine-4 methyltransferase  Set9 
was identified as a direct mediator of AR methylation and was further demonstrated to interact 
with ARE in response to androgen stimulation (Gaughan et al., 2011, Ko et al., 2011). 
Knocking down Set9 abolished AR methylation, preventing AR from binding to the promoter 
of PSA in LNCaP cells, whereas overexpression of Set9 increased AR binding to the PSA 
promoter (Ko et al., 2011).  
1.2.3. Current therapeutic strategy targeting AR in prostate cancer 
Clinically, prostate cancer is monitored by serum levels of prostate specific antigen (PSA) that 
is also regulated by AR (Kuriyama et al., 1980, Edwards et al., 2003). Therefore, the primary 
treatment of hormone-dependent prostate cancer is to reduce the levels of circulating androgens 
and to suppress AR signalling pathway (Jenster, 1999, Taplin, 2007, Kokontis and Liao, 1999). 
Many treatment strategies targeting androgen have been developed to reduce hormone 
concentration, including surgical castration, estrogen, antiandrogens or combinations (Bolla et 
al., 1997). Blocking or removing the function of androgens has been the standard care of 
prostate cancer patient, known as androgen deprivation therapy (ADT). ADT via surgery or 
luteinizing hormone-releasing hormone analogue significantly blocked localised prostate 
cancer growth by reducing circulating testosterone, showing more than 80% response rate for 
initial treatment (Bolla et al., 1997, Lu-Yao et al., 2008). But only a few years later, many 
patients frequently relapse and showed even more aggressive prostate cancer growth, 
indicating the development of castration-resistant prostate cancer (CRPC). However, CRPC is 
not androgen independent, and many studies have demonstrated that the level of testosterone 
within CRPC tumours are restored to equal or even higher levels of that in non-castrate 
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prostates (Geller et al., 1978, Montgomery et al., 2008, Mostaghel et al., 2007). It is because 
that the intra-tumoural testosterone and dihydrotestosterone (DHT) can be converted from 
circulating adrenal androgens (Montgomery et al., 2008, Titus et al., 2005) or possibly 
synthesised de novo by CRPC cells (Locke et al., 2008). In these processes, AR signalling 
remains crucial in regulating tumour growth in majority of patients (Pomerantz and Kantoff, 
2007, Petrylak, 2005, Ferraldeschi et al., 2015).  
Initially, ADT decreases the concentration of PSA and results in tumour regression, thus 
allowing relief of symptoms in most patients. However, it is not long-lasting in patients with 
advanced cancer. After a few years, PSA concentrations elevate again, representing the 
reactivation of androgen receptor signalling pathway and the transition to a castration-resistant 
state, which prone to metastasise and is fatal (de Bono et al., 2011). With further studies of the 
molecular mechanism underlying castration resistance and AR signalling pathway, novel 
therapeutic agents targeting AR have been developed, leading to the enhancement of survival 
rate in CRPC patients (de Bono et al., 2011, Ryan et al., 2013, Scher et al., 2012).  
Several studies have observed an aberrant upregulation of androgen biosynthesis enzymes in 
CRPC, which contributes to increased intratumoural androgen concentrations (Holzbeierlein 
et al., 2004, Stanbrough et al., 2006, Montgomery et al., 2008). Abiraterone acetate is a 
selective and potent inhibitor of androgen biosynthesis enzyme cytochrome P450 c17 (CYP17). 
CYP17A1 plays a critical enzymatic role in testosterone synthesis. As a result, blocking CYP17 
would impede androgen synthesis by the adrenal glands and testes and within the prostate 
tumour (Potter et al., 1995, Attard et al., 2005, Barrie et al., 1997, Jarman et al., 1998). 
Abiraterone acetate has been used in phase I-II trials either as a single agent or in combination 
with low-dose glucocorticoids, such as prednisone, exhibiting marked antitumour activity 
among both patients with progressing CRPC but without chemotherapy and those who had 
received chemotherapy (Attard et al., 2009a, Reid et al., 2010, Attard et al., 2008, Danila et al., 
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2010, Ryan et al., 2010). Treatment with Abiraterone acetate often induces excessive 
mineralocorticoid levels, causing adverse events including hypokalaemia, fluid retention, and 
hypertension (de Bono et al., 2011). However, these events are easily abrogated by co-
administering low-dose glucocorticoids or by supplementing a mineralocorticoid receptor 
antagonist eplerenone (Attard et al., 2008). Phase II trials have shown significantly prolonged 
median overall survival with combinational therapy of Abiraterone and prednisone (Fizazi et 
al., 2012, de Bono et al., 2011). As a result, developing new CYP17A1 inhibitors is of great 
interest, and by more specific target, it is less likely to require co-administration of 
glucocorticoid (Ferraldeschi et al., 2015). There are other CYP17 inhibitors that have been 
developed, and have undergone or are about to undergo clinical trials, indicating blocking 
androgen synthesis as a promising therapy. In addition to CYP17A1, other steroidal enzymes 
are also targeted to block androgen biosynthesis in combination with CYP17A1 inhibitors 
(Kikuchi et al., 2014). 
Antiandrogen agents are a standard treatment for advanced prostate cancer for over three 
decades. It competes with endogenous androgens for the ligand-binding pocket of the AR, thus 
antagonizing the AR via a steric clash (Bohl et al., 2005, Jarman et al., 1998, Osguthorpe and 
Hagler, 2011). The first generation of antiandrogens (bicalutamide, flutamide, or nilutamide) 
are reversible inhibitors of the AR, and possess much lower affinity for the AR compared with 
androgens. Thus, their inhibitory effects do not induce significant degradation or cytoplasmic 
sequestration, and can lead to agonist behaviour (Kolvenbag et al., 1998, Simard et al., 1997). 
To the contrary, the second generation of antiandrogen, enzalutamide has shown promising 
inhibitory effects in phase I/II and later in phase III clinical trials in bicalutamide-resistant 
prostate cancer model with AR overexpression and mutation (Jung et al., 2010, Ferraldeschi et 
al., 2015). Other chemical analogues of enzalutamide have been developed due to the success 
of enzalutamide. ARN-509 and ODM-201 showed similar potency as enzalutamide in 
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antagonizing the AR in phase I/II studies, where ARN-509 showed reduced crossing of the 
blood-brain barrier (Clegg et al., 2012), and ODM-201 does not cross the brain barrier in 
preclinical study (Attard et al., 2008).  
Besides blocking the ligand-binding region of the AR, the hinge region of the AR has also been 
targeted by a third-generation locked antisense oligonucleotides EZN-4176 (Zhang et al., 
2011b). This inhibitor downregulates AR protein expression, however, it only shows modest 
inhibition with dosing limited by significant but reversible transaminitis (Bianchini et al., 2013). 
Another way of the AR blockade is using small peptides to interfere specific protein-protein 
interaction. Peptidomimetics, mimicking protein structure, are small organic molecules capable 
of interacting with the same target protein with high affinity and thus high selectivity and 
efficacy. Moreover, peptidomimetics could permeate plasma membranes as small molecules 
and remain stable from being degraded by protease-mediated proteolysis. Thus 
peptidomimetics are designed to disrupt particular protein-protein interaction at different 
domains of the AR with selective motifs in conformation (Ravindranathan et al., 2013).  
New therapeutic targets have been identified through genetic and molecular studies, leading to 
better understanding of the underlying mechanism of oncogenesis and resistance. One of the 
latest studies has shown that in CRPC, an E3 ubiquitin-protein ligase SPOP (Speckle-type POZ 
protein) - mediated ubiquitination and degradation of protein TRIM24 (transcription 
intermediary factor 1-alpha) interacts with TRIM28 (transcription intermediary factor 1-beta), 
where TRIM28 is a key upstream regulator of TRIM24 and it promotes cancer cell proliferation. 
The overexpression of TRIM28 is associated with high levels of TRIM24 as well as the 
aggressiveness of prostate cancer. TRIM24 and AR co-activate SPOP-mutant prostate cancer, 
and this activation correlates with upregulation of TRIM28. Thus, this study provides a new 
promising therapeutic target (Fong et al., 2018).  
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1.3. Cellular signalling networks in prostate cancer 
1.3.1. Growth factor 
Growth factors (GFs) are defined as polypeptides that stimulate cell proliferation, 
differentiation, and survival of normal cells. GFs have been found in various tissues and organs 
including serum, platelets, and they differ from polypeptide hormones like insulin and 
adrenocorticotropic hormone that function as endocrine (Goustin et al., 1986). Growth factors 
have different cell-type specificities, as interleukin 2 (IL-2) or colony stimulating factor-1 
(CSF-1) in the hematopoietic system could only stimulate one or a few cell types, whereas 
somatomedin C and EGF stimulated a wide range of cell types (Goustin et al., 1986). Growth 
factors are also involved in the pathogenesis of cells that transform from normal cells into 
cancerous cells. This transformation enables neoplastic cells to overexpress growth factor 
receptors, thus making tumour cells more sensitive to low growth factor environment 
(Normanno et al., 2001). Moreover, transformed cells develop less dependency on exogenous 
stimulation of growth factors to sustain a high rate of cell proliferation by producing high levels 
of tumour-derived growth factors through intracrine, paracrine, juxtacrine and/or autocrine 
pathways (Sporn and Roberts, 1992). In addition, a correlation between growth factors and 
protooncogenes has long been established (Aaronson, 1991, Goustin et al., 1986). Many 
protooncogenes encode growth factors, growth factor receptors, or other proteins that are 
involved in signalling transduction related to growth factors. As a result, growth factors play a 
critical role in cell transformation and proliferation leading to tumour progression.  
Growth factors act through their membrane-bound receptors by binding to the extracellular 
ligand binding domain, and propagate signals through, leading to a conformational change of 
the receptors and subsequently activating tyrosine or serine/threonine kinase domains of the 
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receptors. This activation enables the recruitment of diverse substrates, propagating signals that 
mediate a plethora of cellular activities ultimately leading to cell growth (Witsch et al., 2010).  
Growth factors and their receptors are commonly increased in a variety of cancers. The 
expression of epidermal growth factor (EGF) and its receptor (EGFR) significantly increased 
in prostate cancer (De Miguel et al., 1999). This upregulation stimulates downstream signalling 
pathways including the mitogen-activated protein kinase (MAPK) and phosphoinositide 3 
kinase (PI3K)/Akt pathways, leading to active biosynthesis and rapid cell proliferation (Gioeli, 
2005).  
1.3.2. PTEN and PI3K/Akt/mTOR signalling pathway 
PI3K/Akt/mTOR signalling pathways are highly conserved across various species. It plays 
critical roles in the development of multiple types of cancer (Bellacosa et al., 2005). The 
signalling network is outlined in Figure 1.2. This signalling pathway is upregulated in 
approximately 40% of early prostate cancers and 70-100% in advanced disease (Carver et al., 
2011, Taylor et al., 2010). The loss of tumour suppressor gene phosphatase and tensin homolog 
(PTEN) leads to constitutive activation of PI3K/Akt signalling pathway, together with 
amplification and mutation of PI3K and/or Akt, contributes to 30% of primary and 60% of 
castrate-resistant prostate cancers (Vivanco and Sawyers, 2002, Morgan et al., 2009, Martin 
and Blenis, 2002). Once PI3K/Akt is activated by extracellular stimulation, the signal 
propagates to activate many downstream substrates that regulate multiple cascades of cellular 
activities, including cellular metabolism, survival, growth, proliferation, and motility (Dibble 
and Cantley, 2015). One of the key regulators downstream of PI3K/Akt signalling pathway is 
mTORC1. It converges various cascades of stimuli and acts towards its downstream signalling 
nodes to initiate translation and regulate protein synthesis and cell growth (Sarbassov et al., 
2005a).  
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Figure 1.2. PI3K/Akt/mTORC1 signalling pathway and LAT3-mediated leucine transport. 
Growth factors stimulate PI3K signalling pathway via RTK. PI3K catalyses PIP2 to form PIP3, 
which is antagonised by PTEN as a PIP3 phosphatase. PIP3 translocates onto plasma 
membrane and recruits PDK1, where PDK1 phosphorylates Akt at T308. RTK signalling can 
also activate mTORC2, which phosphorylates Akt at S473 to fully activate Akt. Active Akt 
phosphorylates TSC2 within TSC1/2 complex and inhibits the ability of TSC2 to act as a GAP 
for Rheb, allowing Rheb-GTP to accumulate. Rheb activates mTORC1, which subsequently 
phosphorylates its downstream substrates, such as S6K and 4EBP1. LAT3 is a neutral amino 
acid transporter, including leucine. Intracellular level of leucine regulates mTORC1 activation. 
mTORC1 is a central cell growth controller that integrates a wide array of extracellular and 
intracellular signals to regulate cellular metabolism, translation, autophagy and cell growth. 
PI3K: phosphatidylinositol 3 kinase; mTORC: mammalian target of rapamycin complex; EGF: 
epidermal growth factor; EGFR: epidermal growth factor receptor; RTK: receptor tyrosine 
kinases; PIP2: phosphatidylinositol-3,4-bisphosphate; PIP3: phosphatidylinositol-3,4,5-
trisphosphate; PTEN: phosphatase and tensin homolog; PDK1: 3-phosphoinositide dependent 
kinase 1; TSC: tuberous sclerosis complex; GAP: GTPase-activating protein; Rheb: Ras 
homolog enriched in brain; 4EBP1: 4E binding-protein 1.  
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1.3.2.1. PTEN 
PTEN was firstly known as a protein tyrosine phosphatase (PTP) because of the homology of 
its sequence in the catalytic domain to members of the PTP family (Li and Sun, 1997, Li et al., 
1997, Steck et al., 1997). With further study, PTEN has been characterised as a lipid 3-
phosphatase, which mainly dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
to phosphatidylinositol (4,5)-bisphosphate (PIP2). PIP3 is retained in the lipid bilayer of 
plasma membrane and recruits a variety of effectors to translocate onto plasma membrane, 
including phosphoinositide-dependent kinase-1 (PDK1) and Akt (Maehama and Dixon, 1998), 
as they contain Pleckstrin homology domain (PH domain) that can recognise the head group 
of PIP3 (Malek et al., 2017). In turn, the dephosphorylation of PIP3 to PIP2 by PTEN 
inactivates Akt and its downstream substrates (Stambolic et al., 1998, Sun et al., 1999). PTEN 
is a tumour suppressor that negatively regulates PI3K/Akt signalling pathway which is critical 
for cell growth and cancer development (LoPiccolo et al., 2008, Kaarbo et al., 2010, Salmena 
et al., 2008, Manning and Cantley, 2007).  
PTEN expression and function are found to be altered in cancer at high frequency, and PTEN 
has been associated with many cellular activities including nutrient metabolism, cell mobility 
and polarity, cell senescence, cancer stem cell differentiation, tumour microenvironment (Song 
et al., 2012). Emerging evidence indicates that PTEN could translocate into nucleus through 
numerous mechanisms, such as diffusion, major vault protein (MVP)-mediated nuclear import 
and active shuttling by RAN-GTPase, as well as post-translational modifications (PTMs) 
including phosphorylation, sumoylation or monoubiquitination (Lee et al., 2018). Nuclear 
PTEN remains functional and facilitates to maintain genomic stability, as it has been reported 
that absence of nuclear PTEN is associated with more aggressive cancers and loss of genomic 
integrity (Baker, 2007, Lindsay et al., 2006, Gimm et al., 2000, Shen et al., 2007).  
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In addition, PTEN can work in a PI3K/Akt-independent manner as mouse model showed 
differences between PTEN loss and Akt overexpression (Blanco-Aparicio et al., 2007, Kharas 
et al., 2010); the JNK signalling pathway was activated with PTEN loss in an Akt-independent 
way (Vivanco et al., 2007); Other evidence shows that PTEN deficiency could activate 
non-receptor tyrosine kinase SRC, which depends on protein phosphatase activity of PTEN 
rather than its lipid phosphatase activity, resulting in conferring human epidermal growth factor 
receptor 2 (HER2/ERBB2)-inhibitor resistance in breast cancer cells (Zhang et al., 2011a). 
Since non-canonical pathways could be activated due to PTEN loss, it implies that blockade of 
the PI3K/Akt pathway combined with inhibition of other pathways could greatly improve the 
efficacy in treating PTEN-deficient diseases. 
PTEN has been identified as a frequently mutated gene at chromosome 10q23 in primary 
human cancers, xenografts and cancer cell lines (Li et al., 1997, Steck et al., 1997). Genetically 
monoallelic or complete PTEN deletion occurs frequently in prostate cancer, glioblastoma and 
endometrial carcinoma (Salmena et al., 2008). The PTEN gene has been found mutated 
monoallelically in the germ line of patients with PTEN hamartoma tumour syndromes (PHTS), 
and also in a range of sporadic cancers. A large cohort study of 3042 individuals with Cowden 
disease discovered that 25% of the cohort has germline PTEN mutations (Tan et al., 2011). 
Further study showed that PTEN mutations in germline and somatic cells are located in the 
promoter and all nine exons, with numerous types of mutation identified, including missense, 
nonsense, splice site variants, intragenic deletions and insertions and large deletions (Lee et al., 
2018). Many missense, nonsense and splice site mutations result in unstable truncated proteins 
that are barely detectable and thus are functionally similar to the PTEN monoallelic loss. In 
addition to these aberrations, PTEN haploinsufficiency is critical in tumour initiation and 
progression (Papa et al., 2014). However, several tumour-derived PTEN mutations retain 
21 
 
partial or complete catalytic function (Han et al., 2000), suggesting that there are alternative 
mechanisms that inactivate PTEN tumour-suppressive function.  
In prostate cancer, up to 70% of patients have shown PTEN mutation or deletion (Chen et al., 
2005). This is reflected in the two main prostate cancer cell lines, with LNCaP, an androgen-
sensitive prostate adenocarcinoma cell line, containing one deleted allele and one mutated 
allele of PTEN (Vlietstra et al., 1998); and PC-3, an androgen-insensitive cell line, having 
homozygous deletion of PTEN (Vlietstra et al., 1998, McMenamin et al., 1999). The 
dysregulation of PTEN leads to the hyperactivation of the PI3K/Akt pathway that induces 
prostatic tumourigenesis and cancer progression (McMenamin et al., 1999). PTEN mutation 
induces the activation of PI3K/Akt signalling pathway in the mice model of prostate cancer 
(Kinkade et al., 2008), and PI3K/Akt pathway cooperates with ERK/MAPK signalling pathway 
in promoting prostate cancer development (Gao et al., 2006). In the mouse prostate tumour and 
xenograft model derived from conditional inactivation of PTEN, inhibition of mTORC1 
induces the activation of MAPK signalling, and inhibition of MAPK pathway could promote 
the anti-tumour effect of rapamycin (Carracedo et al., 2008). Furthermore, loss of PTEN 
expression is associated with high Gleason score and advanced stage of prostate cancer 
development (Dreher et al., 2004, McMenamin et al., 1999), and increased incidence of lymph 
node metastases (Schmitz et al., 2007).  
However, it has also been observed that complete PTEN loss does not unleash its full tumour 
suppressive function. Rather, complete loss of PTEN functions as potent tumour suppressor 
and leads to much less tumourigenesis than heterozygous loss of PTEN (Lee et al., 2018). This 
discrepancy from its canonical function has been explained, because cellular senescence is 
activated after the complete loss of PTEN, as a failsafe mechanism in a phenomenon called 
obligate haploinsufficiency (Alimonti et al., 2010, Berger et al., 2011, Chen et al., 2005).  
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Consequently, a goal of future studies is to take advantage of complete PTEN loss and the 
activation of cellular senescence for therapeutic benefit. 
1.3.2.2. PI3K 
PI3Ks belong to a family of lipid kinases that phosphorylate the 3’-hydroxyl group of 
phosphoinositides. PI3K has been shown to be involved in regulating numerous cellular 
activities, including cell survival pathways; the regulation of gene expression and cell 
metabolism; and cytoskeletal rearrangements (Cantley, 2002). The PI3K pathway is implicated 
in human diseases including diabetes and cancer, and the high incidence of PI3K signalling 
pathway alteration has been related to the development of various tumours (Manning and 
Cantley, 2007).  
PI3Ks can be activated by active receptor tyrosine kinases (RTKs) upon growth factor 
stimulation via their regulatory subunit or adaptor molecules, for example, insulin receptor 
substrate (IRS) protein. This subsequently allows PI3K to catalyse the phosphatidylinositol 
(3,4)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 activates 
several downstream signalling components, of which Akt has been proved to be a key 
determinant of tumour aggressiveness and an attractive target for therapeutic intervention 
(Mitsiades et al., 2004).  
In prostate cancer, the inactivation of PTEN renders PI3K constitutively active, thus promoting 
PIP3 formation, leading to the activation of PDK1 and Akt, which regulates multiple cellular 
activities by phosphorylating its downstream substrates (Martin and Blenis, 2002, Fruman et 
al., 2017). PI3K signalling has been shown to cross-regulate with AR signalling in PTEN-
deficient cells to maintain the survival of tumour cells, where the inhibition of PI3K pathway 
activates AR signalling and its target gene expression, in turn, AR inhibition activates PI3K 
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downstream effector Akt signalling by reducing levels of the Akt phosphatase (Carver et al., 
2011). 
1.3.2.3. Akt 
Akt, also known as Protein Kinase B (PKB), is a serine/threonine kinase (Staal, 1987). The 
ability to bind to PIP3 with PH domain of Akt enables it to translocate onto the plasma 
membrane, which is the rate-limiting step of Akt activation (Robey and Hay, 2009). At the 
membrane, Akt is phosphorylated by PDK1 at Thr308 residing in the kinase domain (activation 
loop) and at Ser473 in the carboxy-terminal hydrophobic motif by mammalian target of 
rapamycin complex 2 (mTORC2) (Bellacosa et al., 2005, Bhaskar and Hay, 2007).  Active Akt 
mediates a variety of signalling cascades that regulate normal cellular process such as cell 
size/growth, proliferation, survival, glucose metabolism, angiogenesis, and mammalian target 
of rapamycin complex 1 (mTORC1) signalling pathway leading to protein initiation (Manning 
and Toker, 2017).  
Akt has been found to be activated and upregulated in prostate cancer due to the inactivation 
of PTEN and hyperactivation of PI3K. Increased Akt protein expression level was detected in 
all 56 prostatectomy specimens, and showed greater intensity in immunohistochemical staining 
compared to non-cancerous cells (Liao et al., 2003). Moreover, phosphorylation of Akt is also 
significantly upregulated in high-grade prostate tumours, and the level of phosphorylated Akt 
is significantly enhanced in cancer cells compared to normal prostate epithelium and benign 
prostatic neoplasia (Malik et al., 2002). Phospho-Akt levels can be used as a good predictor of 
prostate cancer recurrence in combination with detection of PTEN status (Bedolla et al., 2007).  
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1.3.2.4. mTOR 
There are two distinct mTOR complexes, mTORC1 and mTORC2. Both of the complexes 
share some common components: serine/threonine kinase mTOR, which is the central catalytic 
unit; mLST8 (mammalian lethal with SEC13 protein 8; also known as GβL), which is the 
scaffolding protein; and DEPTOR (DEP domain-containing mTOR-interacting protein), which 
is the mTOR regulatory subunit and is important for mTOR complex assembly and stability 
(Kim et al., 2017). Each complex is defined by its unique accessory protein: Raptor (regulatory 
associated protein of mTOR) for mTORC1, and Rictor (rapamycin-insensitive companion of 
mTOR) for mTORC2 (Hara et al., 2002, Kim et al., 2002, Sarbassov et al., 2004). These 
accessory proteins are scaffold proteins that are critical for the complex assembly, substrate 
binding, subcellular localisation, and complex specific regulation (Hara et al., 2002, Kim et al., 
2002, Nojima et al., 2003, Schalm et al., 2003, Wullschleger et al., 2005, Sancak et al., 2008, 
Sancak et al., 2007). Other unique subunit of mTORC1 is PRAS40 (proline-rich Akt substrate 
of 40 kDa; also known as AKT1S1), a negative regulator of mTORC1 which could be reversed 
by growth factor signalling (Sancak et al., 2007, Vander Haar et al., 2007, Kim and Sabatini, 
2004). Other unique subunit of mTORC2 is mSIN1 (mammalian stress-activated protein kinase 
interacting protein 1; also known as MAPKAP1), which may target mTORC2 to membranes 
(Pearce et al., 2007, Frias et al., 2006, Yang et al., 2006b).   
mTORC1 is the most critical downstream effector of PI3K/Akt signalling axis, which has been 
shown to be involved in many cellular activities. Tuberous sclerosis complex 1 and 2 (TSC1/2), 
known as tumour suppressor proteins, are negative regulators of mTORC1. Active Akt 
inactivates TSC2 by phosphorylation, leading to the disruption of TSC1/2 heterodimer 
formation. It subsequently activates Ras homolog enriched in brain (Rheb), releasing it from 
the surface of lysosome as a GTPase activating protein (GAP), which promotes Rheb binding 
to GTP as a small GTPase to become active. Rheb interacts with the N-terminal of mTOR in 
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kinase domain, resulting in mTORC1 activation (Long et al., 2005b). However, other studies 
have shown that when amino acids are depleted, mTORC1 activity is abolished and this does 
not coincide with a reduction of GTP-bound Rheb, indicating mTORC1 requires a second 
signal sensor of amino acid other than TSC complex or Rheb. mTORC1 signalling promotes 
protein synthesis by phosphorylating p70 S6K, which promotes mRNA translation in ribosome 
by phosphorylation of S6 (Kim and Sabatini, 2004, Long et al., 2005a, Martin and Blenis, 
2002); and eukaryotic initiation factor 4E binding-protein 1 (4E-BP1), which activates cap-
dependent mRNA translation by dissociation with eIF4E; resulting in upregulation of anabolic 
process and inhibition of autophagy (Gingras and Sonenberg, 1997, Proud, 2004).  
Full activation of mTORC1 kinase requires concerted inputs from growth factor signalling and 
intracellular amino acids. Once active, mTORC1 enhances cell growth by promoting protein 
translation as well as biosynthesis of lipids and nucleotides. mTORC1 also increases cell 
surface amino acid transporter levels, but suppresses lysosomal catabolism of proteins derived 
from endocytosis or autophagy, thereby rendering cells dependent on availability of free amino 
acids (Palm and Thompson, 2017).  
The PI3K/Akt pathway is subject to many negative feedback loops as all other signalling 
pathways to ensure that cellular signals are sensed and transduced in a transient manner 
(Manning and Toker, 2017). As a downstream effector of Akt, mTORC1 signalling provides 
negative feedback including inhibition of the PI3K/Akt pathway at many different levels. 
Activated S6K1 inhibits PI3K/Akt pathway by phosphorylating insulin receptor substrate 1 
(IRS1) at multiple sites. IRS1 is a scaffolding protein connecting insulin and IGF1 to PIK3/Akt, 
and the phosphorylation leads to its degradation and change of localisation (Harrington et al., 
2004, Hartley and Cooper, 2002, Haruta et al., 2000, Takano et al., 2001). As a result, inhibition 
of mTORC1/S6K increases IRS1 stability, leading to undisrupted insulin or IGF1 signalling to 
the PI3K/Akt pathway. This is consistent with previous study which has demonstrated that 
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short-term treatment with the mTORC1 inhibitor rapamycin enhances the responsiveness of 
Akt to RTK signalling, especially to insulin and insulin-like growth factor 1 (IGF1) (Manning, 
2004). Another adaptor protein, growth factor receptor bound protein 10 (GRB10), has also 
been identified as a direct target of mTORC1 that negatively regulates RTK signalling (Hsu et 
al., 2011b, Yu et al., 2011). The phosphorylation of GRB10 by mTORC1 stabilises the protein, 
resulting in direct inhibition of IRS proteins, thus reducing signals from the insulin/IGF1 
receptors and/or IRS proteins and blocking PI3K/Akt activation (Yu et al., 2011).  
Unlike mTORC1, mTORC2 is insensitive to acute rapamycin treatment but chronic exposure 
to the drug can disrupt its structure (Laplante and Sabatini, 2012). Emerging evidence has shed 
light on the role of mTORC2 being a core component of aberrant growth factor receptor 
signalling in many cancer types (Masui et al., 2013, Masui et al., 2015, Tanaka et al., 2011). 
mTORC2 can be activated by growth factor-stimulated RTK in a PI3K-dependent manner 
through enhanced mTORC2-ribosome association (Sarbassov et al., 2005b, Zinzalla et al., 
2011). Active mTORC2 subsequently translocates to the plasma membrane through the mSin1 
subunit (Liu et al., 2015), allowing mTORC2 present in close proximity with Akt and to 
phosphorylate Akt at hydrophobic motif Ser473 for maximal activation (Bellacosa et al., 2005, 
Bhaskar and Hay, 2007). Interestingly, in PTEN null prostate cancer, where PI3K/Akt is 
hyperactive, loss of mTORC2 is unable to fully activate Akt, however, its absence inhibits 
tumourigenesis, suggesting the potential tumour suppressive role of mTORC2 signalling in 
PTEN mutation and/or PI3K/Akt amplification (Guertin et al., 2009). mTORC2 has been found 
to phosphorylate other AGC kinase family members, serum- and glucocorticoid-regulated 
kinase (SGK), and several members of protein kinase C (PKC), other than aforementioned Akt. 
These kinases are of great importance in regulating cell survival, cell cycle progression and 
anabolism (Facchinetti et al., 2008, Garcia-Martinez and Alessi, 2008, Ikenoue et al., 2008, 
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Sarbassov et al., 2005b, Jacinto and Lorberg, 2008, Kennedy and Lamming, 2016, Pearce et 
al., 2010).  
Furthermore, mTORC2 has also recently been identified as being responsive to nutrient levels 
(Masui et al., 2013, Moloughney et al., 2016), and it is involved in regulating several essential 
metabolic pathways in cancer, including glycolysis, glutaminolysis, lipogenesis, and 
nucleotide and ROS metabolism (Aramburu et al., 2014, Dang, 2012, Lamming and Sabatini, 
2013, Masui et al., 2014). mTORC2 regulates glycolysis in a comprehensive way. First of all, 
it activates Akt, leading to the increased expression of glucose transporters; it also 
phosphorylates hexokinase 2 (HK2) and allosterically activates phosphofructokinase-1 (PFK-
1) to mediate the first and rate-limiting steps in glycolysis respectively (Deprez et al., 1997, 
Gottlob et al., 2001, Kohn et al., 1996). Second, mTORC2 controls c-MYC levels in 
conjunction with mTORC1 to regulate glycolytic metabolism in cancer, as c-Myc is a master 
effector that coordinates growth factor receptor signalling with nutrient uptake in biomass 
accumulation as well as cell proliferation in many cancers (Vander Heiden et al., 2009, Dang, 
2012, DeBerardinis et al., 2008, Koppenol et al., 2011, Levine and Puzio-Kuter, 2010). Third, 
mTORC2 can potentially reduce the transcription of gluconeogenic genes in a FoxO-dependent 
manner, leading to the diversion of glucose-derived carbons to other metabolic pathways to 
promote their metabolic flexibility (Masui et al., 2013, Wang et al., 2011b). In addition, 
mTORC2 mediates actin cytoskeletal organisation and cell polarisation (Sarbassov et al., 
2005b, Sarbassov et al., 2004, Jacinto et al., 2004).  
There has been several evidence indicating cross-talk between mTORC1 and mTORC2 that 
affect the full activation of Akt. mTORC2 activity could be supressed by mTORC1 activation 
via a series of post-translational modifications (Julien et al., 2010, Liu et al., 2013, Liu et al., 
2014b). When mTORC1 is active, S6K1 phosphorylates Rictor on Thr1135, and inhibits 
mTORC2-dependent phosphorylation of Akt at Ser473 (Julien et al., 2010). S6K1 could also 
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phosphorylate mSIN1 on Thr86 and Thr398, resulting in the dissociation of mSIN1 from the 
mTORC2 complex to decrease the phosphorylation of Akt at Ser473 (Liu et al., 2013). The 
initial phosphorylation of Akt at Thr308 does not require phosphorylation at Ser473, so that 
sole phosphorylation of Akt-Thr308 is sufficient to fulfil a subset of its physiological functions 
(Dibble and Cantley, 2015). However, several studies have demonstrated that mTORC2-
dependent phosphorylation of Akt at Ser473 could increase or maintain phosphorylation at 
Thr308, as well as Akt and mTORC1 activity (Sarbassov et al., 2005b, Hresko and Mueckler, 
2005, Peterson et al., 2009). Thus, mTORC2-dependent phosphorylation of Akt is required for 
the full range of PI3K-dependent signalling to mTORC1. The feedback loop and crosstalk 
between two mTOR complexes add one extra layer of complexity onto the PI3K/Akt/mTOR 
signalling pathway. 
1.3.3. PI3K/Akt/mTORC1 plays an important role in nutrient metabolism 
With the stimulation of growth factors, Akt signalling regulates nutrient uptake and metabolism 
in a cell-intrinsic and cell-type-specific manner via various downstream targets (Manning and 
Cantley, 2007). One of the Akt isoforms, Akt2, has been shown to acutely stimulate glucose 
uptake in response to insulin (Calera et al., 1998). It promotes the translocation of glucose 
transporter 4 (GLUT4) onto the plasma membrane, thus increasing the glucose uptake. The 
Akt-mediated mTORC1 activation regulates the main glucose transporter GLUT1 in 
expression levels. The frequent activation of PI3K/Akt signalling in human cancer contributes 
to the transcription of GLUT1 and translation of GLUT1 mRNA, resulting in the enhancement 
of glucose uptake (Taha et al., 1999, Zelzer et al., 1998). 
Akt signalling regulates the conversion of glucose 6-phosphate, an active form of glucose when 
entering cells, into glycogen, and the glycolysis to produce cellular energy (Manning and 
Cantley, 2007). Akt stimulates glycogen synthesis by phosphorylating and inhibiting glycogen 
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synthase kinase 3 (GSK3), and promotes the glycolysis rate by enhancing the expression of 
glycolytic enzymes via hypoxia inducible factor α (HIFα) (Lum et al., 2007, Majumder et al., 
2004, Semenza et al., 1994).  
Akt signalling also regulates lipid metabolism via phosphorylation and inhibition of GSK3, 
which was the first Akt substrate being identified (Cross et al., 1995). GSK3 substrates promote 
the degradation of sterol regulatory element-binding proteins (SREBPs), which 
transcriptionally switch on the expression of genes encoding fatty acid biosynthesis (Sundqvist 
et al., 2005). Phosphorylation of GSK3 by Akt inhibits its ability to activate downstream 
effectors, resulting in the promotion of SREBPs and fatty acid production. It has been shown 
that silencing of SREBP blocks Akt-dependent lipogenesis and attenuates the increase in cell 
size in response to Akt activation in vitro (Porstmann et al., 2008). In addition, mTORC1 
signalling could activate SREBP1 to induce de novo lipogenesis, while the SREBP1 and 
SREBP2 transcription factors are required for the mTORC1 induced expression of fatty acid 
and sterol biosynthesis genes (Duvel et al., 2010). The mTORC1 inhibitor rapamycin is able to 
block the accumulation of SREBP1 and the expression of SREBP target genes (Porstmann et 
al., 2008). 
The frequent occurrence of PTEN deletion, and/or PI3K/Akt mutations constitutively activate 
mTORC1, leading to the activation of its substrates P70S6K and 4E-BP1 to regulate protein 
synthesis with various amino acids (Hara et al., 1997, Martin and Blenis, 2002, Long et al., 
2005a). As a result, the changes in mTORC1 signalling would affect protein synthesis and 
amino acid metabolism, and the changes in intracellular level of nutrients (glucose, amino acid, 
lipid) would also mediate mTORC1 signalling (Mossmann et al., 2018). This mutual 
dependency indicates the complexity of the interaction between mTORC1 and nutrients, and 
may provide useful insight in understanding the underlying mechanism. 
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1.3.4. Amino acid sensing mechanism  
Amino acid sensing is critical because amino acids are the building blocks for proteins, the 
most abundant macromolecules in cells. Protein synthesis is energetically expensive and 
complex; accordingly, cells sense extracellular and intracellular amino acids to couple their 
abundance to use (Yuan et al., 2013, Tee et al., 2003, Efeyan et al., 2015). When amino acids 
are scarce, proteins constitute reservoirs of amino acids that can be accessed by catabolic 
programs such as proteasome-mediated degradation and autophagy. Amino acids are 
subsequently recycled and allocated for the synthesis of specific proteins required under 
nutrient limitation (Zhang et al., 2003). Furthermore, during periods of prolonged starvation 
and hypoglycaemia, amino acids are catabolised for the production of other forms of energy, 
such as glucose and ketone bodies, which are required to supply the particular needs of certain 
organs (for example, the brain). Hence, the accurate sensing of amino-acid levels is a key 
process for the efficient regulation of protein and amino-acid synthesis and catabolism (Inoki 
et al., 2003, Garami et al., 2003). 
In addition to TSC1/2 complex, mTORC1 can also be activated by amino acids, namely, 
leucine, glutamine and arginine (Hara et al., 1998, Sancak et al., 2010, Nicklin et al., 2009, 
Duran et al., 2012). The sensing of amino acids started with another family of GTPase, the Rag 
GTPase. Rag family contains four isoforms that can form heterodimers by either RagA /RagB, 
with either RagC /RagD (Hirose et al., 1998, Schurmann et al., 1995, Sekiguchi et al., 2001). 
The Rag GTPase recruits mTORC1 onto the surface of lysosome, where Rheb resides (Buerger 
et al., 2006). A trimeric complex Ragulator, containing the p18, p14, and MP1 proteins, anchors 
the Rag GTPase to the lysosome, and it is necessary for mTORC1 activation by amino acids 
(Saito et al., 2005). The Ragulator and Rag heterodimer form an amino acid-mediated docking 
site for mTORC1 on the lysosome surface (Sancak et al., 2010). An inside-out model (Figure 
1.3) of amino acids sensing by lysosome was discovered a few years ago (Zoncu et al., 2011a). 
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Amino acids accumulate inside the lysosome lumen, generating an activating signal and 
transmitting to the Rag GTPase through vacuolar H+-ATPase (v-ATPase)-Ragulator 
interaction. As a result, Rag GTPase recruits mTORC1 to the lysosomal surface, leading to the 
activation of mTORC1. Recently, an amino acid transporter SLC38A9 was identified as an 
arginine sensor on the lysosomal membrane interacting with Ragulator, and is required for 
mTORC1 activation (Wang et al., 2015b) (Figure 1.3). Further study has identified that leucine 
directly binds to Sestrin2, and disrupts the interaction of Sestrin2 and GATOR2 (an upstream 
regulator complex of mTORC1, including Mios, WDR24, WDR59, Seh1L, and Sec13), 
leading to the activation of mTORC1 at lysosome surface (Chantranupong et al., 2014, 
Wolfson et al., 2016). Sestrin2 mutant that is unable to bind to leucine cannot activate 
mTORC1 in the presence of leucine, indicating Sestrin2 as a primary leucine sensor upstream 
of mTORC1 (Wolfson et al., 2016).  
Leucine, as an essential amino acid, cannot be synthesised de novo in mammalian cells, so that 
it must be sourced from diet and it requires amino acid transporters to cross the cell membranes 
(Ananieva et al., 2016). As the most abundant cellular amino acid, leucine is the major building 
block for protein synthesis, and it is also a key indicator of cellular level of free amino acids 
(Nie et al., 2018). Furthermore, leucine functions as signalling molecules that can activate 
mTORC1 via above mentioned mechanism. Therefore, leucine and its transporter are 
interesting targets for further investigation.   
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Figure 1.3. Amino acid sensing mechanism. Amino acids activate Rag GTPases by v-ATPase 
inside lysosome lumen (Zoncu et al., 2011a); and an amino acid sensor protein SLC38A9 on 
the lysosomal membrane interacts with Ragulaor and transmits signal to activate mTORC1, 
adapted from (Wang et al., 2015b) 
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1.4. Transporters 
1.4.1. Transporters 
Transporters are membrane proteins that regulate the uptake and translocation of their 
substrates across biological membranes (International Transporter et al., 2010). Transporters 
are ubiquitously expressed throughout the body, especially in the epithelia of major organs, 
such as the liver, intestine, kidney, and organs with barrier functions, such as the brain, testes 
and placenta (Lin et al., 2015). Different transporters are localised to different positions, 
including plasma membrane and multiple subcellular organelle membranes, thus regulating 
desired substrates for particular functions, and maintaining the balance of substrates as well as 
cellular homeostasis (Schlessinger et al., 2010).  
There are two main superfamilies of transporters. One is the ATP-binding cassette (ABC) 
superfamily, and the other one is the solute carrier (SLC) superfamily (Lin et al., 2015). ABC 
transporters function as efflux transporters by utilising the energy from ATP hydrolysis 
(Gottesman and Ambudkar, 2001, Hediger et al., 2013), while SLC transporters mainly mediate 
the uptake of small molecules into cells (Schlessinger et al., 2010).  
Due to the hydrophobicity of the cell membrane, extracellular molecules (including charged 
molecules) cannot directly diffuse across membranes and thus rely on membrane protein, such 
as channels, pumps or transporters to move in and out of cells as well as subcellular organelles 
(Hediger et al., 2013). SLC transporters are predominantly facilitative or secondary-active 
which means that they rely either on an electrochemical gradient to facilitate the movement of 
substrates across membranes, or on ion gradients generated by ATP-dependent pumps to 
transport substrates against the concentration gradient (Lin et al., 2015).  
SLC consists of the largest family of membrane proteins in the human organism (Hediger et 
al., 2013). It includes over 400 members organised into 65 families. SLC members facilitate 
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the transport of many essential elements that cells need, including glucose, amino acids, fatty 
acids as nutrients source, and neurotransmitters as signalling molecules, purines and 
nucleotides as DNA synthesis materials, and metal ions as enzymatic co-factors (Rask-
Andersen et al., 2013). All of these extracellular materials contribute to cell growth, internal 
signal propagation, various cellular activities and maintain balanced cell status. For example, 
SLC2 family (glucose transporters, GLUTs) includes 14 members that transport glucose, 
fructose, galactose, etc. They are widely expressed in almost every cell type across different 
organs and tissues to regulate glucose uptake, since glucose is one of the critical circulating 
fuels for cells (Mueckler and Thorens, 2013); SLC27 family (fatty acid transporter proteins, 
FATPs) includes 6 members that transport long chain fatty acid (LCFA). FATPs are 
differentially expressed in a wide variety of tissues and cell types, including adipose tissue, 
liver, skeletal muscle, heart, intestine, skin, and endothelial cells, introducing fatty acid for 
membrane synthesis, intracellular signal transduction, energy metabolism, posttranslational 
modifications, and transcriptional regulation of metabolic genes (Anderson and Stahl, 2013); 
SLC39 family (Zinc Transporters, ZIPs) includes 14 members that transport metal ions such 
as Zn, Mn, Cd, and Fe. These transporter proteins are also widely expressed throughout various 
tissues and organs, controlling cellular Zn homeostasis that is critical for human health, as zinc 
deficiency would lead to immune dysfunction, metabolic disorders, cognitive impairment, and 
many other diseases, however, excess intake of zinc is toxic (Jeong and Eide, 2013). 
1.4.2. Amino acid transporters 
In addition to abovementioned SLC transporters, amino acid transporters are also critical for 
cells. On one hand, amino acids are indispensable for protein synthesis, cellular signalling, cell 
mass accumulation as well as many other cellular functions; on the other hand, mammalian 
cells are unable to synthesise 9 essential proteinogenic amino acids, which make up nearly a 
quarter of cell dry mass (Hosios et al., 2016), and have to acquire them from diet and transport 
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into cells with the assistance of amino acid transporters. There are 12 SLC families that 
transport amino acids in various tissue and cell types (Table 1.1). Most of SLC families have 
multiple members that transport a similar range of amino acids; while some SLC families only 
have a few members that transport different categories of amino acids. Amino acid transporters 
are widely expressed in many tissues and organs, and have been connected to many types of 
disease, such as inherited aminoacidurias, Alzheimer’s disease, Huntington’s disease, 
Parkinson disease and cancer (Fotiadis et al., 2013, Bodoy et al., 2013, Pramod et al., 2013, 
Kanai et al., 2013).  
Table 1.1. List of amino acid transporters in SLC families (adapted from 
http://slc.bioparadigms.org/) 
SLC 
family 
DESCRIPTION TISSUE AND CELLULAR EXPRESSION 
DISEASE 
TYPE 
SLC1 
High-affinity glutamate and 
neutral amino acid transporter 
family 
Brain, liver, heart, skeletal muscle, intestine, kidney, 
pancreas, placenta, lung, large intestine 
Cancer 
SLC3 
Heavy subunits of the heteromeric 
amino acid transporters 
kidney, small intestine, liver, pancreas 
Cancer, 
cystinuria 
SLC6 
Sodium- and chloride-dependent 
neurotransmitter transporter family 
Brain, peripheral nervous system, adrenal gland, 
placenta, epithelium cells, platelets, thymus, spleen, 
ovary, lung 
Schizophrenia, 
Parkinson 
disease, autism 
SLC7 
Cationic amino acid 
transporter/glycoprotein-associated 
family 
Brain, ovary, testis, placenta, spleen, colon, 
blood–brain barrier, fetal liver, lymphocytes 
Cancer, 
cystinuria 
SLC15 
Proton oligopeptide cotransporter 
family 
small intestine, kidney, pancreas, bile duct, liver, 
lung, spleen, thymus, brain, eye 
Inflammatory 
bowel disease  
SLC17 
Vesicular glutamate transporter 
family 
heart, muscle, brain, placenta, lung, liver kidney, 
pancreas, small intestine, testis, colon 
Gout, sialic acid 
storage disease 
SLC18 Vesicular amine transporter family 
all CNS aminergic neurons, mast cells, platelets, 
some GI neurons, adrenal medulla, cholinergic 
neurons, pancreatic stellate cells, tracheal brush cells 
Unknown 
SLC25 Mitochondrial carrier family 
liver, testis, spleen, lung, pancreas, small intestine, 
brain, kidney, heart, skeletal muscle, testis 
Obesity, type 2 
diabetes, 
congenital 
hyperinsulinism 
SLC32 
Vesicular inhibitory amino acid 
transporter family 
CNS Unknown 
SLC36 
Proton-coupled amino acid 
transporter family 
brain, intestine, colon, kidney, lung, liver, spleen, 
heart, muscle, testis, adrenal gland, thymus, sciatic 
nerve 
Iminoglycinuria, 
Spinocerebellar 
Ataxia 45 
SLC38 
System A and System N sodium-
coupled neutral amino acid 
transporter family 
brain, retina, heart, placenta, adrenal gland, liver, 
skeletal muscle, kidney, pancreas, adipose tissue, 
stomach, lung, small intestine, spleen, colon 
Cancer 
SLC43 
Na+-independent, system-L-like 
amino acid transporter family 
Placenta, kidney, peripheral 
blood leukocytes, small intestine 
Cancer 
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Cancer cells grow much faster than most normal cells, hence requiring much more nutrients to 
sustain their rapid proliferation, including glucose, proteins, and fatty acids. Cells have many 
ways in uptaking proteins that are available in the extracellular matrix and convert into amino 
acids for their own needs, such as transporter-based nutrient uptake, receptor-mediated 
endocytosis, macropinocytosis, as well as entosis (Palm and Thompson, 2017). Since the 
majority of transport of extracellular amino acids relies on their transporters, the expressions 
of transporters are highly upregulated in many cancer types, such as Alanine-Serine-Cysteine 
Transporter 2 (ASCT2/SLC1A5) in triple negative breast cancer, prostate cancer, melanoma 
and non-small cell lung cancer (NSCLC) (van Geldermalsen et al., 2016, Wang et al., 2014b, 
Wang et al., 2015a, Hassanein et al., 2015), LAT1 (SLC7A5) in endometrial cancer (Marshall 
et al., 2016), ATB0,+ (SLC6A14) in colorectal cancer (Gupta et al., 2005), xCT (SLC7A11) 
in glioma (Lyons et al., 2007) and in NSCLC (Ji et al., 2018). It has been reported that growth 
factor signalling pathways can also play an instructive role in regulating nutrient transporters 
via PI3K/Akt, which induces the phosphorylation and translocation of glucose transporter 1 
(GLUT1) to cell surface to increase glucose uptake upon growth factor stimulation (Russell et 
al., 1998, Palm and Thompson, 2017). 
Among these amino acid transporters, the L-type amino acid transporters are drawing 
increasing attention because of their function and overexpression in cancers, such as LAT1 in 
endometrial cancer (Marshall et al., 2016), in breast cancer (Furuya et al., 2012, Shennan, 1994), 
in prostate cancer (Patel et al., 2013, Sakata et al., 2009, Wang et al., 2011a, Wang et al., 2013), 
in melanoma (Fukumoto et al., 2013), in pancreatic cancer (Yanagisawa et al., 2012); LAT2 in 
myeloma (Kuhne et al., 2007), and in uterine leiomyoma (Luo et al., 2009); LAT3 in prostate 
cancer (Cole et al., 1998, Babu et al., 2003, Wang et al., 2011a, Wang et al., 2014c, Wang et 
al., 2013), in leukemia (Xu et al., 2013), and in liver cancer (Ritchie and Taylor, 2010); LAT4 
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in colorectal and head and neck carcinoma (Haase et al., 2007). Thus, we focus on LAT family, 
in particular, LAT3, which plays an important role in prostate cancer. 
1.4.3. L-type amino acid transporters (LAT) family 
LATs are the major membrane proteins transporting large neutral amino acids into cells in a 
sodium-independent manner (Kanai et al., 1998a). This family includes four members: LAT1, 
LAT2, LAT3 and LAT4. The crystal structure of LAT1 has been solved by cryo-electron 
microscopy recently (Yan et al., 2019). It contains 12 transmembrane (TM) domains as 
predicted, whereas the structures of LAT2, LAT3 and LAT4 remain unsolved (Wang and Holst, 
2015). 
LAT1 (SLC7A5) and LAT2 (SLC7A8) belong to a subfamily of solute carrier family 7 (SLC7). 
Both LAT1 and LAT2 associate with 4F2hc/CD98 (SLC3A2) glycoprotein to form 
heterodimeric complexes in order to initiate their transport activities (Kanai et al., 1998b). 
LAT1 preferentially transports neutral branched-chained and aromatic amino acids as an 
obligatory exchanger (Mastroberardino et al., 1998). LAT2 shares 52% identity to that of LAT1 
(Rossier et al., 1999), and shows broad specificity for small and large zwitterionic amino acids, 
as well as bulky analogues (Pineda et al., 1999). However, LAT1 and LAT2 exhibit distinct 
expression pattern in cancerous/proliferative cells and normal cells. Several types of cancerous 
cells express higher level of LAT1 with low level or no expression of LAT2, including human 
oral cancer cells (Yun et al., 2014),  Saos2 human osteogenic sarcoma cells (Kim et al., 2006), 
C6 rat glioma cells (Kim et al., 2004); however, normal human oral cells (Yun et al., 2014), 
normal skin cells (Wang et al., 2014b), express high level of LAT2 with weak LAT1 expression.  
LAT3 (SLC43A1) and LAT4 (SLC43A2) are structurally and functionally different from 
LAT1 and LAT2. LAT3 was firstly found as prostate cancer overexpressed gene 1 (POV1) 
(Cole et al., 1998), and it was then identified as a major transporter of large neutral branched 
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chain amino acids (BCAAs) in a Na+-independent manner encoded by SLC43A1 (Babu et al., 
2003). LAT4 (SLC43A2) shares 57% identity to that of LAT3. LAT4 is a symmetrical 
facilitative transporter for neutral essential amino acids localising at the basolateral side of 
(re)absorbing epithelia and is necessary for early nutrition and development (Bodoy et al., 
2005). LAT3 and LAT4 deliver a narrower range of neutral amino acids into cells, including 
leucine, isoleucine, valine, phenylalanine, and methionine (Babu et al., 2003, Bodoy et al., 
2005, Fukuhara et al., 2007). Thus, LAT3 and LAT4 are classified as system L2 due to low 
affinity and narrower substrate selectivity. However, LAT3 and LAT4 do not require the 
formation of a heterodimer by binding to 4F2hc/CD98 for functional expression, therefore 
denoting a new SLC family SLC43 as part of the L-type amino acid transporter (Babu et al., 
2003, Bodoy et al., 2005). Since LAT3 is overexpressed in prostate cancer and is one of the 
main transporters of leucine, it is important to understand and investigate how LAT3 
contributes to the development of prostate cancer.  
1.4.4. LAT3/SLC43A1 
Human LAT3 cDNA was isolated from hepatocarcinoma cells FLC4 by expressing cloning 
(Babu et al., 2003). LAT3 has 559 amino acids that consists of 12 transmembrane domains, but 
there is no structure being solved yet. It contains a relatively long extracellular loop with 
putative N-linked glycosylation sites between transmembrane domains 1 and 2, and a long 
intracellular loop that is predicted to exist between transmembrane (TM) domains 6 and 7, 
which contains putative phosphorylation sites (S262 and S267), and one ubiquitination site 
(K264) (Babu et al., 2003).  
LAT3 is substantially expressed in prostate specimens, as well as in adult colon, small intestine, 
ovary, spleen, pancreas, liver and skeletal muscle; in fetal kidney, liver, and lung (Cole et al., 
1998, Fukuhara et al., 2007). Similarly to other amino acid transporters, LAT3 has been shown 
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to be highly upregulated in primary and recurrent prostate cancer (Wang et al., 2013), leading 
to increased intracellular levels of leucine, and ultimately stimulates mTORC1 signalling to 
promote cell cycle, cell growth and proliferation, in response to growth factor stimulation. 
Moreover, lentiviral shRNA knockdown of LAT3 reduces leucine uptake and represses cell 
growth in prostate cancer cell lines (Wang et al., 2011a). Knockdown of LAT3 in the androgen-
independent cell line (PC-3) significantly suppressed cell growth and metastasis in a mouse 
xenograft model (Wang et al., 2013). These data indicate that LAT3 plays a critical role in the 
progression of CRPC, making it a potential therapeutic target in CRPC. 
1.4.5. LAT3 specific inhibitor 
A leucine analogue, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), is a Na+-
independent system L specific substrate, used as an inhibitor of LAT family transporters 
(Christensen, 1990). Because BCH targets all four LAT members and its concentration is in 
millimolar quantities, making it unsuitable as a LAT inhibitor in vivo. Wang et al (Wang et al., 
2014c) established a function based high-throughput screen using a pre-fractionated natural 
product library and identified two novel monoterpene glycosides inhibitors ESK242 and 
ESK246. ESK242 and ESK246 were isolated as optically active clear oil with the same 
molecular formula C23H36O7 (Wang et al., 2014c). ESK242 and ESK246 are the isomers of 
each other, and they showed an identical number of 1H and 13C resonances in the NMR spectra. 
ESK246 contains a senecioyl group at C-3, while ESK242 shows two methyl vinyl resonances 
with each coupled to an olefin proton. Using tritium labelled leucine uptake assay, both 
compounds were able to reduce leucine uptake in a concentration-dependent manner, and their 
IC50 values were more than two orders lower than BCH, in micromolar range. Moreover, 
ESK246 exhibited good specificity in LAT3 inhibition, whereas ESK242 inhibited a small 
extra portion of LAT1 transport in addition to LAT3. The mechanism of LAT3 inhibition by 
ESK242 and ESK246 is investigated via oocyte uptake, and kinetic analysis indicates that these 
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compounds act in a mixed competitive/noncompetitive manner. Both ESK242 and ESK246 
block mTORC1 activation, reduce cell cycle protein expression and proliferation in prostate 
cancer cell lines (Wang et al., 2014c). In addition, ESK246 reduces the rate of cells entering 
cell cycle to the greatest extent.  These compounds and their derivatives could be potential 
therapeutic agents for castration-resistant prostate cancer.  
1.4.6. Regulation of LAT3 
Several studies have discovered that LAT3 can be transcriptionally regulated. Previous study 
has shown that LAT3 is regulated by androgen receptor signalling in prostate cancer (Wang et 
al., 2011a). It shows that mRNA expression levels are dramatically increased in the presence 
of synthetic androgen agonist R1881 in androgen-sensitive cells LNCaP. Furthermore, LAT3 
expression is increased in a dose-dependent manner with DHT treatment, and this increase 
could be blocked by the androgen receptor inhibitor bicalutamide in LNCaP cells, indicating 
that LAT3 expression is regulated by androgen receptor signalling. Chromatin 
immunoprecipitation (ChIP)-Seq and quantitative polymerase chain reaction (qPCR) data have 
revealed two transcription factor-binding region on LAT3, which is confirmed by luciferase 
assay (Wang et al., 2011a). 
A recent study has reported that oncogenic MYC protein regulates LAT3 expression (Yue et 
al., 2017). MYC directly upregulates LAT3 transcription, and preferentially upregulates LAT3 
expression among many other SLC transporters. In turn, the absence of amino acids caused by 
the inhibition of LAT3 activates the GCN2 (general control nonrepressed-2)-eIF2α (eukaryotic 
initiation factor 2α) amino acid stress response pathway, and suppresses eIF4F (eukaryotic 
initiation factor 4F)-dependent transcription initiation, leading to downregulation of MYC 
mRNA levels.   
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Post-translational modifications are also important in regulating protein functions. LAT3 has 
been shown to have several PTM sites from various high throughput proteomic discovery mass 
spectrometry studies. Among these studies, the phosphorylation of S267 has been reported for 
15 times, and S262 for 8 time; the ubiquitination of K264 has been reported for 32 times 
(https://www.phosphosite.org/proteinAction?id=10260&showAllSites=true#appletMsg). All 
these sites are located between the transmembrane domain 6 and 7 of LAT3, which is the 
functional domain for its transporting activity. Since Phosphorylation and ubiquitination 
regulates protein activation/inactivation and degradation, these PTMs are critical in protein 
function and expression. 
1.5. Aim of the study 
Given the transport function of LAT3 and the importance of leucine, LAT3 plays a critical role 
in mediating intracellular level of amino acids which mediates mTORC1 activation. However, 
the signalling network that regulates PTMs of LAT3 function, expression and degradation 
remains largely unclear, and how leucine uptake is regulated in the context of signalling 
network needs to be evaluated. Therefore, we aim to investigate how PI3K/Akt/mTORC1 
signalling pathway involves in leucine uptake, since the dysregulation of PI3K/Akt signalling 
pathway frequently occurs; Also, we aim to examine the effect of EGF in regulating leucine 
uptake and LAT3 expression as an extracellular stimulation of PI3K/Akt signalling, including 
the examination of cellular and surface expression of LAT3. 
Since the structure of LAT3 hasn’t been solved yet, it is difficult to predict the interaction or 
binding site of LAT3. We aim to apply a novel genetic code expansion (GCE) method, to 
incorporate an unnatural amino acid (Uaa) into LAT3 protein during translation. This Uaa 
possesses photo-crosslinking property, which can form covalent bond to crosslink with proteins 
in close proximity of LAT3 with UV induction. We aim to apply this method to capture novel 
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interactors of LAT3 in a site-specific manner to examine the functions of particular sites, such 
as the reported phosphorylation sites. We also aim to explore the composition of the complex 
formed by photo-crosslinking using mass spectrometry to identify novel interactor(s) of LAT3. 
This will help us to better understand the regulation of LAT3, and potentially provide additional 
therapeutic targets. 
Leucine is an essential amino acid that is required for protein synthesis and many other 
biosynthetic processes. We aim to investigate the metabolism of leucine in prostate cancer cells, 
and to examine the changes of leucine metabolism under inhibition of PI3K/Akt signalling 
pathway and inhibition of transporter.  
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Chapter 2. Materials and Methods 
2.1 Cell culture 
2.1.1 Cell lines 
Human prostate cancer cell lines LNCaP and PC-3, as well as human embryonic kidney 293 
cells (HEK293) were purchased from American Type Culture Collection (ATCC, Rockville, 
MD, USA). We use low passage original stocks, and confirmed LNCaP and PC-3 cell identity 
by short tandem repeat (STR) profiling in 2014 (Cellbank, Australia). Cell lines were routinely 
tested for mycoplasma using a polymerase chain reaction (PCR) detection kit. All cell culture 
procedures were performed in a sterile environment using Class II biosafety cabinets (BSC).  
2.1.2 Cell culture and storage of cell lines 
Cell lines were initially transported from liquid nitrogen storage to the lab with dry ice. Frozen 
cells were thawed quickly in 37℃ water bath. Thawed cells were transferred into proper pre-
warmed growth medium slowly in BSC to prevent cell bursting. The cells were incubated at 
37℃ incubator with 5% CO2.   
Cells were routinely cryopreserved in a mixture of 90% (v/v) fetal bovine serum (FBS, Gibco) 
and 10% (v/v) dimethyl sulfoxide (DMSO) in cryovials at -80℃ and transferred into liquid 
nitrogen. Cells were collected at 1,500rpm, 5min and resuspended with freezing medium (90% 
FBS and 10% DMSO) at the density of 1-10×106 cell/mL, then aliquot 1 mL into pre-labelled 
cryovials (In Vitro Technologies). Cells could slowly cool down in Mr FrostyTM freezing 
container (Thermo Fisher Scientific) filled with isopropyl alcohol, as it decreases the 
temperature at 1℃/min. When it reaches -80℃, the cells could be transferred to the vapour 
phase of liquid nitrogen for long term storage. 
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LNCaP and PC-3 cells were cultured in RPMI-1640 media (Life Technologies) containing 10% 
(v/v) fetal bovine serum (FBS, Gibco), 1 mM sodium pyruvate (Life Technologies) and 100 
units/mL penicillin-streptomycin solution (Life Technologies). HEK293 were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) medium (4.5 g/L glucose, Gibco), 10% FBS, 
2 mM glutamine, 100 units/mL penicillin - streptomycin (Life Technologies). Cells were 
maintained at 37°C in a fully humidified atmosphere containing 5% CO2.  
HEK293 cells were used for transfection with plasmids containing suppressor tRNA and 
aminoacyl tRNA synthetase (aaRS) for genetic code expansion (refer to Section 2.9). HEK293 
cells were also used to generate lentivirus titre for making shControl and shLAT3 cells in 
prostate cancer cells (refer to Section 3.2.3.8). Empty vector pLKO.1 was used to generate 
shControl cell lines, and short hairpin RNA (shRNA) targeting LAT3 was used to knock down 
LAT3, and generated stable LAT3 knockdown cell line with LNCaP. 
2.1.3 Growth factor and inhibitors 
Epidermal growth factor (EGF, Sapphire Bioscience) was diluted with sterile phosphate 
buffered saline (PBS) and used with 10 ng/mL as final concentration. Inhibitors were dissolved 
in appropriate solvent, including MK2206 (10 µM, Selleck Chemicals; H2O); LY294002 (20 
µM, Merck; H2O); BCH (10 mM, Sigma; H2O); Rapamycin (50 nM, Merck; DMSO); JPH203 
(10 µM, Selleck Chemicals; DMSO); MG132 (50 µM, Sigma; DMSO). 
2.2 Immunoblotting 
2.2.1 Whole cell lysate preparation  
Cells were seeded at a density of 5×105/well in 6-well plates or 1×106 in 10 cm plate in normal 
growth media, allowed to adhere overnight. Once cells reached ~70% confluent, treat with 
required conditions of growth factors or various inhibitors for required time. Then cells were 
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washed with 1× PBS briefly and lysed with radio immunoprecipitation assay buffer (RIPA 
buffer, 150 mM sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% (v/v) sodium 
deoxycholate, 0.1% (v/v) sodium dodecyl sulfate (SDS), 50 mM Tris, pH 8.0) supplemented 
with 1× protease inhibitor cocktail III (PIC, 100× dilution, Sigma Aldrich) and 1× phosphatase 
inhibitor cocktail (100× dilution, Cell Signalling Technology). The cells were incubated with 
lysis buffer on ice for 5 min, and whole cell lysates were collected into pre-chilled tubes. Cell 
lysates were sonicated with Bioruptor® Plus sonicating device (Diagenode) with high power at 
4℃ for 15 cycles (30 sec ON/ 30 sec OFF), followed by centrifugation at 4℃ with max speed 
for 10 min. Supernatant was collected into fresh pre-chilled tubes on ice.  
2.2.2 Protein concentration quantification 
To quantify the protein concentration in the whole cell lysate, Micro-BCA protein assay 
(PierceTM BCA Protein Assay Kit, Thermo Fisher Scientific) was used. Cell lysates were 
diluted 50 times with Milli-Q (MQ) water in a 96-well plate in duplicate with a total volume 
of 100 µL each. Standard protein samples were generated by serial dilution of 2 mg/mL bovine 
serum albumin (BSA) with MQ water, into 5 µg/mL, 10 µg/mL, 20 µg/mL, 50 µg/mL and 100 
µg/mL respectively. 100 µL of BSA standard was added into a 96-well plate. BCA reagent A, 
B, and C were mixed in the ratio of 50:48:2, and 100 µL of the working solution was added 
into each standard and sample. Gently tap the plate to mix and incubate at 37℃ for 1 hr. The 
absorbance was measured at wavelength 562nm with microplate reader (Infinite® 200 PRO, 
TECAN).  
Microsoft Excel was used for data analysis. Absorbance data of standards were plotted as 
standard curve and polynomial regression trend line was drawn. The fitness (R2) should be 
higher than 0.98. Protein concentration of unknown sample was then calculated based on the 
equation of regression and dilution factor.  
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2.2.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
Equal amount of protein (20-50 µg) was resuspended in 1× NuPAGE LDS sample buffer (Life 
Technologies), with 0.1M dithiothreitol (DTT, Sigma) to reduce the disulfide bonds. Samples 
were heated at 65℃ for 5 min before loaded on a NuPAGE Novex 4-12% gradient gel 
(Invitrogen, Australia). Pre-stained molecular weight marker (Precision Plus Protein™ Dual 
Colour Standards, Bio-Rad) was loaded along with samples to indicate the protein size. 
Electrophoresis was performed at 130V for 100 min with MOPS running buffer (Life 
Technologies) to allow the dye front reaching the bottom of the gel.   
2.2.4 Western blotting 
After electrophoresis, protein that has been resolved from the gel was transferred to 
polyvinylidene difluoride (PVDF) membrane (Immobilon-P, Millipore) using semi-dry 
transfer apparatus (Mini Blot Module, Invitrogen B1000) at 20V for 70 min. Dilute 100 mL 
Tris glycine transfer buffer (10×, Sigma) in 800 mL MQMQ water and 100 mL methanol to 
become 1× with 10% (v/v) methanol. Filter papers and PVDF membranes were cut into proper 
size that fit transfer module. Sponges and filter papers used for transfer were pre-soaked in 
transfer buffer, and PVDF membrane was activated with 100% methanol before stacking into 
the transfer sandwich in accordance with instructions of transfer module.  
Once the transfer completed, block the membrane with 2.5% (w/v) BSA (Sigma, A7906-100G) 
in Tris-buffered saline (TBS; Sigma, T6664) with 0.1% (v/v) Tween20 (Sigma, P1379, TBS-
T) for at least 30 min at room temperature with rocking. Primary antibodies were diluted 1000× 
in 4 mL 2.5% BSA/TBS-T (1:1000). After rinse briefly with TBS-T, the membrane was 
incubated with the primary antibodies at 4℃ overnight with rolling. The next day, wash the 
membrane 3×5 min in TBS-T. Then incubated with secondary antibodies at room temperature 
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for 2 hrs or at 4℃ overnight with rolling. Suitable secondary antibodies were diluted 5000× in 
5 mL 2.5% BSA/TBS-T. Membrane was washed 3×5 min in TBS-T again before imaging.  
2.2.5 Western blot imaging 
Horseradish peroxidase (HRP)-conjugated secondary antibodies generated strong signal when 
exposed to enhanced chemiluminescence (ECL) reagents (PierceTM, Thermo Fisher Scientific), 
and could be visualised on ChemiDocTM Touch imaging system (Bio-Rad). Densitometry 
analysis was performed with Image Lab (Version 6.0.0 Build 25, Bio-Rad) and ImageJ 
(Version 1.52e, NIH). To control protein loading and normalise densitometry, the membrane 
was also probed with primary antibodies of loading control proteins that are highly abundant, 
such as Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Abcam) (see section 2.2.5). If 
re-blotting were required for another protein, membrane was stripped with 1× re-blotting 
reagent (Re-blot Plus 10×, Millipore) for 10 min, and re-blocked with 2.5% BSA/TBS-T for 
30 min before incubating with another primary antibody. 
2.2.6 Antibodies 
Antibodies used for immunoblotting, immunoprecipitation (section 2.3), surface protein 
isolation (section 2.4), immunofluorescence staining (section 2.6), proximity ligation assay 
(section 2.6), rapid immunoprecipitation-mass spectrometry of endogenous protein (RIME, 
section 2.10.1), and in-gel enzymatic digestion (section 2.10.2) in this study and their 
concentration are listed in Table 2.1, including anti- LAT3 (affinity purified from rabbit serum 
made by The Institute of Medical and Veterinary Science, Adelaide, Australia), pS473-Akt, 
Akt, pT389-p70S6K, p70S6K, hemagglutinin (HA)-tag, (peptide sequence YPYDVPDYA; 
Cell Signalling), BCAR1, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
ubiquitin (Abcam). Horseradish peroxidase–conjugated donkey anti-mouse IgG, donkey anti-
rabbit IgG (Millipore) and Trueblot (Rockland) were used as western blot secondary antibodies. 
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Normal rabbit IgG (200 µg/0.1 mL) from Santa Cruz was used as control for 
immunoprecipitation. Alexa-Fluor488-conjugated goat anti-rabbit IgG (Invitrogen) was used 
as a secondary antibody for immunofluorescence staining. 
Table 2.1. List of antibodies  
ANTIBODY SPECIES DILUTION SUPPLIER CATALOGUE # 
LAT3 Rabbit 1:1000 
Institute of Medical and 
Veterinary Science, Adelaide 
N/A 
Akt Rabbit 1:1000 Cell Signalling Technologies 9272 
Phospho-Akt (Ser473) Mouse 1:1000 Cell Signalling Technologies 4051 
P70S6K Rabbit 1:1000 Cell Signalling Technologies 9202 
Phospho-P70S6K 
(Thr389) 
Rabbit 1:1000 Cell Signalling Technologies 9205 
LAT1 Rabbit 1:1000 Cell Signalling Technologies 5347 
Na, K-ATPase Rabbit 1:1000 Cell Signalling Technologies 3010 
HA-tag Rabbit 1:1000 Cell Signalling Technologies 3724 
BCAR1 (p130 Cas) Rabbit 1:1000 Cell Signalling Technologies 12015 
Ubiquitin Rabbit 1:1000 Abcam ab7780 
GAPDH Mouse 1:2000 Abcam ab8245 
Ha-Tag (CHIP Grade) Rabbit 1:1000 Abcam ab9110 
Normal Mouse IgG Mouse 1:1000 Santa Cruz sc-2025 
Normal Rabbit IgG Rabbit 1:1000 Santa Cruz sc-2027 
HRP Conjugated Donkey 
Anti-Rabbit 
Rabbit 1:5000 Millipore AP182P 
HRP Conjugated Donkey 
Anti-Mouse 
Mouse 1:5000 Millipore AP192P 
Trueblot Rabbit 1:1000 Rockland 18-8816-31 
 
2.3 Immunoprecipitation (IP) 
Cell lysates were prepared as described above (section 2.2.1) in cell lysis buffer (Table 2.2). 
After quantification of protein concentration, cell lysates were diluted into 1 µg/µL in cell lysis 
buffer containing 1× protease inhibitor cocktail and 1× phosphatase inhibitor cocktail. 
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Magnetic protein A/G beads (SurebeadsTM Bio-Rad) were balanced with PBS three times, 
mixing beads with PBS by inverting the tubes, and remove PBS using magnetic separation rack 
(Bio-Rad). To pre-clear lysate, 20 µL of the washed beads were added to 500 µL of the diluted 
lysates and rotate at 4℃ for 2 hrs. Transfer 500 µL pre-cleared lysate into a fresh tube and add 
5 µL antibody to form antibody-antigen (Ab-Ag) complex, and rotate at 4℃ for another 2 hrs. 
At the meantime, block another 20 µL beads with 2.5% BSA at 4℃ with rotation for 2 hrs. 
After 2 hrs, remove BSA from beads with magnetic separation rack and transfer Ab-Ag 
complex onto the beads, then rotate on an orbital rocker at 4°C overnight.  
The next day, remove the supernatant using magnetic separation rack and wash the beads with 
1 mL IP wash buffer 1 once, and 1 mL IP wash buffer 2 (Table 2.2) twice by inverting and 
shaking the tubes 10-15 times. Centrifuge at 1,000×g for 1 min and remove the residue of wash 
buffer.  Add 25 µL NuPAGE LDS sample buffer with 0.1M DTT into the beads, and boil at 
85℃ for 5 min. After elution, 10 µg of protein is resolved by SDS-PAGE and western blotting 
analysis. 
Table 2.2. Recipe for buffers used in IP 
Buffer Recipe 
Cell lysis buffer 150 mM sodium chloride 
 1.0% Triton X-100 
 50 mM Tris pH 8.0 
IP wash buffer 1 1M HEPES (pH 7.6) 
 300mM NaCl 
 10% NP-40 
 1M Na3VO4 
IP wash buffer 2 1M HEPES (pH 7.6) 
 150mM NaCl 
 10% NP-40 
 1M Na3VO4 
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2.4 Surface protein isolation 
2.4.1 Biotinylation 
Cell surface protein extraction was performed with PierceTM Cell Surface Protein Isolation Kit 
(Thermo Fisher Scientific). As per user guide of the kit, seed LNCaP cells into 4 flasks of T75. 
When reaching 90-95% confluent, remove media from the flasks. Wash cells with 8 mL ice-
cold PBS per flasks briefly, allowing no more than 5 sec in contact with PBS to prevent cell 
rounding and detaching.  Dissolve the contents of one vial of Sulfo-NHS-SS-Biotin powder in 
48 mL of ice-cold PBS. And add 10 mL of the biotin solution to each flask. Rock the flasks on 
an orbital shaker and gently agitate for 30 min at 4℃ for even coverage of cells with labelling 
solution. Quench the labelling reaction by adding 500 µL quenching solution and gently tip 
back and forth to reach homogenous. Gently collect all cells with cell scraper and transfer cell 
in all four flasks into a 50 mL conical tube. Rinse all four flasks with 10 mL TBS and collect 
remaining cells into the tube. Centrifuge at 500 ×g for 3 min to pellet the cells and remove the 
supernatant. Wash the cell pellet with 5 mL TBS by pipetting up and down twice with a 
serological pipette, before centrifuge at 500×g for 3 min again and discard supernatant. 
2.4.2 Cell lysis 
Lyse the cell pellet with 500 µL Lysis Buffer containing 1× protease inhibitor, and transfer into 
1.5 mL microcentrifuge tube. Resuspend and lyse the cells completely before sonication 
(Bioruptor® Plus, Diagenode) for 10 min with 30 sec ON/ 30sec OFF. Incubate cell lysate on 
ice for 30 min and vortex every 5 min for 5 sec. Centrifuge the cells at 10,000×g for 2 min at 
4℃ and collect supernatant into a new tube. 
2.4.3 Isolation of labelled protein 
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Insert a column into a collection tube, and swirl NeutrAvidin Agarose slurry bottle to obtain 
an even suspension before add 500µL onto the column and cap the column. Centrifuge at 
1,000×g for 1 min and discard the flow-through. Wash the agarose gel with 500 µL Wash 
Buffer by centrifuging at 1,000×g for 1 min, repeat twice. Apply bottom cap to column, add 
clarified cell lysate to the gel, and then apply top cap to column. Incubate for 60 min at room 
temperature by mixing using a rotator to bind biotinylated protein onto agarose gel. Remove 
top cap and then bottom cap from column and place column in the collection tube, and replace 
top. Centrifuge column for 1 min at 1,000 × g and discard flow-through. Then add 500 µL 
Wash Buffer with protease inhibitor and centrifuge for 1 min at 1,000 × g, repeat wash for three 
times.  
2.4.4 Elution 
Reconstitute lyophilised DTT with 50 µL ultrapure water into 1 M, and add 23.7 µL DTT 
solution into 450 µL SDS-PAGE sample buffer to make a final concentration of 50 mM DTT. 
Then add 400 µL of the sample buffer containing DTT onto the gel and incubate at room 
temperature for 60 min by mixing using a rotator. Centrifuge at 1,000×g for 2 min to elute 
biotinylated membrane protein. (Alternatively, after adding sample buffer, place the column in 
a fresh collection tube and heat at 95℃ for 5 min, and centrifuge at 1,000×g for 2 min to elute).  
The isolated membrane protein is subject to SDS-PAGE and western blot analysis. Any unused 
lysate can be stored at -30℃ for long term. 
2.5 [3H]-L-leucine Uptake Assay 
Cells were cultured in 6-well plates in RPMI media. After collecting and counting, cells 
(3×104/well) were incubated with 0.3µCi [3H]-L-leucine (200 nM; Perkin Elmer) in leucine-
free RPMI media (Invitrogen) in the absence or presence of EGF or inhibitors for the required 
time at 37°C. Cells were collected, transferred to filter paper using a 96-well plate harvester 
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(MicroBeta FilterMat-96 Cell Harvester, PerkinElmer), dried, exposed to scintillation fluid and 
counts were measured using a liquid scintillation counter (PerkinElmer). 
2.6 Immunofluorescent staining 
Cells were seeded on BD FalconTM culture slides (Becton Dickinson) at a density of 1×104 
cells/well and allowed to adhere overnight. Fresh media was added, and the cells were 
incubated for 24 h before fixation using 4% (w/v) paraformaldehyde (Sigma-Aldrich) for 20 
min, and permeabilisation using 0.1% (v/v) Tween 20 in PBS (PBS-T) for 15 min. Cells were 
washed and incubated with 5% (v/v) normal goat serum in 2% (w/v) BSA/PBS for 30 min 
before addition of the LAT3 antibody (1:200 dilution in BSA/PBS) at 4°C for overnight 
incubation. The cells were washed in PBS before addition of a goat anti-rabbit IgG conjugated 
with AlexaFluor 594 (Invitrogen, A12381) for LAT3 antibody or a goat anti-mouse IgG 
conjugated with AlexaFluor 488 (Invitrogen, A12379) for pAkt antibody for 1 h at room 
temperature, and nuclear staining with DAPI (5 µg/mL, Thermo Fisher) for 5 min. After cells 
were washed in PBS for 3×5 min, coverslips were immersed in glycerol and placed on a slide. 
Stained cells will be visualised using a DeltaVision confocal microscope (GE Healthcare Life 
Science). 
2.7 Proximity ligation assay (PLA) 
Cells were seeded on coverslip which has been immersed in poly-L-lysine (Sigma, P4707) at 
a density of 5×105 cells/well and allowed to adhere overnight. Cells were incubated in serum 
free media for 30 min, followed by EGF (10 ng/μL) treatment for 30 min. The cells were fixed 
using 4% (w/v) paraformaldehyde for 20 min, and permeabilisation using PBS-T for 15 min. 
Cells were washed and incubated with 5% (v/v) normal goat serum in 5% (w/v) BSA/PBS for 
30 min before adding Blocking Solution and adding the rabbit anti-mouse LAT3 antibody 
(1:50) and mouse anti-human pAkt antibody (1:50) at 4°C overnight. For negative control, 
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mouse pAkt antibody and rabbit IgG or rabbit LAT3 antibody and mouse IgG were added 
(1:50). As a positive control, mouse pAkt and rabbit Akt antibody (1:50) were added. All 
antibodies were diluted with Antibody Diluent provided by DUOLinkTM kit (OLINK, Uppsala, 
Sweden).  
Next day, remove the primary antibody solution from the cover slip followed by washing with 
Wash Buffer A for 5 min twice. Two PLA probes were diluted in Antibody Diluent (1:5) and 
were added onto cover slip and incubated at 37℃ for 1 h. After incubation, PLA probe solution 
was removed and Ligation Stock was added after diluted in high purity water. Remove solution 
and wash the cover slip with Wash Buffer A for 5 min twice. Ligase was diluted in Solution 9 
(1:40) and added it onto cover slip to incubate at 37 ℃ for 30 min. After incubation, the 
Ligation-Ligase solution was removed and Amplification Stock was added after diluted in high 
purity water (Amplification Stock is light sensitive). Remove Amplification solution and wash 
the cover slip with Wash Buffer A for 2 min twice and add Polymerase diluted in Solution 13 
(1:80), and incubate at 37℃ for 100 min. After incubation, remove Polymerase Solution and 
wash with Wash Buffer B for 10 min twice, and then wash with 1% Wash Buffer B for 1 min. 
Keep the cover slip at room temperature in the dark until dry. Cover slip was mounted carefully 
with minimal volume of Mounting Medium with DAPI onto slide and sealed properly. The 
cover slips were visualised using a DM6000B microscope (Leica, Germany). Quantification of 
PLA signals was measured using Volocity software (Version 6.3, PerkinElmer). 
2.8 DNA manipulation 
2.8.1 Plasmid construct 
Plasmid constructs of wild type and site-specific mutant of LAT3 were subcloned into 
mammalian expressing vectors pcDNA3.1-HA and peGFP-N1. The gene encoding human 
LAT3 was amplified by PCR from the plasmid pHIV-1SDmCMVhLAT3ireseGFPpre (Wang 
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et al., 2011a, Tiffen et al., 2010) by designing oligonucleotides with restriction sites of 5’ EcoRI 
and 3’ XbaI, and subcloned into pcDNA3.1-HA vector to generate the pcDNA3.1-LAT3-HA 
construct (refer to section 2.8.2). Primer sequences used were 
tccttgaattcgccagcATGGCCCCCACGCT at 5’ and 
aaagaaTCTAGACCACTGCCTGATGCGGTCACCTCAGAGCCGC at 3’. Similarly, LAT3 
gene was amplified by PCR from the same plasmid with restriction sites of 5’ EcoRI and 
3’AgeI, and subcloned into peGFP-N1 vector to generate the LAT3-peGFP-N1 construct (refer 
to section 2.8.2). Primer sequences used were tccttgaattcgccagcATGGCCCCCACGCT at 5’ 
and AAGATAACCGGTCCGGATCCCGATGCGGTCACCTCAGAGCCG at 3’. 
Two different DNA polymerases, KAPA (KAPA HiFi PCR Kit, KAPA Biosystem) and Pfu 
(PfuUltra High-Fidelity DNA Polymerase, Agilent Technologies) were used to perform PCR to 
obtain LAT3 fragment. PCR mixture per reaction was prepared as follows:  
Table 2.3. Master mix for PCR reaction 
 KAPA Pfu 
Template DNA 1ul 2ul 
Primer forward 1ul 0.8ul 
Primer reverse 1ul 0.8ul 
H2O 15.5ul 16.4ul 
Buffer 5ul (5x) 2.5ul (10x) 
10mm DNTPs 1ul 1ul 
Polymerase 0.5ul 0.5ul 
DMSO - 1ul 
 
Make a master mix by multiplying the number of reactions. PCR was conducted with PCR 
machine (Mastercycler® nexus gradient, Eppendorf)  
PCR product was purified by Dpn1 (Invitrogen) digestion to remove template and subsequently 
checked by DNA electrophoresis. Set 1% agarose gel (0.5g in 50 mL TAE buffer) 
supplemented with 10,000× SYBR® Safe DNA gel stain (Invitrogen) with proper comb, and 
load a mixture of 2 µL PCR product, 1µL DNA loading dye (6×, Invitrogen), and 3 µL PCR 
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H2O. Electrophoresis was performed at 120V, 30 min, and visualised by gel imager (Gel Doc
TM 
XR+, Bio-Rad) to confirm the successful amplification of PCR products.  
2.8.2 Restriction enzyme digestion and Ligation 
In order to achieve successful ligation, PCR products and pcDNA3.1vector were double-
digested with restriction enzymes EcoRI and XbaI; PCR products and peGFP-N1 vector were 
double-digested with restriction enzymes EcoRI and AgeI with proper buffer at 37℃ for 2 hr. 
After restriction enzyme digestion, both vectors and PCR products were resolved by DNA 
electrophoresis. After imaging, the bands on the gel were cut at expected size of vector and 
PCR product. Then the bands containing DNA fragments were purified by gel purification kit 
(QIAquick gel extraction kit, QIAGEN).  
Enzyme digestion creates sticky ends of vector and LAT3 fragments. In the presence of ligase 
(Invitrogen) and rapid buffer (2×, Invitrogen), LAT3 fragments were inserted into pcDNA3.1 
containing HA-tag at C-terminal to create pcDNA3.1-hLAT3-HA; or into peGFP-N1 vector to 
achieve C-terminal fusion of LAT3 with eGFP. The sequence of ligated plasmid was confirmed.  
2.8.3 Bacterial transformation 
E. coli. (Escherichia coli) strain DH5α competent cells (Subcloning Efficiency™ DH5α™, 
Invitrogen) were used for plasmid transformation. Thaw DH5α cells on ice and mix 30 µL of 
competent cells with 5 µL of DNA plasmid in a pre-chilled Eppendorf tube, and incubate on 
ice for 20 min. Heat shock at 42℃ water bath for exactly 90 sec, and return to ice immediately 
to incubate another 3 min. Then add 750 µL of Lysogeny Broth (LB) media into the mixture 
in bacterial hood. The transformed cells were incubated at 37℃ for at least 1 hr with shaking 
at 220 rpm. Then spread 100 µL transformation mixture onto LB agar plates with appropriate 
antibiotics (ampicillin and kanamycin), and incubate at 37℃ inverted overnight.  
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The next day, inoculate a single transformed colony from antibiotics plates into culture tubes 
with 3 mL of LB media containing 3 µL of appropriate antibiotics (100 µg/mL of ampicillin or 
50 µg/mL of kanamycin). Shake at 220 rpm at 37℃ overnight (~16 h) to amplify the plasmid. 
The next day, bacteria were harvested for plasmid purification.  
2.8.4 Plasmid purification and glycerol stock storage 
Bacteria cells were harvested by spinning down at 5,000 rpm at 4℃ for 10 min after overnight 
culture, and LB media was aspirated. Plasmid DNA purification was performed using 
PureLinkTM Quick Plasmid Miniprep Kit (Invitrogen) or QIAGEN Plasmid Plus Midi Kit 
(QIAGEN).  
For mini prep, as per instruction of the kit, bacteria cell pellet was resuspended with 250 µL 
Resuspension Buffer (R3) with RNase A until homogenous. The bacteria cells were lysed by 
adding 250 µL Lyse Buffer (L7) and were mixed by inverting the tubes gently for multiple 
times until homogenous, and were incubated at room temperature for 5 min. Precipitation 
Buffer (N4, 350 µL) were added and mixed immediately by inverting the tubes for multiple 
times until homogenous, and centrifuge the lysate at 14,000×g for 10 min. After centrifugation, 
collect the supernatant and load onto a spin column in a 2 mL wash tube, and then spin down 
at 12,000×g for 1 min to bind DNA onto the column. Discard flow-through after centrifugation 
and wash the column with 700 µL Wash Buffer (W9) with ethanol, then centrifuge at 12,000×g 
for 1 min. Repeat the centrifugation one more time to remove all wash buffer, and place the 
column onto fresh recovery tube before adding 75 µL TE Buffer (TE) and incubate at room 
temperature for 1 min. Then elute purified DNA by centrifuging the column at 12,000×g for 2 
min.  
The quality and concentration of purified plasmid DNA was assessed by NanoDrop™ 2000C 
spectrophotometer (Thermo Fisher Scientific). Blank the spectrophotometer probe with 2 µL 
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TE buffer, and then load 2 µL of plasmid DNA. The ratio between absorbance at 260 nm and 
280 nm (A260/280 ratio) and A260/230 reflect the purity of plasmid, as A260/280 determines 
protein contamination and A260/230 determines organic contamination such as phenol, TRIzol 
etc. Pure DNA sample has A260/280 around 1.8, and A260/230 around 2.0, and it will be 
suitable for subsequent applications. Purified plasmid DNA samples could be stored at -20℃.  
For long term storage, glycerol stock was made before purification. Mix transformed bacterial 
culture with 50% glycerol (Sigma, G5516) to reach the final concentration as 75% (v/v), and 
aliquot 1 mL into cryovials to store at -80℃ until expansion is required.  
2.9 MTT cell viability assay 
Cells were seeded at the density of 1×104 per well in 96-well plate with 100µL growth media, 
and incubate at 37℃ overnight. Cells were treated with inhibitors and control with required 
concentration for required time. At the end of the time point, add 10 µL of MTT dye (10 mg/mL, 
Sigma) into 100µL media in each well, gently tap the plate to mix, and incubate at 37℃ for 4 
more hours before adding solubilisation solution (isopropanol with HCl). MTT is a yellow 
tetrazole and it would be reduced into purple coloured formazan by viable cells. Dissolve the 
formazan with solubilisation solution by pipetting up and down several times before reading 
with a plate reader (Infinite® M200 PRO, TECAN). Two wavelengths are used to measure the 
absorbance of the purple media. Wavelength of 570 nm measures the absorbance of samples 
and 630 nm is used as reference wavelength to be subtracted as background noise. The cell 
viability is calculated as below, 
% 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙 =
𝐴𝑏𝑠(𝑠𝑎𝑚𝑝𝑙𝑒) − 𝐴𝑏𝑠(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
𝐴𝑏𝑠(𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝐴𝑏𝑠(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
× 100% 
2.10 Statistical analysis 
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Data are expressed as mean ± SEM. All experiments were performed in duplicate or triplicate, 
with at least 3 replicate experiments. All experiments were analysed by two-tailed student’s t-
test or two-way ANOVA or one-way ANOVA in GraphPad Prism 6 unless otherwise specified.  
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Chapter 3. EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating 
LAT3 expression in prostate cancer 
3.1. Declarations 
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3.2.1. Abstract 
Background: Growth factors, such as EGF, activate the PI3K/Akt/mTORC1 signalling 
pathway, which regulates a distinct program of protein synthesis leading to cell growth. This 
pathway relies on mTORC1 sensing sufficient levels of intracellular amino acids, such as 
leucine, which are required for mTORC1 activation. However, it is currently unknown whether 
there is a direct link between these external growth signals and intracellular amino acid levels. 
In primary prostate cancer cells, intracellular leucine levels are regulated by L-type amino acid 
transporter 3 (LAT3/SLC43A1), and we therefore investigated whether LAT3 is regulated by 
growth factor signalling. 
Methods: To investigate how PI3K/Akt signalling regulates leucine transport, prostate cancer 
cells were treated with different PI3K/Akt inhibitors, or stable knock down of LAT3 by shRNA, 
followed by analysis of leucine uptake, western blotting, immunofluorescent staining and 
proximity ligation assay. 
Results: Inhibition of PI3K/Akt signalling significantly reduced leucine transport in LNCaP 
and PC-3 human prostate cancer cell lines, while growth factor addition significantly increased 
leucine uptake. These effects appeared to be mediated by LAT3 transport, as LAT3 knockdown 
blocked leucine uptake, and was not rescued by growth factor activation or further inhibited by 
signalling pathway inhibition. We further demonstrated that EGF significantly increased LAT3 
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protein levels when Akt was phosphorylated, and that Akt and LAT3 co-localised on the 
plasma membrane in EGF-activated LNCaP cells. These effects were likely due to stabilization 
of LAT3 protein levels on the plasma membrane, with EGF treatment preventing ubiquitin-
mediated LAT3 degradation. 
Conclusion: Growth factor-activated PI3K/Akt signalling pathway regulates leucine transport 
through LAT3 in prostate cancer cell lines. These data support a direct link between growth 
factor and amino acid uptake, providing a mechanism by which the cells rapidly coordinate 
amino acid uptake for cell growth.  
Keywords: EGF; PI3K/Akt signalling pathway; L-type amino acids transporter 3; LAT3; 
SLC43A1; Prostate cancer.  
 
Abbreviations: 
EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; PI3K: 
phosphoinositide 3 kinase; mTORC1: mechanistic target of rapamycin complex 1; MAPK: 
mitogen-activated protein kinase; PTEN: phosphatase and tensin homolog; PIP3: 
phosphatidylinositol (3,4,5)-trisphosphate; PIP2: phosphatidylinositol (3,4)-bisphosphate; 
TSC1/2: tuberous sclerosis complex 1/2; GAP: GTPase activating protein; BCAA: branched 
chain amino acid; LAT3: L-type amino acid transporter 3, SLC43A1; BCH: 2-amino-bicyclo 
[2,2,1] hepta-2-carboxylic acid; PLA: proximity ligation assay; PBS: phosphate buffered saline; 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
 
3.2.2. Introduction 
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Binding of growth factors to the extracellular ligand binding domain of their membrane-bound 
receptors leads to a conformational change of the receptors, thereby activating tyrosine or 
serine/threonine kinase domains. This activation enables the recruitment of diverse substrates, 
propagating signals that mediate a plethora of cellular activities ultimately leading to cell 
growth (Witsch et al., 2010). The uptake and metabolism of extracellular nutrients is one of the 
most critical cellular activities required to provide the building blocks and energy necessary to 
produce new cells (Hosios et al., 2016). While numerous studies have suggested that growth 
factors can regulate uptake of nutrients, whether by transporters, or by macropinocytosis, a 
direct link to transport has not yet been established (Yoshida et al., 2015, Palm et al., 2015, v 
et al., 1997). 
Growth factors and their receptors are commonly increased in a variety of cancers, with 
expression of epidermal growth factor (EGF) and its receptor (EGFR) significantly increased 
in prostate cancer (De Miguel et al., 1999). Binding of EGF to EGFR stimulates downstream 
signalling pathways including the mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3 kinase (PI3K)/Akt pathways. In addition, the PI3K/Akt signalling pathway 
is commonly activated in cancers, either through activating mutations or inactivation of the 
tumour suppressor phosphatase and tensin homolog (PTEN) (Dibble and Cantley, 2015, 
Manning and Cantley, 2007). In prostate cancer, up to 70% patients have PTEN mutation or 
deletion (Chen et al., 2005), thereby allowing unconstrained growth factor activated PI3K/Akt 
signalling, cell proliferation and tumour growth.  
The PI3K/Akt signalling axis activates mechanistic target of rapamycin complex 1 (mTORC1) 
through phosphorylation, thus negatively regulating tuberous sclerosis complex 1/2 (TSC1/2) 
formation and releasing Rheb, a GTPase activating protein (GAP), to bind to the kinase domain 
of mTORC1 on the surface of lysosomes, leading to mTORC1 activation (Long et al., 2005a). 
In addition, intracellular levels of free amino acids, in particular leucine, arginine and 
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glutamine, regulate mTORC1 activation (Wise and Thompson, 2010, Hara et al., 1998). Amino 
acids sufficiency can be sensed by mTORC1 through the interaction between Rag GTPase 
heterodimers and Ragulator on the surface of lysosomes (Han et al., 2012, Bonfils et al., 2012, 
Sheen et al., 2011, Sancak et al., 2010, Kim et al., 2008). Sestrin2 has been identified as a 
leucine sensor upstream of mTORC1 by binding with leucine which is required for mTORC1 
activation (Saxton et al., 2016, Wolfson et al., 2016). Thus, mTORC1 integrates upstream 
signalling pathways as well as amino acid availability to mediate protein synthesis, cell growth 
and proliferation.  
The supply of intracellular amino acids is mediated by amino acid transporters, which are 
commonly upregulated in cancer cells. One such transporter, LAT3, mediates uptake of large 
neutral branched chain amino acids (BCAA) including leucine. LAT3, encoded by the gene 
SLC43A1, was originally named prostate cancer overexpressed gene 1 (POV1) (Cole et al., 
1998), and was later identified as a major uniporter of leucine, isoleucine, valine, phenylalanine 
and methionine (Babu et al., 2003). Human LAT3 is predicted to contain 12 transmembrane 
(TM) domains. A long intracellular loop between transmembrane domains 6 and 7 contains 
putative serine phosphorylation sites and a tyrosine phosphorylation site (Fukuhara et al., 2007). 
LAT3 protein expression is high in primary and recurrent prostate cancer, driven by direct 
androgen receptor (AR) transcription (Wang et al., 2011a, Wang et al., 2013). Increased LAT3 
levels result in increased intracellular leucine levels and subsequent activation of mTORC1 
(Wang et al., 2013, Wang et al., 2011a). Moreover, shRNA knockdown of LAT3 blocks leucine 
uptake and cell growth in prostate cancer cell lines both in vitro (Wang et al., 2011a) and in 
vivo (Wang et al., 2013).  
Since both the growth factor-activated PI3K/Akt signalling pathway and amino acid 
transporters are required for mTORC1 activation, we investigated whether there were any 
direct links between PI3K/Akt signalling and LAT3 activity. In this study, we show that EGF-
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activated PI3K/Akt signalling directly regulates leucine transport in prostate cancer cells by 
stabilising LAT3 expression on the cell surface. These data suggest that there is a coupling of 
growth signals to amino acid uptake in prostate cancer, which may provide new avenues to 
control cancer cell growth, and should be examined across a range of transporters and cancer 
types.  
3.2.3. Materials and Methods 
3.2.3.1. Cell lines 
Human prostate cancer cell lines LNCaP-FGC and PC-3 were purchased from ATCC 
(Manassas, VA, USA). We used low passage original stocks, and confirmed LNCaP and PC-3 
cell identity by short tandem repeat profiling in 2014 (Cellbank, Australia). Cells are tested 
monthly by PCR to ensure they are free of mycoplasma contamination. Cells were cultured in 
RPMI 1640 medium (Invitrogen) containing 10% (v/v) fetal bovine serum (FBS), penicillin-
streptomycin solution (Sigma-Aldrich) and 1 mM sodium pyruvate (Invitrogen). Cells were 
maintained at 37°C in a fully humidified atmosphere containing 5% CO2.  
3.2.3.2. Leucine uptake assay 
The [3H]-L-leucine uptake was performed as detailed previously (Wang et al., 2011a). Briefly, 
cells were cultured in 6-well plates in RPMI media. After serum starvation for 2 h, cells 
(3×104/well) were incubated with 0.3 µCi [3H]-L-leucine (200 nM; PerkinElmer) in leucine-
free RPMI media (Invitrogen) in the absence or presence of EGF (10 ng/mL, Sapphire 
Bioscience) or dialysed FBS, or inhibitors, MK2206 (10 µM, Selleck Chemicals), LY294002 
(20 µM, Merck), BCH (10 mM, Sigma), rapamycin (50 nM, Merck), JPH203 (10 µM, Selleck 
Chemicals), for the required time at 37°C. Cells were collected, transferred to filter paper using 
a MicroBeta FilterMat-96 Cell Harvester (PerkinElmer), dried, exposed to scintillation fluid 
and counts were measured using a MicroBeta2 liquid scintillation counter (PerkinElmer). 
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3.2.3.3. Western blot 
Cells were seeded at a density of 5×105 in 6-well plates, allowed to adhere overnight, before 
incubation with EGF and/or inhibitors, MK2206, LY294002, BCH, rapamycin, MG132 (50 
µM, Sigma) for required time. Cells were lysed by addition of lysis buffer (200 µL) with 
Protease Inhibitor Cocktail III (Bioprocessing Biochemical) and Phosphatase Inhibitor 
Cocktail (100×, Cell Signalling Technology). Equal protein (micro-BCA method; PierceTM, 
Thermo Scientific) was loaded on 4-12% gradient SDS-PAGE gels (Invitrogen), 
electrophoresed and transferred to PVDF membrane (Millipore). The membrane was blocked 
with 2.5% (w/v) bovine serum albumin (BSA, Sigma-Aldrich) in PBS containing 0.1% (v/v) 
Tween 20 (0.1% PBS-T), and incubated with the primary antibodies overnight. The next day, 
membrane was washed with 0.1% PBS-T three times and incubated with secondary antibodies. 
After washing, the membrane was visualised by using enhanced chemiluminescence reagents 
(ECL, PierceTM, Thermo Scientific) on a Kodak Imager (Kodak) and ChemiDocTM TOUCH 
imager (Bio-Rad). Antibodies used in this study include phospho-P70S6K (Thr398, #9205, 
1:1000), P70S6K (#9202, 1000), phospho-Akt (Ser473, #4051, 1:1000), Akt (#9272, 1:1000), 
Na, K-ATPase (#3010, 1:1000) from Cell Signalling Technology (CST); ubiquitin (ab7780, 
1:1000), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, ab8245, 1:2000) from Abcam; 
mouse IgG (sc-2025, 1:1000) and rabbit IgG (sc-2027, 1:1000) from Santa Cruz. LAT3 rabbit 
polyclonal antibody was generated against a peptide (TGGKERETNEQRQ) from mouse 
LAT3 (The Institute of Medical and Veterinary Science, Adelaide, Australia) and affinity 
purified from rabbit serum (Fukuhara et al., 2007). Horseradish peroxidase (HRP)-conjugated 
donkey anti-mouse IgG (AP192P, 1:5000), and donkey anti-rabbit IgG (AP182P, 1:5000) from 
Millipore were used as secondary antibodies. Densitometry of western blots was analysed by 
ImageJ (NIH).  
3.2.3.4. Immunofluorescent staining 
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Cells were seeded on BD FalconTM culture slides (Becton Dickinson) at a density of 1×104 
cells/well and allowed to adhere overnight. Fresh media was added, and the cells were 
incubated for 24 h before fixation using 4% (w/v) paraformaldehyde (Sigma-Aldrich) for 20 
min, and permeabilisation using 0.1% PBS-T for 15 min. Cells were washed and incubated 
with 5% (v/v) normal goat serum in 2% (w/v) BSA/PBS for 30 min before addition of the 
LAT3 antibody at 4°C for overnight incubation. The cells were washed in PBS before addition 
of a goat anti-rabbit IgG conjugated with AlexaFluor 594 (Invitrogen, A12381) for LAT3 
antibody or a goat anti-mouse IgG conjugated with AlexaFluor 488 (Invitrogen, A12379) for 
pAkt antibody for 1 h at room temperature, and nuclear staining with DAPI (5 µg/mL, Thermo 
Fisher) for 5 min. Cells were washed in PBS, and coverslips were immersed in glycerol and 
placed on a slide, and visualised using a DeltaVision confocal microscope (GE Healthcare Life 
Science).  
3.2.3.5. Proximity ligation assay (PLA) 
Cells were seeded on coverslip which has been immersed in poly-L-lysine (Sigma, P4707) at 
a density of 5×105 cells/well and allowed to adhere overnight. Cells were incubated in serum 
free media for 30 min, followed by EGF (10 ng/μL) treatment for 30 min. The cells were fixed 
using 4% (w/v) paraformaldehyde for 20 min, and permeabilisation using 0.1% PBS-T for 15 
min. Cells were washed and incubated with 5% (v/v) normal goat serum in 5% (w/v) BSA/PBS 
for 30 min before addition of the rabbit LAT3 antibody (1:50) and mouse pAkt antibody (1:50) 
at 4°C overnight. For negative control, mouse pAkt antibody and rabbit IgG or rabbit LAT3 
antibody and mouse IgG were added (1:50). As a positive control, pAkt and Akt antibody (1:50) 
were added.  PLA was performed using the DUOlinkTM kit (OLINK, Uppsala, Sweden) 
following the manufacturer’s instruction. The cells were visualised using a DM6000B 
microscope (Leica, Germany). Quantification of PLA signals was measured using Volocity 
software (Version 6.3, PerkinElmer). 
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3.2.3.6. Cell surface protein isolation 
LNCaP cells were cultured in T75 flasks with RPMI 1640 medium containing 10% FBS, 
penicillin-streptomycin solution and 1 mM sodium pyruvate to reach 90-95% confluence. 
LNCaP cells were incubated with serum free media for 2 h, followed by EGF (10 ng/μL) 
treatment for 30 min. Surface protein isolation was performed using the PierceTM Cell Surface 
Protein Isolation Kit (Thermo Scientific) following the manufacturer’s instructions. Briefly, 
cells were biotin-labelled, harvested, and lysed, and NeutrAvidin resin was used to isolate the 
protein. Protein was eluted with SDS-PAGE sample buffer (NuPAGETM Life Technologies) 
containing 50 mM 1,4-dithiothreitol (DTT, Sigma-Aldrich). The eluate was analysed by SDS-
PAGE and western blot. 
3.2.3.7. Immunoprecipitation 
LNCaP cells were seeded at a density of 5 × 105 in 6-well plates and allowed to adhere 
overnight. The next day, cells were pre-treated with MK2206 or MG132 (50 µM, Merck) in 
serum free RPMI 1640 media for 30 min, before addition of EGF (10 ng/μL) to each well for 
30 min. Cells were lysed by addition of lysis buffer with Protease Inhibitor Cocktail III and 
Phosphatase Inhibitor Cocktail. Protein concentration of cell lysates was determined by the 
micro-BCA method. Cell lysates were incubated with magnetic protein A/G beads 
(SurebeadsTM Bio-Rad) coupled with LAT3 antibody or rabbit IgG at 4°C overnight.  Protein-
bound beads were washed with E1A buffer (50 mM HEPES, 150 mM NaCl, 0.1% NP-40, 1 
mM Na3VO4) three times. Protein was eluted with sample buffer (NuPAGE
TM, Life 
Technologies) containing 0.1 M DTT, heated at 85°C for 5 min, before SDS-PAGE and 
western blot.  
3.2.3.8. Knockdown of LAT3 in LNCaP cells 
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LAT3 shRNA knockdown was performed as previously described (Wang et al., 2011a). Briefly, 
empty vector pLKO.1 or containing short hairpin (shRNA) targeting LAT3 
(CCGGCAAATCCATCAGACCACGCTACTCGAGTAGCGTGGTCTGATGGATTTGTT
TTTG) was mixed with pMDLg/prre, pRSVRev and pMD2.VSV-G packaging plasmids and 
the calcium phosphate precipitation method used to transfect 70% confluent HEK293T cells 
(Wang et al., 2011a). After 8 h, the media was changed, and viral supernatant was collected 
and filtered 24 h later. The viral supernatant was used to transduce 70% confluent LNCaP with 
8 µg/mL polybrene. After 2 days, transduced cells were selected by 10 µg/mL puromycin for 
7 days. Expression of the LAT3 protein was determined using SDS-PAGE and western blot as 
described above.  
 
3.2.3.9. Statistical analysis 
Data are shown as mean ± SEM. All experiments were performed with at least 3 biological 
replicates. All experiments were analysed by two-tailed student’s t-test or two-way ANOVA 
or one-way ANOVA in GraphPad Prism 6. 
 
3.2.4. PI3K/Akt signalling pathway regulates leucine transport 
To model the effects of growth factors on prostate cancer, we utilised the androgen-sensitive 
prostate adenocarcinoma cell line LNCaP, which contains one deleted allele and one mutated 
allele of PTEN (Vlietstra et al., 1998), and the androgen-insensitive cell line PC-3, which has 
a homozygous deletion of PTEN (Vlietstra et al., 1998, McMenamin et al., 1999), leading to 
the hyperactivation of the PI3K/Akt pathway. Leucine uptake is predominantly mediated by 
LAT3 in LNCaP cells, while PC-3 cells rely on both LAT3 and LAT1 (SLC7A5) for leucine 
uptake (Wang et al., 2011a). To investigate how PI3K/Akt signalling affects LAT3-mediated 
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leucine uptake in the presence of serum, we utilised a PI3K inhibitor LY294002, an Akt 
inhibitor MK2206, an L-type amino acid transporter inhibitor BCH and a LAT1 selective 
inhibitor JPH203 (Kanai et al., 1998b, Wempe et al., 2012, Toyoshima et al., 2013, Yun et al., 
2014). In LNCaP cells, leucine transport was inhibited to 59% of control in the presence of 
LY294002, 67% of control with MK2206 and 54% of control with JPH203, whereas BCH 
reduced leucine uptake to 24% of control (Figure 3.1A). In PC-3 cells, the leucine transport 
was reduced to 81% of control by LY294002, and 94% by MK2206, which exhibited less 
inhibitory effect compared to BCH (12% of control) and JPH203 (6% of control; Figure 3.1B), 
consistent with the dominant role of LAT1 in mediating leucine uptake in PC-3 cells (Wang et 
al., 2011a). Western blots showed that both LY294002 and MK2206 reduced Akt 
phosphorylation (pS473-Akt) in LNCaP and PC-3 cells after 30 min treatment. The LAT 
inhibitors, BCH and JPH203, had no effect on Akt phosphorylation (Figure 3.1C and 3.1D). 
These results suggest that PI3K/Akt signalling pathway regulates leucine uptake, which is more 
likely through LAT3 rather than LAT1. 
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Figure 3.1. Leucine transport is regulated by PI3K/Akt signalling. A and B, leucine transport 
was examined in the presence of LY294002, MK2206, BCH and JPH203 in LNCaP (A) and 
PC-3 cells (B). One-way ANOVA was performed. Data are the mean ± SEM, n=4. C and D, 
Akt activation was examined in the presence of LY294002, MK2206, BCH and JPH203 in 
LNCaP (C) and PC-3 cells (D) by western blot. GAPDH was used as the loading control. All 
western blot images are representative of three independent experiments. 
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3.2.5. LAT3 is required for PI3K/Akt regulated leucine uptake 
To determine if LAT3 is the target of PI3K/Akt signalling, we used shRNA to knock down 
LAT3 expression in LNCaP cells, which have higher LAT3 expression compared to PC-3 cells 
(Wang et al., 2011a). Western blots showed that LAT3 expression levels were decreased in 
LNCaP shLAT3 compared to shControl (Figure 3.2A). Leucine uptake assays were performed 
in both LNCaP shControl and shLAT3 cells. RPMI media supplemented with dialysed FBS 
was used as control, and was compared to serum-free media, or addition of MK2206 or BCH. 
Dialysed FBS contains normal level of growth factors but low level of amino acids. In 
shControl cells, leucine uptake was reduced to 79.6% of control in the absence of serum, and 
MK2206 decreased leucine uptake to similar level, 72.7% of control. Meanwhile, BCH 
inhibited leucine uptake further down to 41.1% of control. Under the same conditions, 
knockdown of LAT3 in LNCaP cells showed a significant reduction in leucine uptake 
compared to shControl cells, with only 16.3% of control (Figure 3.2B), suggesting that LAT3 
has been efficiently knocked down in LNCaP cells. Serum depletion and inhibition by MK2206 
for shLAT3 cells showed no significant difference in leucine uptake compared to control 
(Figure 3.2B), indicating that signalling pathway activates leucine uptake in a LAT3 dependent 
manner. BCH treatment decreased leucine uptake down to 10.2% of control (Figure 3.2B), 
likely via inhibition of LAT1.  
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Figure 3.2. LAT3 is required for PI3K/Akt stimulated leucine uptake. A, LAT3 expression 
levels were examined by western blot in shControl and shLAT3 of LNCaP cells. B, leucine 
uptake was examined in RPMI supplemented with or without dialysed FBS, MK2206 or BCH, 
in both shControl and shLAT3 of LNCaP cells. Two-way ANOVA was performed. Data are 
the mean ± SEM, n=3. All western blot images are representative of three independent 
experiments. 
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3.2.6. EGF stimulation regulates leucine uptake via LAT3 
To specifically test whether EGF mediates activation of PI3K/Akt signalling pathway and 
leucine uptake, EGF treatment was carried out on LNCaP and PC-3 cells. EGF stimulation for 
5 min, 15 min and 30 min significantly increased LNCaP cells by 30.3%, 33.7% and 79.0%, 
respectively (Figure 3.3A). In PC-3 cells, there was no change in leucine uptake at either 5 or 
15 min post EGF, however, there was a significant increase after 30 min (Figure 3.3B). To 
determine whether this corresponded with downstream activation of signalling from the EGF 
receptor, we next examined the level of phosphorylated Akt (pS473-Akt) over the same time 
course. In LNCaP cells, Akt phosphorylation increased by 5 min, and remained at similar levels 
between 15 min and 30 min (Figure 3.3C). PC-3 cells also rapidly increased Akt 
phosphorylation at 5 min, however, this phosphorylation was downregulated by 15 and 30 min 
post stimulation (Figure 3.3D).   
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Figure 3.3. EGF stimulation increases leucine uptake and LAT3 protein levels. A and B, 
leucine uptake was examined 5, 15 or 30 mins after EGF stimulation of LNCaP (A) or PC-3 
cells (B). Two-tailed student’s t-test was performed. Data are the mean ± SEM, n=4. C and D, 
the phosphorylation of Akt was examined 5, 15 or 30 mins after EGF stimulation of LNCaP 
(C) or PC-3 cells (D). GAPDH was used as loading control. All western blot images are 
representative of three independent experiments.  
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3.2.7. Leucine transport is dependent on EGF-activated PI3K/Akt signalling 
EGF stimulates the PI3K/Akt signalling pathway, subsequently activating mTORC1 signalling 
and driving protein synthesis. To determine which kinase in the PI3K/Akt/mTORC1 pathway 
axis was involved, we tested a PI3K inhibitor, LY294002, and an mTORC1 inhibitor, 
rapamycin, in combination with EGF treatment. As expected, 30 min pre-incubation with 
LY294002 blocked the activation of both Akt and downstream P70S6K (Figure 3.4A and 3.4B) 
signalling, while rapamycin treatment decreased phosphorylation of P70S6K (Figure 3.4A and 
3.4B), but had no effect on upstream Akt phosphorylation. In addition, while LY294002 
treatment significantly reduced leucine transport in both LNCaP and PC-3 cells (Figure 3.4C 
and 3.4D), rapamycin showed no effect on leucine uptake in either cell line (Figure 3.4C and 
3.4D). These data suggest that the PI3K/Akt signalling pathway can regulate leucine transport, 
and this occurs upstream of mTORC1 signalling. 
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Figure 3.4. Leucine transport is dependent on EGF-stimulated PI3K/Akt signalling. A and B, 
Akt and P70S6K activation was examined in the presence of rapamycin and LY294002 in 
LNCaP (A) or PC-3 cells (B). GAPDH was used as loading control. C and D, leucine transport 
was examined in the presence of rapamycin or LY294002 in LNCaP (C) and PC-3 cells (D). 
Two-tailed student’s t-test was performed. Data are the mean ± SEM, n=3. All western blot 
images are representative of three independent experiments. 
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3.2.8. EGF stimulation promotes co-localisation of LAT3 with pAkt  
To determine the relationship of PI3K/Akt signalling and LAT3, we examined the co-
localisation of phosphorylated Akt and LAT3 using confocal microscopy in LNCaP, as LAT3 
is highly expressed in LNCaP cells but not in PC-3 cells. LAT3 was strongly expressed at the 
plasma membrane of cells that were in contact with the extracellular environment, but showed 
lower expression in areas of cell-cell contact (Figure 3.5A). By contrast, pAkt was detected in 
the majority of the plasma membrane of LNCaP cells (Figure 3.5A). The merged image showed 
a number of areas of co-localisation of LAT3 and pAkt (Figure 3.5A, arrows), as well as 
distinct areas of single staining of each protein/phosphoprotein.  
To confirm these confocal microscopy data, we next performed a proximity ligation assay 
(PLA) to determine whether pAkt and LAT3 were closely associated in LNCaP cells. We 
treated cells with or without EGF and detect the PLA signals using LAT3 and pAkt antibodies. 
PLA signal generated by rabbit LAT3 and mouse pAkt in the absence of EGF was significantly 
less than EGF stimulated signal (Figure 3.5B). We set up two groups of negative controls: 
rabbit IgG with mouse pAkt, and rabbit LAT3 with mouse IgG, which showed a basal level of 
PLA signals (Figure 3.5C). In comparison with the positive control, mouse pAkt and rabbit 
Akt, where these two antibodies bound to the same target, result in high level of signals (Figure 
3.5B). PLA signals were quantified with Volocity (Version 6.3, Quorum Technologies) and 
presented as signals per cell (Figure 3.5C). EGF treatment in LNCaP cells dramatically 
enhanced the PLA signals of LAT3 and pAkt, leading to more than 4-fold change (Figure 3.5C), 
indicating that EGF enhanced the co-localisation of phosphorylated Akt and LAT3.  Given the 
fact that PLA resolution is within 3-6 Å, pAkt and LAT3 were in close proximity. Since LAT3 
lack the binding motif of Akt (RxRxxS/T), we speculate that phosphorylated Akt and LAT3 
may form a multi-protein complex in response to the extracellular signals, leading to 
upregulation of amino acid uptake required for cell division.  
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Figure 3.5. Co-localisation of LAT3 and pAkt in prostate cancer. A, co-localisation of LAT3 
and pAkt was examined in LNCaP cells in the presence of EGF. Scale bar = 10 µm. B, PLA 
signals were examined in the pair of LAT3 and pAkt (Control), LAT3 and pAkt with EGF 
(EGF), pAkt and rabbit-IgG (r-IgG), pAkt and Akt, and mouse-IgG (m-IgG) and LAT3. Scale 
bar = 50 µm. C, quantification of PLA signals of each pair in LNCaP cells was measured using 
Volocity software (Version 6.3, PerkinElmer). One-way ANOVA was performed. Data are the 
mean ± SEM, n=4. 
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3.2.9. EGF stimulation enhanced surface expression of LAT3  
To determine the mechanism of PI3K/Akt regulated leucine transport, we examined LAT3 and 
LAT1 expression by western blots in the presence of EGF. LAT3 protein levels were elevated 
within 5 min of EGF treatment and maintained for 30 min in LNCaP cells (Figure 3.6A). In 
PC-3 cells, LAT3 protein levels increased at 15 min and maintained this increase for 30 min 
(Figure 3.6B), indicating that EGF-induced leucine uptake may result from upregulated LAT3 
surface expression. This late elevation of LAT3 in PC-3 cells might explain why changes in 
leucine uptake are delayed, although this may also be due to physical differences in the analysis 
of adherent (western blot) and suspension (uptake assay) cells (Figure 3.3B). As LAT1 is the 
major transporter in PC-3 cells, we examined LAT1 expression after EGF treatment. LAT1 
protein levels did not change after 30 min EGF treatment, suggesting that LAT1 is not involved 
in the EGF-stimulated upregulation of leucine transport (Supplementary Figure 1A). To 
confirm this, we next examined EGF stimulation of leucine transport in the presence of the 
LAT1 inhibitor JPH203 (Supplementary Figure 1B). Despite blocking LAT1-mediated leucine 
transport, JPH203 had no effect on the EGF-stimulated leucine uptake, confirming that LAT1 
does not play a role in EGF stimulation of PC-3 cells. Importantly, the Akt inhibitor MK2206 
suppressed Akt phosphorylation as well as LAT3 expression even in the presence of EGF in 
LNCaP and PC-3 cells (Figure 3.6C and 3.6D), suggesting EGF-activated Akt is required for 
increased LAT3 expression.  
Since LAT3 needs to be stabilised at the plasma membrane to fulfil its transport function, the 
expression level at cell surface is critical in response to EGF stimulation. Cell surface proteins 
were isolated and LAT3 was examined by western blot in the presence or absence of EGF. 
After 30 min treatment with EGF, LAT3 expression was increased 1.7-fold at the plasma 
membrane compared to control (Figure 3.6E and Supplementary Figure 1C), suggesting that 
LAT3 levels were increased at the cell surface. To determine whether EGF treatment affects 
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either LAT3 synthesis or LAT3 degradation, we next treated EGF-stimulated cells with 
MK2206 or a proteasome inhibitor MG132, which reduces the ubiquitin-conjugated 
degradation of protein in proteasome. After 30 min MG132 and MK2206 treatment, 
ubiquitinated LAT3 (~90 kDa) was increased 1.5-fold and 1.8-fold in the anti-LAT3 
immunoprecipitates respectively (Figure 3.6F). In addition, we showed that ubiquitinated 
LAT3 (~90 kDa) is decreased after EGF treatment in both LNCaP and PC-3 cells 
(Supplementary Figure 1D and 1E). After MG132 treatment, unmodified LAT3 protein levels 
(~55 kDa) are increased compared to control (Supplementary Figure 1F). These results suggest 
that inhibition of EGF-activated PI3K/Akt signalling may induce ubiquitin-mediated 
degradation of LAT3. 
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Figure 3.6. EGF treatment increases LAT3 expression on the plasma membrane. A and B, 
LAT3 expression levels were examined 5, 15 or 30 min after EGF stimulation of LNCaP (A) 
or PC-3 cells (B). C and D, LAT3 and Akt expression levels were examined in the presence or 
absence of MK2206 in combination with EGF in LNCaP (C) or PC-3 cells (D). GAPDH was 
used as loading control. E, LAT3 protein levels were examined in the absence or presence of 
EGF in LNCaP cells by cell surface protein isolation; Na, K-ATPase was used as loading 
control. GAPDH was used to confirm cell surface fraction purity. F, Ubiquitin and LAT3 were 
examined after immunoprecipitation with isotype IgG or anti-LAT3 IgG in the presence or 
absence of MK2206 or MG132 with EGF stimulation in LNCaP cells. Input of cell lysates pre-
immunoprecipitation was examined using LAT3 and GAPDH antibodies. Ratio of IB: 
ubiquitin expression level is shown relative to Input: LAT3. All western blot images are 
representative of three independent experiments.   
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3.2.10. Discussion 
Rapidly proliferating cancer cells require sustained growth factor stimulation and more nutrient 
supply for protein synthesis and cell mass accumulation (Hosios et al., 2016). Growth factors, 
such as EGF, activate multiple downstream signalling pathways and have an important role in 
cancer progression, including proliferation, invasion and migration (Russell et al., 1998). Its 
downstream PI3K/Akt signalling, and amino acids are required for mTORC1 to regulate 
protein synthesis. In this study, we reported that EGF-activated PI3K/Akt signalling pathway 
regulates leucine uptake through the amino acid transporter LAT3 in prostate cancer. 
Cells have many ways of uptaking nutrients that are available in the extracellular matrix, such 
as transporter-based nutrient uptake, receptor-mediated endocytosis, macropinocytosis, as well 
as entosis (Palm and Thompson, 2017). The transport of majority extracellular amino acids 
relies on their membrane-bound transporters due to their hydrophilicity, and the expression of 
transporters is highly upregulated in many cancer types, such as Alanine-Serine-Cysteine 
Transporter 2 (ASCT2/SLC1A5) in triple negative breast cancer, prostate cancer and 
melanoma (van Geldermalsen et al., 2016, Wang et al., 2014a, Wang et al., 2015a), LAT1 
(SLC7A5) in endometrial cancer (Marshall et al., 2016), ATB0,+ (SLC6A14) in colorectal 
cancer (Gupta et al., 2005), xCT (SLC7A11) in glioma (Lyons et al., 2007). Growth factor 
signalling pathways play an instructive role in regulating nutrient transporters via PI3K/Akt, 
which induces the phosphorylation and translocation of glucose transporter 1 (GLUT1) to cell 
surface to increase glucose uptake upon growth factor stimulation (Wieman et al., 2007, Lee 
et al., 2015). PI3K/Akt signalling also affects transcription factor MYC, which induces the 
expression of glutamine transporters ASCT2 and SNAT5 and promotes glutaminolysis to 
provide glutamine carbon for the TCA cycle in response to growth factor (Wise et al., 2008, 
Gao et al., 2009). A recent study has shown that active MYC could preferentially upregulate 
LAT3 among many other SLC transporters in neuroblastoma cells, and that inhibition of LAT3 
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would in turn downregulate MYC mRNA levels (Yue et al., 2017). In this study, we have 
observed that total and surface LAT3 protein levels are increased within 5-30 minutes after 
EGF stimulation. When LAT3 is knocked down in LNCaP cells, leucine transport becomes 
less sensitive to the stimulation or inhibition of the signalling pathway. Importantly, 
ubiquitinated LAT3 levels are increased after inhibition PI3K/Akt signalling, suggesting that 
EGF-activated PI3K/Akt signalling may affect the protein stabilisation or translocation of the 
LAT3 to maintain its activity, therefore regulating leucine uptake. Activated Akt has been 
shown to be able to maintain the surface expression of other transporters (Edinger and 
Thompson, 2002), which is consistent with what we observed in this study.  
Akt, as a major effector in PI3K/Akt signalling axis, has an important role in activating 
mTORC1 signalling. Recent studies have shown that inhibition of mTORC1 signalling 
increases ubiquitin ligase Nedd4-2 expression, therefore upregulating ubiquitination of SNAT2 
and LAT1 transporters in primary human trophoblast cells (Rosario et al., 2016). However, our 
data clearly show that LAT3-mediated leucine transport does not rely on downstream 
mTORC1 signalling, but instead is regulated by Akt or other upstream molecules. Akt contains 
a Pleckstrin homology (PH) domain which binds to phosphoinositides on the plasma membrane 
(Datta et al., 1995), thereby allowing it to phosphorylate several multi-transmembrane proteins, 
such as G protein coupled receptor EDG-1 (Lee et al., 2001), and Na+/H+ exchanger SLC9A1 
(NHE1) (Snabaitis et al., 2008). Our data showed that phosphorylated Akt co-located with 
LAT3 on the plasma membrane of LNCaP cells. Although mass spectrometry data have shown 
that LAT3 possesses multiple phosphorylation sites at Y251, S262, S267, and S277, and two 
ubiquitination sites at K244 and K264 within its transmembrane domains (Zhou et al., 2013a, 
Phanstiel et al., 2011, Wilson-Grady et al., 2013), we have no direct evidence to show that Akt 
binds and phosphorylates LAT3 directly. It is possible that LAT3 and Akt are part of a larger 
membrane-localised protein complex formed after EGF stimulation. Subsequent Akt activation 
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in that complex may induce another kinase to phosphorylate LAT3 at residues S262 or S267. 
This may then inhibit K264 ubiquitination, thus permitting LAT3 stabilisation at the plasma 
membrane.  
Our study emphasises a central role of growth factor activated PI3K/Akt signalling in response 
to environment changes. With growth factor stimulation, PI3K/Akt signalling increased 
stabilisation of the LAT3 transporter and its localisation on the plasma membrane, thereby 
enhancing leucine transport. Elevated intracellular levels of leucine are then available for 
mTORC1 signalling activated by PI3K/Akt signalling. With a low growth factor-stimulation, 
our data suggest that more LAT3 will be degraded and less proteins recycled to the plasma 
membrane, resulting in decreased leucine transport and protein synthesis. This would be an 
economic strategy for cells, while still allowing rapid upregulation of leucine transport upon 
growth factor stimulation.  
This is the first study to show that growth factor-activated PI3K/Akt signalling pathway 
regulates leucine transport through LAT3 in prostate cancer cell lines. These data support a 
direct link between growth factor and amino acid uptake, providing a mechanism by which the 
cells rapidly coordinate amino acid uptake for cell growth. Previous studies have shown that 
LAT3 protein expression is increased in the primary and recurrent prostate cancer patient 
samples and regulates cancer cell growth (Wang et al., 2013, Wang et al., 2011a). In addition, 
LAT3 is expressed in liver, pancreas and muscle cells (Fukuhara et al., 2007). Leucine is 
critical for insulin secretion in pancreatic β cells (Yang et al., 2006a). LAT3 is also important 
for podocyte development and function in kidney (Sekine et al., 2009). Therefore, our study on 
the regulatory mechanisms of LAT3 is important for understanding the metabolism of leucine 
across many systems, and potentially for developing novel cancer therapies targeting the LAT3 
transporter.  
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Chapter 4. Incorporation of unnatural amino acid AzF into LAT3, and analysis of 
interacting proteins by mass spectrometry  
4.1. Introduction 
In order to further investigate the proteins that interact and regulate the function and expression 
of LAT3, we collaborated with Dr Shixin Ye from Institut de Biologie de l'École Normale 
Supérieure (IBENS) in Paris, France, to implement a novel genetic code expansion (GCE) 
methodology. GCE has been widely used to identify protein-protein interactions, as 
introducing particular unnatural amino acids (Uaas) with various physical, chemical properties 
into protein of interest gives rise to new means to study structure-function of proteins.  
In this chapter, we introduced an Uaa, p-azido-L-phenylalanine (AzF), into LAT3 by GCE 
method. AzF is modified from tyrosine, with an azido moiety that is photo-crosslinkable under 
UV excitation. This property can facilitate in trapping and seizing transient protein-protein 
interaction. Then, we conducted mass spectrometry studies to investigate the protein complexes 
formed by photo-crosslinking with LAT3-AzF. We used different methods to purify the protein 
complex and analysed by mass spectrometry to identify potential regulator(s) or interactor(s) 
of LAT3. 
4.1.1. Unnatural amino acids (Uaas) 
There are 20 canonical amino acids in all organisms that are used as building blocks for proteins, 
and different combinations of these amino acids sequences give rise to a large variety of 
proteins that possess various functions (Liu and Schultz, 2010). However, proteins require a 
higher degree of chemical complexity to fulfil their functions, such as through post-
translational modifications (PTMs) and enzymatic activities on cofactors (Young and Schultz, 
2010). All these events introduce additional functional groups onto the side chain of amino 
acids or catalyse the side chain to conduct chemical reactions with other molecules. Therefore, 
introducing a particular reacting group and specific properties into amino acids is achievable 
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and useful. And incorporating modified amino acids in the process of protein translation 
provides extra tools for research, enabling the functional and structural study of a particular 
residue in the protein sequence, and capturing protein-protein interactions under particular 
conditions with introduced probes (Liu and Schultz, 2010). As a result, a great number of 
unnatural amino acids have been developed through chemical approaches with all kinds of 
properties that are absent from canonical amino acids (Wang et al., 2006b). Approximately 70 
Uaas (Figure 4.1) have been incorporated into the genetic codes of Escherichia coli, yeast, and 
mammalian cells (Liu and Schultz, 2010).  
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Figure 4.1. Chemical structures of unnatural amino acids encoded into proteins (Young and 
Schultz, 2010, Liu and Schultz, 2010). 
  
94 
 
4.1.2. Incorporation of Uaas with orthogonal pair of transfer RNA and aminoacyl-
tRNA synthetase 
As transfer RNA (tRNA) contains an anti-codon that complements a codon in an mRNA, it 
delivers required amino acid to the ribosome where protein is synthesised. A codon is made 
from 4 types of nucleotides, including adenine, uracil, cytosine and guanine, which gives rise 
to 64 combinations of codons. Among 64 codons, 61 codons encode 20 proteinogenic amino 
acids, and leaving three codons (UAG, amber; UAA, ochre; UGA, opal) as translational stops. 
Researchers (Noren et al., 1989) have utilised the redundancy of these “blank” stop codons 
along with the ribosomal biosynthesis machinery to incorporate unnatural amino acids into 
proteins in vitro in a site-specific manner, in response to the amber stop codon. This was firstly 
achieved by chemically aminoacylating a nonsense suppressor tRNA, such as tRNACUA, the 
amber suppressor tRNA, with the desired Uaa and subsequently adding the aminoacyl-tRNA 
to a cell-free transcription/translation system to express the gene of interest containing a TAG 
mutation at the target site (Mendel et al., 1995, Martin and Schultz, 1999). This method was 
later extended to incorporate a great many Uaas with various structures and properties. But, the 
yield of protein expressed from cell-free systems are relatively low and the process of 
generation of aminoacyl-tRNA is relatively complex (Wang et al., 2006b). 
Another approach used in living cells is through wild-type aaRS to incorporate Uaas that are 
structural analogues of canonical amino acids (Link et al., 2003, Hendrickson et al., 2004).  A 
strain of the auxotrophic for one canonical amino acid is used to replace this amino acid with 
its Uaa analogue. As a result, the canonical amino acid at all sites is replaced by the Uaa, and 
the newly synthesised protein has efficiently incorporated the Uaa at all sites. This method has 
been used to substitute of methionine with selenomethionine so that a heavy atom can be 
incorporated into proteins for crystallographic phasing experiments (Yang et al., 1990, Liu and 
Schultz, 2010). However, this method is residue-specific rather than site-specific, resulting in 
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unsustainable cell proliferation. Furthermore, it is limited with Uaas that are only structurally 
close to canonical amino acids. 
In order to better control the structure and function of protein by incorporation of Uaas both in 
vitro and in living cells in a site-specific manner, protein translation machinery is used to 
genetically synthesise protein with Uaas. By site-directed mutagenesis, the DNA sequence of 
the protein of interest can be modified to one of blank codons, thus translating to the protein 
with desired Uaa.  
Protein translation is a complex biological process in which mRNAs are used as templates for 
the assembly of amino acids into a polypeptide chain through tRNA. As an adapter molecule, 
tRNA serves as the physical link between mRNA and amino acid sequence of protein. Amino 
acids are specifically loaded onto each isoacceptor tRNA (iso-tRNA) set by aminoacyl-tRNA 
synthetase (aaRS), which is specific to its corresponding amino acid substrate as well as its 
own unique set of iso-tRNA (Giege et al., 1998, Ibba and Soll, 2000, Ibba and Soll, 2004). This 
gives an orthogonal pair of tRNA and its aaRS, which means that each aaRS will only recognise 
its cognate amino acid and iso-tRNA set, and the tRNA will only be catalysed by its cognate 
aaRS and charged by specific amino acid (Chin, 2006).  
Based on this template-directed biosynthesis machinery and the orthogonality of the pair, 
introducing an engineered orthogonal pair of tRNA and cognate aaRS could effectively 
incorporate a Uaa into synthesised protein with high fidelity as a canonical amino acid. The 
new tRNA must have the proper anticodon to recognise a blank codon (nonsense, frameshift, 
or otherwise unused) in mRNA (Liu and Schultz, 2010). For example, the anticodon of tRNA 
that recognises amber stop codon (UAG) is tRNACUA (it reads from 5’ of tRNA to 3’ of mRNA), 
and it suppresses this stop codon. After being aminoacylated by engineered aaRS, tRNA is 
loaded with desired Uaa and subsequently brings the Uaa to the ribosome and participates in 
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peptide synthesis (Figure 4.2). It requires the orthogonality of tRNA and aaRS, as the tRNA 
must not be aminoacylated by endogenous synthetase and the orthogonal aaRS must only take 
the desired UAA as a substrate and load it onto the tRNA. Furthermore, the Uaa must be able 
to be delivered efficiently into the cytoplasm when supplemented in the growth medium, and 
remain stable in the presence of endogenous metabolic enzymes, and most important, not 
recognisable to endogenous tRNA and aaRS pair.  
However, it is challenging to fulfil the orthogonality as well as the specificity to a particular 
Uaa of the tRNA and aaRS pair. Encoding Uaas into different species and strict selection 
strategies have been explored.  
A heterologous aaRS/tRNA pair from archaea, such as Methanocaldococcus jannaschii 
(MjTyrRS/MjtRNATyr), was transformed in E. coli, with the anticodon of tRNA being mutated 
to suppress the blank codon tRNASB (tRNA that suppresses blank codon).  Since the amber 
stop codon (UAG) is the least used stop codon in E. coli (Young and Schultz, 2010), it was 
reassigned to a Uaa that would have minimal impact on the native proteome when amber stop 
codon was suppressed. A library of mutant was generated based on tRNASB, and was 
transformed into E. coli cells containing toxic barnase gene with an amber codon at permissive 
sites for selection. Only the clones with mutant tRNASBs that cannot be aminoacylated by 
endogenous aaRSs would survive. These tRNASBs were subsequently transformed into E. coli 
cells that harbour a β-lactamase gene with an amber codon at a permissive site in the presence 
of heterologous aaRS. During this selection step, ampicillin in the growth media would kill all 
clones with non-functional tRNASB, and tRNASB that can be recognised by the heterologous 
aaRS would survive. Therefore, this heterologous aaRS/tRNASB pair is highly orthogonal and 
functional in E. coli after selection.  
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Figure 4.2. Genetic code expansion methodology - incorporation of unnatural amino acid (Uaa) 
into target protein, adapted from (Lehmann, 2006). Blue represents endogenous tRNA 
synthetase (aaRS), tRNA, natural amino acid, and ribosome; Red represents exogenously 
added orthogonal aaRS, suppressor tRNA and the Uaa; Before entering ribosome, an amber 
stop codon on the mRNA is read through by a suppressor tRNA aminoacylated with a desired 
Uaa; A poly-peptide is synthesised with a particular Uaa at a specific site. 
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The specificity of the heterologous aaRS/tRNA needs to be altered to uniquely recognise a 
desired Uaa. A similar two-step selection process was used to achieve this. A large library of 
randomised residues in the amino acid-biding site of aaRS was constructed based on the 
available crystal structure (Wang et al., 2001). In the first step, all mutant aaRSs were 
transformed into E. coli cells expressing tRNASB and harbouring a chloramphenicol 
acetyltransferase (CAT) gene with an amber mutation at a permissive site. The cells were 
grown with chloramphenicol and the Uaa of interest. This positive selection step narrowed 
down the aaRS mutants with the ability to aminoacylate tRNASB with either endogenous amino 
acids or unnatural amino acid. In the second step, it was set out to select against mutants that 
could aminoacylate tRNASB with endogenous amino acids (Anderson and Schultz, 2003). All 
surviving aaRSs and tRNASB were transformed into E. coli that contains the toxic barnase gene 
with amber mutant at permissive sites. The cells were grown in the absence of Uaa of interest. 
As a result, this negative selection eliminated the clones with mutant aaRSs that aminoacylate 
endogenous amino acid, and the mutant aaRSs that can aminoacylate tRNASB with Uaa would 
survive (Wang et al., 2001). In general, this two-step selection needs to be repeated for two to 
three additional rounds to produce a Uaa-specific mutant aaRS (UaaRS). Through this stringent 
selection, over 30 Uaas with distinct structures and properties have been successfully encoded 
into E. coli through amber stop codon with orthogonal UaaRS/tRNA pairs derived from 
MjTyrRS/MjtRNATyr in a Uaa specific manner (Wang et al., 2006b). 
Mammalian cells have relatively low transformation efficiency, slow doubling time and 
complicated growth conditions (Liu and Schultz, 2010, Young and Schultz, 2010). Thus, the 
two-step selection strategy is not applicable to select aaRSs with modified Uaa specificity. 
Fortunately, many orthogonal aaRS/tRNA pairs in E. coli or in S. cerevisiae remain orthogonal 
and functional in mammalian cells. The development of Uaa specificity can be done in E. coli 
or S. cerevisiae, and the resultant pair can therefore be transferred into mammalian cells. Many 
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UaaRS/tRNA pairs have been developed from various bacterial strain or yeast cells, including 
M. mazei PylRS/M. mazei tRNAPyl pair, which is orthogonal in both E. coli and mammalian 
cells (Mukai et al., 2008, Chen et al., 2009); and E. coli TyrRS/Bacillus stearothermophilus 
tRNATyr (EcTyrRS/BstRNATyr) pair, which is orthogonal in eukaryotes (Sakamoto et al., 2002, 
Liu et al., 2007); and EcTyrRS/BstRNATyr has been further developed within S. cerevisiae and 
transferred into mammalian cells to incorporate about 10 Uaas in Chinese hamster ovary cells, 
293T cells, and primary cells (Liu et al., 2007). 
In summary, this innovative technique takes advantage of cellular biosynthetic machinery that 
could effectively introduce Uaas into proteins and overcomes the issues of scalability and 
protein size that limit synthetic and semisynthetic methods of incorporation (Young and 
Schultz, 2010). It also broadens the means of studying protein structure, function and 
interaction with precise incorporation of specific Uaa, and enables further understanding both 
in width and in depth.  
4.1.3. Applications of Uaas 
There are many Uaas that possess unique properties that can facilitate investigation of proteins 
structure and function, and can engineer protein for various purposes. One class of Uaas that 
possesses orthogonal chemical reactivity is able to modify proteins with diverse chemical tools 
in site-specific manner (Young and Schultz, 2010). For example, an Uaa containing a keto 
group in the side chain (Amino acids 1-3 in Figure 4.1) can be selectively modified with 
aminooxy groups, and Uaas with an azide (7 in Figure 4.1) or alkyne group (6 in Figure 4.1) 
can be selectively modified through click chemistry (Chin et al., 2002, Wang et al., 2003, 
Deiters and Schultz, 2005). Another class of Uaas contains cellular probes in their side chains 
(12–33, 36, 44, 45–47, 53–63, 65, 66, and 69 in Figure 4.1). Once the protein containing this 
class of Uaas are expressed, they can be used as infrared (IR) spectroscopy, nuclear magnetic 
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resonance (NMR) spectroscopy, fluorescent and X-ray crystallographic probes for structure 
detection and function examination, such as 15N-, 13C-, or 19F-labeled residues incorporation 
into fatty acid synthetase for NMR to detect conformational change (Cellitti et al., 2008); Uaas 
that contains metal-chelating (34, 35 in Figure 4.1) or iodine side chains (17 in Figure 4.1) can 
facilitate the detection of crystal structures of target protein (Lee et al., 2009); a derivative of 
hydroxycoumarin that contains sensitive fluorogenic probe (46 in Figure 4.1) is used to 
characterise the local unfolding of myoglobin (Wang et al., 2006a). Photo-crosslinking Uaas 
can be used as probes for investigating protein-protein or protein-nucleic acid interactions. For 
example, p-azido-L-phenylalanine (AzF, 7 in Figure 4.1) and p-benzoyl-L-phenylalanine (BzF, 
36 in Figure 4.1) have been incorporated into integral membrane protein drug targets, such as 
into C-X-C chemokine receptor type 4 (CXCR4), a type of G protein-coupled receptors 
(GPCRs), to covalently form receptor-ligand complex to map the specific sites for interaction 
(Grunbeck et al., 2012, Grunbeck et al., 2011). Moreover, Uaas are useful in protein 
engineering in introducing new functions including metal ion-binding, photo-isomerisation, 
and photocage (Xie et al., 2007a, Deiters et al., 2006, Chin et al., 2003, Liu et al., 2007, Wang 
et al., 2007, Wu et al., 2004). Also, Uaas that would mimic post-translational modification 
(PTM) in site-specific incorporation of protein enable study of PTMs under complicated 
conditions (Xie et al., 2007b).  
In this study, we genetically encoded an unnatural amino acid p-azido-L-phenylalanine (AzF), 
an analogue of tyrosine (Figure 4.3A), by read-through the amber stop codon introduced into 
LAT3 in a site-specific manner. The orthogonal pair of tRNATyr, and AzF-RS (engineered from 
Tyr-RS) was used to suppress amber stop codon and incorporate AzF into LAT3. AzF, with a 
reactive azido moiety, is a photoactivatable cross-linker that would react with neighbouring 
primary amines or aliphatic hydrogens (within 3-6 Å of distance) (Naganathan et al., 2013b, 
Grunbeck et al., 2011). The photo-crosslinking property of AzF may be able to trap LAT3 and 
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its interactor(s) in native and physiological active status (Figure 4.3B), and to reveal the 
regulation/binding site of LAT3, thus allowing subsequent mass spectrometric analysis to 
investigate the identity of interactors. LAT3 is predicted to contain 12 transmembrane domains, 
and a long intracellular loop exists between transmembrane domains 6 and 7, which contains 
putative phosphorylation sites (S262 and S267), and one ubiquitination site (K264), shown in 
Figure 4.4 (Babu et al., 2003). All these sites are conserved across various species from 
platypus to human, indicating they are important in regulating the function of LAT3. Therefore, 
the post-translational modifications of these sites are important targets for incorporation of 
unnatural amino acid to study their functions. 
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Figure 4.3. A. Unnatural amino acids, p-azido-L-phenylalanine (AzF) and p-amino-L-
phenylalanine (AmF), derivatives from tyrosine. B. AzF can form covalent bonds with 
neighbouring substrates (within 3-6 Å of distance) under UV excitation.  
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Figure 4.4. Predicted LAT3 structure and conserved sequence across various species. A, 
predicted structure of LAT3 based on the outward-facing X-ray structure of E. coli YajR 
transporter (PDB: 3wdoA) using I-TASSER (Roy et al., 2010). The predicted structure of 
LAT3 contains 12 trans-membranes. Two phosphorylation sites (S262 and S267) and a 
ubiquitination site (K264) situated in the intracellular loop between TM6 and TM7 (6L7), are 
shown. B, the phosphorylation and ubiquitination sites of LAT3 are highly conserved in 
humans through to platypus. 
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4.1.4. Proteomic study by mass spectrometry  
4.1.4.1. Proteomics 
Proteomics refers to the global study of proteins, involving their structure, functions and 
physiological roles in large scale (de Hoog and Mann, 2004). Mass spectrometry (MS) 
technology has advanced greatly in facilitating the investigation of proteomics, allowing more 
accurate and quantitative detection of protein mass and its composition (Walther and Mann, 
2010). More specifically, MS measures the mass-to-charges (m/z) ratios, which can be used to 
calculate the mass of the fragment and map it to a specific protein identity (Aebersold and 
Mann, 2003). The measurement of m/z in most mass spectrometers is in two steps. The first 
step is survey scan or MS1 scan, at which the m/z of ionised parent peptides are measured. The 
ionised peptides are subsequently filtered by their relative abundance and subjected to the 
second step. The selected peptides are fragmented by collision with inert gas such as nitrogen 
or helium at low pressure (Walther and Mann, 2010), which is called collision induced 
dissociation (CID). The m/z of this fragment is measured by detector and generated as MS/MS 
or MS2 spectrum (Dunham et al., 2012).  
MS can be coupled with gas chromatography (GC) or liquid chromatography (LC) for 
separating the compounds prior to  ionisation (de Hoog and Mann, 2004, Aebersold and Mann, 
2003). An electromagnetic field is applied in a vacuum to divert charged molecules based on 
its m/z ratio, and a detector captures ionised molecules and generates signals based on the 
intensity of the current (de Hoog and Mann, 2004). Then the mass analyser can calculate the 
relative abundance of each hit and plot it on the y axis against m/z on the x axis, which 
comprises of a mass spectrum. Mass spectrometers can accurately determine the value of m/z 
based on the oscillation frequency of the ion on its trajectory, leading to the accurate 
measurement of the mass of the molecule (Walther and Mann, 2010).  
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Proteomics has been applied in profiling the dynamic composition and localisation in cell 
biology (Walther and Mann, 2010), and in identifying biomarkers or drug targets in tumour 
samples (Iglesias-Gato et al., 2016). Affinity purification coupled with MS (AP-MS) is based 
on the affinity of antibody to the target protein, and it has been widely used to characterise 
protein-protein interactions (PPIs) in a near-physiological condition (Dunham et al., 2012). 
Post-translational modifications (PTMs) have been proven to be of great importance in 
regulating protein structure and property as a biochemical switch (Prabakaran et al., 2012). 
PTMs affect the tertiary structure of proteins, leading to conformational changes that activate 
or deactivate their own functions or alter/activate the function of their substrates. 
Phosphorylation is the most frequently occurring PTM, and is involved in almost every aspect 
of cellular activities (Cohen, 2002).  The use of MS has also been expanded by coupling with 
more sophisticated experimental and analytic means, for example, with enrichment of 
phosphorylated peptides for phosphorylation analysis to decode post-translational modification 
events in cell signalling networks and to delineate the dynamics of these signalling events 
(Choudhary and Mann, 2010, Humphrey et al., 2015b). 
4.1.4.2. Protein-protein interactions 
Proteins are involved in all biological activities, however, they rarely work alone. In order to 
fulfil their functions, individual proteins need to be coordinated to work together for particular 
cellular processes under stimulation or inhibition. The phenomenon that proteins having 
physical contacts through molecular docking in a cell or in a living organism in vivo is defined 
as protein-protein interaction (PPI) (De Las Rivas and Fontanillo, 2010). This physical 
interaction between neighbouring proteins defines how proteins are regulated, and affects the 
structural and functional properties of proteins, thus playing critical roles in the control of many 
different aspects of cell behaviours. It is very important to note that the interaction in PPI should 
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be intentional molecular contact rather than accidental contact or merely a functional contact 
or during a generic process such as being synthesised, folded, or degraded (De Las Rivas and 
Fontanillo, 2010, Mackay et al., 2007, Chatr-Aryamontri et al., 2008).  
PPIs, by their interactive nature, can be characterised into different types (Nooren and Thornton, 
2003). First, homo- or hetero-oligomeric complexes, depending on whether the interacting 
individuals are identical or non-identical; Second, non-obligate or obligate complexes, 
depending on whether the composing proteins could form well-folded conformation on its own 
or not; Third, permanent or transient complexes. Permanent interactions are strong, stable and 
irreversible, and could be purified as an intact complex, and each individual protein participates 
as a subunit (Perkins et al., 2010). Transient interactions are temporary in nature, where 
proteins associate and dissociate (Nooren and Thornton, 2003). The transient interactions are 
involved in regulating cellular processes and biological networks by inducing protein folding 
and translocation, transducing signals, and modifying proteins, under specific conditions (De 
Las Rivas and Fontanillo, 2010). The individual protein of the complex may vary significantly 
in their stoichiometry and affinity, however, the interaction between each component provides 
critical functional roles to the complex as a whole (Nooren and Thornton, 2003, Perkins et al., 
2010). Thus, purification and analysis of the complex could offer great insight of the complex 
formation and function, as well as how individual components are regulated within a biological 
context (Mohammed et al., 2016).  
4.1.4.3. Affinity purification coupled with mass spectrometry (AP-MS) 
The most widely used methods for capturing protein complexes rely on the affinity strategies 
using antibodies as ligands. The target of affinity binding of an antibody can be an endogenous 
or epitope-tagged protein (Dunham et al., 2012). The purification is generally performed 
through immobilisation of the antibody onto a solid support, such as agarose or magnetic beads, 
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then pull down the protein of interest together with its interactor. The complex is then eluted 
from the beads as purified protein, followed by either washing and processing for direct MS, 
or by SDS-PAGE to reduce sample complexity and in-gel enzymatic digestion before MS 
analysis (Dunham et al., 2012, Morris et al., 2014). AP-MS mostly detects stable interactions 
and thus better indicates functional in vivo PPIs (Brettner and Masel, 2012, Wodak et al., 2013). 
In addition, mapping protein-protein interactions in specific biological context can provide 
important information in uncovering the mechanism of certain cellular activities.  
4.2. Method 
4.2.1 Genetic code expansion- incorporation of unnatural amino acid 
The unnatural amino acid p-azido-L-phenylalanine (AzF) was purchased from Chem-Impex 
International (Wood Dale, IL).  DNA sequencing was performed according to the ABI 3730 
Capillary Sequencer protocol.  
4.2.1.1 Expression of suppressor tRNA, AzF-RS and generation of amber mutations 
Plasmids for expression suppressor tRNA (Yam) and AzF-RS (tRNA Synthetase) genes in 
mammalian were obtained from Dr Shixin Ye (originally from Dr Thomas P. Sakmar at the 
Rockefeller University) 
To create a range of amber codon mutations at potential post-translational modification (PTM) 
positions Y251, S262, K264, S267, and neighbouring positions T252, Q263, A265, P266, L268, 
oligonucleotides were designed to introduce UAG, an amber stop codon, by site-directed 
mutagenesis using PfuUltra High-fidelity DNA Polymerase. Mutant constructs were purified and 
confirmed by DNA sequencing. 
4.2.1.2 Transfection of plasmids and incorporation of AzF  
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Human embryonic kidney 293 (HEK293) cells were seeded at the density of 5×105 per well in 
6-well plate or 2×106 in 100 mm-plate, and allowed to adhere overnight. When reaching 70% 
to 80% confluence, cells were transfected with plasmid DNA using Lipofectamine LTX 
(Invitrogen, Australia) according to manufacturer’s protocol. For transfection in a 6-well 
culture plate, DNAs including 1 μg of pcDNA3.1-LAT3amb-HA, 1 μg of Yam (tRNA), and 
0.1 μg of AzF-RS (aaRS), and 2 μL Plus reagent were diluted in OptiMEM (Invitrogen, 
Australia) media. Then, 5 μL lipofectamine was diluted with OptiMEM media and incubated 
at room temperature for 5 min. Add DNA mix into the lipofectamine, and mix DNA and 
lipofectamine by inverting the tube, and incubate at RT for another 5 min. Change the media 
of HEK293 cells to dialysed FBS containing DMEM media to minimise the presence of 
tyrosine. Spread 100 μL of the lipo-DNA complex into cells in a drop-wise manner in each 
well. After transfection, cells were fed with or without AzF.  AzF was dissolved directly in 
DMEM at a stock concentration of 10 mM and supplemented to the medium at the final 
concentration of 1mM. After 24 h, medium was changed and supplemented with 1 mM AzF. 
Cells expressing wild type LAT3 or LAT3 variants with AzF were harvested 48 h post-
transfection for crosslinking and other functional assays. 
4.2.1.3 Cross-linking AzF incorporated LAT3 variants in live cells  
Photo-cross-linking with UV irradiation. 
HEK293 cells over-expressing LAT3-AzF mutants were washed with PBS 48 h post-
transfection and irradiated with UV light for 10 min using the UVL-23R Compact UV Lamp 
(UVP, 4W, 365nm). After UV light exposure, the cells were lysed with Triton-X100 lysis 
buffer supplemented with protease inhibitors cocktail and phosphatase inhibitor cocktail, and 
kept on ice for 5 min. The cell lysates were subjected to immunoprecipitation, stringent wash, 
enzymatic digestion and desalting for rapid immunoprecipitation-mass spectrometry of 
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endogenous protein (RIME, refer to section 4.2.2.1) and in-gel enzymatic digestion (refer to 
section 4.2.2.2), followed by mass spectrometric analysis.   
Crosslinking by formaldehyde  
Formaldehyde preferentially crosslinks via lysine side chains, and lysine residues have been 
reported to have the most reactive functional groups in native proteins (Hoffman et al., 2015). 
The small size of formaldehyde does not affect protein tertiary structure in general (Toews et 
al., 2010). However, amino acid specificity decreases with increasing crosslinking time and 
formaldehyde concentration, additional residues that are susceptible to reacting with 
formaldehyde at elevated incubation periods and concentrations include histidine, tryptophan, 
asparagine and arginine residues (Metz et al., 2004). Small molecules like glycine and Tris can 
react with formaldehyde, thus quenching the crosslinking reaction induced by formaldehyde 
(Hoffman et al., 2015). 
After 48 h post-transfection, remove the medium of HEK293 cells over-expressing LAT3-AzF 
mutants, and wash cells with PBS twice. Detach the cells with TrypLE, and collect cells with 
PBS, before pelleting the cells by centrifuging at 1,500 rpm for 5 min at RT. Remove the 
supernatant as much as possible, and then resuspend with 10 mL PBS in a 15 mL falcon tube. 
Count the cells to ensure equal cell number across different sample and not exceeding 20 
million. To crosslink proteins, add 625 µL of 16% EM grade formaldehyde (Thermo Fisher, 
28906) to reach 1% as final concentration to each condition, and incubate for 10 min on a roller 
at RT. Quench the cross-linking by adding 500 µL 2 M glycine to reach 0.1 M as final 
concentration, and incubate for 5 min on a roller at RT. Pellet the cells by centrifuge at 1,500 
rpm for 5 min at 4 ℃ and remove supernatant. Resuspend the cells with 1 mL ice cold PBS 
supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail. Repeat the 
washing step again, and remove the supernatant. Cell pellets can be snapped frozen with dry 
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ice and stored at -80℃, and are subjected to further preparation including immunoprecipitation 
and stringent wash for rapid immunoprecipitation-mass spectrometry of endogenous protein 
(RIME) (refer to section 4.2.2.1).  
4.2.2 Mass spectrometry experiments 
4.2.2.1 Rapid Immunoprecipitation-Mass spectrometry of Endogenous protein (RIME)  
The workflow of RIME is summarised in Figure 4.5. As described before, transfected cell 
lysates or pellets were further processed by immunoprecipitation and enzymatic digestion for 
mass spectrometric analysis. More specifically, add 100 µL magnetic beads (Magna ChIP™ 
Protein A+G Magnetic Beads, Millipore) into 1.5 mL tube and block with cold blocking buffer 
(0.5% BSA in PBS). Collect the beads with magnetic rack and remove blocking buffer, 
followed by two more washes with blocking buffer. Then add 15 µg antibody of HA-tag 
(Abcam) or normal rabbit IgG (Santa Cruz) into beads, and top up with blocking buffer to 250 
µL as the total volume. Incubate beads with antibody at 4℃ overnight with rotation. Next day, 
wash the beads with blocking buffer three times and resuspend in 100 µL blocking buffer and 
it is then ready for mixing with cell lysates (Mohammed et al., 2016).  
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Figure 4.5. Schematic workflow of RIME. After co-transfection of site-specific amber mutant 
of LAT3 with the orthogonal pair of tRNA and AzF-RS, culture the cells for 48 hours in the 
presence of AzF. Before lysing the cells, photo-crosslink with UV (365nm) excitation for 10 
min, followed by immunoprecipitation enrichment with anti-HA tag. Immunoprecipitated 
protein complexes were then subject to stringent washes, enzymatic digestion, clean-up and 
acidification for mass spectrometric analysis.  
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To prepare cell lysates, three lysis buffer (Table 4.1) needs to be made and stored at 4℃, and 
all lysis buffer needs to be supplemented with 1× protease inhibitor cocktail and 1× 
phosphatase inhibitor cocktail immediately before use. Cell pellet was lysed with 10 mL cold 
LB1, and rotate on a roller at 4℃ for 10 min. Centrifuge at 4500 rpm for 5 min at 4℃, and 
remove supernatant. Then resuspend pellet with 10 mL cold LB2, and rotate on a roller at 4℃ 
for 5 min. Centrifuge at 4,500 rpm for 5 min at 4℃, and remove supernatant. Resuspend cell 
pellet in 300 µL cold LB3, and transfer to fresh eppendorf tubes for sonication. In order to 
maximise the sonication efficiency, sonicate no more than 20 million cell per 300 µL at 4℃ 
for 15 cycles with 30 sec on and 30 sec off. Split into multiple tubes if necessary. Keep 
sonicated cell lysates on ice and add 30 µL Triton X. Invert the tubes multiple times to mix it 
well. Then centrifuge the lysate at 18,000 ×g for 10 min at 4℃ to pellet the debris. Combine 
supernatant where applicable, and collect 10% of supernatant into separate tubes as input, and 
store at -80℃. Transfer the rest supernatant into fresh tubes and adjust the final volume to 
1,000 µL with LB3. Mix the supernatant with 100 µL magnetic beads that have pre-bound with 
antibodies or IgG, and incubate on a rotator overnight at 4℃.  
The next day, collect the magnetic beads with magnetic rack, and transfer supernatant into fresh 
tubes as control. Wash the beads with 1 mL cold RIPA buffer (Table 4.1) for 10 times and flick 
the tube to ensure the beads are fully resuspended. Incubate for 1 min between washes, and 
briefly spin down before removing the RIPA buffer. Then, wash bead with freshly made cold 
100mM ammonium hydrogen carbonate (AMBIC) solution as quickly as possible for 2 times. 
After second wash, spin down the tubes at 960×g for 3 min and remove the residue of AMBIC 
buffer. Once being washed, beads can be snap frozen and stored at -20℃, or continue to trypsin 
digestion.  
Trypsin (Trypsin Gold, MS grade, Promega) was reconstituted in freshly made 100 mM 
AMBIC buffer to reach the final concentration of 10 µg/mL. Add 20 µL trypsin solution into 
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magnetic beads, and vortex samples for 15 sec every 2-3 min for the first 15 min to ensure the 
beads are fully resuspended and well covered in trypsin solution. Then incubate at 37℃ 
overnight without any further agitation. The next day, add another 10 µL of trypsin solution 
into each sample, and further digest for 4 hr at 37℃. Place samples in the magnetic rack to 
collect supernatant that contains digested peptides, and transfer to fresh tubes. Add 1.5 µL 100% 
formic acid (FA, Sigma) into each sample to acidify digested peptides at a final concentration 
of 5% (v/v). The samples can be stored at -20℃.  
Table 4.1. Recipe for RIME buffers 
RIME Buffer RECIPE 
Lysis Buffer 1 (LB1) 50 mM HEPES-KOH, (pH 7.5) 
 140 mM NaCl 
 1 mM EDTA 
 10% (vol/vol) glycerol 
 0.5% (vol/vol) NP-40 
 0.25% (vol/vol) Triton X-100 
Lysis Buffer 2 (LB2) 10 mM Tris-HCL (pH 8.0) 
 200 mM NaCl 
 1 mM EDTA 
 0.5 mM EGTA 
Lysis Buffer 3 (LB3) 10 mM Tris-HCl (pH 8.0) 
 100 mM NaCl 
 1 mM EDTA 
 0.5 mM EGTA 
 0.1% (wt/vol) sodium deoxycholate 
 0.5% (vol/vol) N-lauroylsarcosine 
RIPA Buffer for RIME 50 mM HEPES (pH 7.6) 
 1 mM EDTA 
 0.7% (wt/vol) sodium deoxycholate 
 1% (vol/vol) NP-40 
 0.5M LiCl 
 
 
Since the washing buffer contains high concentration of salt, all samples need to be desalted 
before analysed by mass spectrometer. C18 ZipTip (Millipore) was used to perform the clean-
up steps with freshly made wetting/condition solution, equilibration/wash solution, and elution 
buffer (Table 4.2). Aliquot 10 µL elution buffer in fresh tubes with labels for each sample. 
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Firstly, balance the C18 column with 10 µL condition solution twice and equilibrate with 10 
µL equilibration solution twice. Secondly, load the peptides with C18 column and pipette up 
and down slowly for 20 times. Thirdly, wash C18 column with 10 µL wash solution for 4 times 
and discard wash solution. Finally, elute the bound peptides from C18 column in 10 µL elution 
buffer twice in a fresh collection tube, and the samples are now desalted.  
The desalted peptides were dried in a centrifugal vacuum concentrator (5301, Eppendorf) for 
10-30 min, and reconstituted in 20 µL loading buffer 3% acetonitrile (ACN) and 0.1% formic 
acid (FA). The samples can be stored at 4℃ for short term and at -20℃ for long term. For MS 
analysis, 10 µL samples were loaded into either 96-well plate or PCR strip according to 
specification of the mass spectrometer.  
Table 4.2. Buffers for C18 ZipTip clean-up 
Clean-up Buffer Recipe 
Wetting/Conditioning solution 100% acetonitrile 
Equilibration/ Wash Solution 0.1% formic acid 
Elution Buffer 0.1% formic acid,60% acetonitrile 
 
 
4.2.2.2 In-gel enzymatic digestion 
The workflow of in-gel enzymatic digestion is summarised in Figure 4.6. Cell lysates that were 
transfected with LAT3 amber mutant plasmid were immunoprecipitated with anti-HA tag 
antibody, and were subsequently resolved by SDS-PAGE with the input of 3-5 g of total protein. 
Rinse the gel briefly with PBS-T and then stained it with Coomassie Blue (Bio-Safe™ 
Coomassie Stain #1610786, Bio-Rad) overnight at room temperature with rocking. The next 
day, de-stained with water for 2 hr at room temperature with rocking. After de-staining, bands 
became visible on the gel. Use clean scalpels to excise bands, cut into 1 mm3 gel pieces, and 
collect into fresh micro tubes. De-stain the gel pieces using freshly made 50% (v/v) acetonitrile 
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(Sigma, 34967) in 25 mM AMBIC solution. Vortex the samples using a thermomixer at 1,000 
rpm at room temperature for 15 min, and repeat de-staining process till all Coomassie stain is 
removed. If the stain is too strong, add neat acetonitrile and incubate at RT with vortex or until 
the gel pieces turn white and shrink, and then remove acetonitrile. Dry the gel pieces in 
centrifugal vacuum concentrator for 10-30 min.  
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Figure 4.6. Schematic workflow of in-gel digestion coupled with LC-MS analysis (adapted 
from https://www.thermofisher.com/au/en/home/life-science/protein-biology/protein-biology-
learning-center/protein-biology-resource-library/pierce-protein-methods/sample-preparation-
mass-spectrometry.html, Thermo Fisher). Immunoprecipitation enriched proteins are resolved 
by 1D SDS-PAGE, followed by Coomassie stain overnight. After destain, cut the protein band 
into 1mm3 pieces and perform reduction, alkylation and tryptic digestion. Peptides are 
extracted and cleaned up before LC-MS analysis. 
  
117 
 
To reduce the samples, add 100 µL of freshly made 10 mM DTT in 25 mM AMBIC solution 
and incubate at 56℃ for 30 min. Remove DTT solution using a fine gel loading tips (Bio-Rad, 
223-9915EDU). To alkylate the protein, add 50 µL of 55 mM iodoacetimide (IAE, Sigma) 
freshly prepared in 25 mM AMBIC solution, and incubate in the dark (in dark tubes or wrapped 
in foil) for 15 min at RT since iodoacetimide is light sensitive. Remove iodoacetimide solution 
using the fine gel loading tips. Wash the gel piece with 50% ACN/ 25 mM AMBIC for 10 min 
with vortex at RT twice, before dry the gel pieces in centrifugal vacuum concentrator for 10-
30 min.  
Reconstitute trypsin in 25 mM AMBIC into 12.5 ng/µL as final concentration. Add 50 µL 
trypsin buffer to rehydrate gel pieces on ice for 30 min. Make sure all gel pieces were covered 
in solution before incubate in the thermomixer at 1,000 rpm at 37℃ overnight.  
The next day, collect the supernatant that contains digested peptides into fresh tubes. Add 30 
µL 5% FA/50% ACN to the gel pieces and shake for 15 min. Collect the remaining supernatant 
into the tube containing digested peptides. Reduce the sample volume by centrifugal vacuum 
concentrator for 10-30 min. Digested peptides were subsequently desalted with C18 ZipTip 
and reconstituted as described before (refer to section 4.2.2.1).  
4.2.2.3 Mass spectrometer setup and data analysis  
Liquid chromatography tandem mass spectrometry (LC-MS/MS) experiments were carried out 
at the Mass Spectrometry Core Facility at Charles Perkins Centre of the University of Sydney 
using high-resolution TripleTOF® 6600 Quadrupole Time-Of-Flight (QTOF) and Q 
ExactiveTM mass spectrometers. Samples prepared for MS with RIME or in-gel enzymatic 
digestion method were reconstituted in loading buffer and were loaded into mass spectrometer 
with 10 µL. Each sample contained peptide mixture, and was separated by liquid 
chromatography (LC) based on hydrophobicity and then ionised by electrospray (ESI). Mass 
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spectrometer detects the intensity of ion signals as a function of retention time, as well as 
precursor ions and product ions of peptides based on mass-to-charge (m/z) ratios.  
TripleTOF® 6600 Quadrupole Time-Of-Flight (QTOF, SCIEX) mass analyser provides high 
sensitivity, mass resolution and mass accuracy of tandem mass spectrometer in both precursor 
(MS) and product ion (MS/MS) modes (Morris et al., 1996, Shevchenko et al., 1997). It has 
been widely used as a powerful and robust tool with unique capabilities. The QTOF system has 
a series of quadrupole filters that transmit ions according to their mass-to-charge (m/z) value. 
The first quadrupole is the QJet® ion guide. It is located between the orifice plate and the Q0 
region, and it doesn’t filter the ions generated by ionisation but focuses them before they enter 
Q0. In Q0 region, ions are focused again before passing into Q1. The pre-focus of large ion 
flux enhances the sensitivity of the instrument and improves signal-to-noise ratio. The Q1 
quadrupole filters the ions before they enter Q2 quadrupole. The Q1 quadrupole can pass all 
ions within a specified m/z range to the Q2 collision cell, known as a TOF MS scan and all 
ions are analysed by the TOF system; or it can only pass one ion with a specified m/z ratio to 
the Q2 collision cell, known as a TOF MS/MS scan, and only the selected ion is analysed. 
Within the Q2 collision cell, the internal energy of parent ions is increased by collisions with 
gas molecules to break the molecular bonds and thus generating product ions. After passing 
through the Q2 collision cell, the ions enter the TOF region for additional mass analysis. Due 
to the different m/z ratio, each ion reaches the detector at different time and generates a current 
that is subsequently converted into a voltage pulse. The number of pulses depends on the 
quantity of ions entering the detector. The mass spectrometer converts the voltage pulses to a 
signal and then correlates the signal to the time it takes each ion to reach the detector. The 
signal reflects the ion intensity and the time to reach the detector represents a specific m/z value. 
The mass spectrometer displays this data as a mass spectrum, including spectra of TIC (total 
ion chromatogram) and XIC (extracted ion chromatogram).   
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Q ExactiveTM is a Quadrupole-OrbitrapTM mass spectrometer. The Orbitrap is an ion trap mass 
analyser that is comprised of two outer electrodes and a central electrode, which functions as 
both an analyser and detector (Hu et al., 2005). The injected ions that enter the Orbitrap are 
trapped and squeezed by increasing electric field, making the ions oscillate around the axial 
and in between of the outer electrodes. Different ions oscillate at different frequencies and 
separate from one another. The measurements of the oscillation frequencies caused by ions 
reaching on the outer electrodes are converted into the mass spectra of the ions by image current 
detection. The Orbitrap mass analyser is actually a Fourier Transform mass analyser analogue 
of FT-ion cyclotron resonance (ICR) technology, with smaller instrument size and easier 
operation. Orbitrap mass spectrometer is able to identify, quantify and confirm more 
compounds rapidly and with more confidence. The nanometre-range electrodes, high voltage 
supply and wider range of mass detection provides better sensitivity, selectivity, resolution, 
and accuracy.  
There are two solvents used for HPLC-MS/MS. Solvent A is 0.1% (v/v) formic acid (FA) and 
Solvent B is 0.1% (v/v) FA +80% (v/v) acetonitrile (ACN). HPLC solvents are prepared by 
core facility and replaced monthly. These solvents are sonicated for 10 min in a water bath 
sonicator to minimise the likelihood of introducing bubbles into the nanoHPLC system.  
All proteolytic digested samples were separated by nano-liquid chromatography (nano-LC) 
using Ultimate 3000 HPLC and autosampler system (Dionex). A total of 10 μL of reconstituted 
peptide solution were loaded onto AcclaimTM PepMapTM C18 micro-column (Thermo Fisher) 
15 μL/min. Peptides were eluted with a linear gradient of H2O: ACN (98:2, 0.1 % FA) to H2O: 
ACN (64:36, 0.1 % FA) at 250 nL/min over 60 min with a nanoflow of 0.3 μL/min. Positive 
ions were generated by electrospray and captured by detector and analyser. 
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A survey scan m/z 350-1800 was acquired in the Orbitrap operated in data dependent mode 
(Resolution = 60,000 at m/z 400, with automatic gain control target of 1,000,000 ions counts). 
Up to the 20 most abundant ions (>5,000 ion counts) with charges over +2 were sequentially 
isolated and fragmented by collision induced dissociation (CID). M/z ratios selected for 
MS/MS were dynamically excluded for 30 seconds. 
 
Proteome Discoverer 2.2 (Thermo Fischer Scientific) and Mascot (Matrix Science) were used 
to collect and analyse MS data. The result data were converted to peak list files to query at 
Mascot search engine for MS/MS ions match in the SwissProt Database 
(uniprot_SwissProt_Human_2018-04.fasta) with an FDR (false discovery rate) <1%. The 
parameters used to search for protein were allowed up to two missed cleavages for trypsin; one 
fixed modification (carbamidomethyl of Cys); one variable modifications for oxidation of Met; 
mass tolerance of 10 ppm for the precursor ion and mass tolerance of 0.8 Da for the fragment 
ion. The search results included a list of identified peptides for further analysis. Scaffold 4 
(Proteome Software) was used to combine and compare search results to identify biological 
relevance, display spectrum details and counts and create comprehensive lists of target proteins 
classified by their molecular function or involvement in biological processes. 
4.3. Result 
4.3.1 Generating LAT3 mutants and UV photo-crosslinking with AzF incorporation 
As described in section 4.2.1, LAT3 amber mutants were generated at multiple sites within 
transmembrane domain 6 and 7, including potential post-translational modification (PTM) sites 
Y251, S262, K264 and S267, as well as neighbouring sites T252, Q263, A265, P266, L268. 
Mutant constructs were confirmed by DNA sequencing and western blots of transfected 
HEK293 cell lysates in the presence or absence of AzF (Figure 4.7). In the presence of AzF, 
amber stop codons were able to be translated and full length LAT3 proteins (~55kDa) were 
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able to be expressed. From the western blot, the expression level and band size showed slight 
difference from site to site. This is probably due to the site-specific mutation to AzF which 
may affect the structure and conformation of LAT3 protein. Because AzF has different 
structure to the original residues, it may cause different modifications of protein and affect the 
binding affinity of antibody leading to different expression level and band size. 
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Figure 4.7. LAT3 amber mutants at various sites. A. sequencing results showed site-specific 
mutation into amber stop codon (TAG) was successful. B. expression of LAT3 in HEK293 cell 
lysates transfected with LAT3 amber mutants at various sites in the presence or absence of 1 
mM AzF. GAPDH is loading control.    
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We transfected different HA-tagged LAT3 amber mutants, S262 and Q263, into HEK293 cells, 
and examined the expression of Akt after HA immunoprecipitation in the presence or absence 
of AzF and UV. Western blots of IP-ed sample showed migration of bands at 100 kDa in all 
three conditions (Figure 4.8). In the absence of AzF in IP-ed sample, we observed protein bands 
around 100 kDa when probing with anti-Akt antibody. This indicated that read-through may 
have happened during translation (Since AzF is modified from tyrosine, there are chances that 
the AzF-RS would charge tyrosine onto tRNA, resulting in protein expression), resulting in the 
expression of HA-tagged LAT3 and co-IP of Akt. For Q263amb-HA (Figure 4.8B), the read-
through was less significant compared to S262amb-HA (Figure 4.8A). In the Input samples, in 
the absence of AzF, there was a low level of read-through for Q263, which was further enriched 
by immunoprecipitation with anti-HA antibody and resulted in migrated bands around 100 kDa. 
Moreover, in the presence of AzF, migrated protein bands show stronger expression in the 
absence of UV compared to UV induced samples (Figure 4.8B). It suggested the photo-
crosslinking properties at Q263 could be induced by ambient light.  
The UV treatment may affect the efficiency of affinity purification of HA-tagged LAT3 with 
the mutation of S262 and Q263. For S262, in the unbound phase (the supernatant after 
incubating lysate with magnetic beads overnight), the expression level of Akt was significantly 
higher in the absence of AzF after UV treatment compared to non-UV treatment; while, for 
Q263, in the unbound phase, UV treatment increased the expression level of Akt compared to 
non-UV treatment. The phosphorylation of S262 may be affected by the mutation, leading to 
the alteration of conformational change and protein folding of LAT3, thus affecting the 
interaction with Akt. S262 and Q263 are very close to ubiquitination site K264, and may affect 
the binding of ubiquitin to K264. In addition, the stability of AzF may contribute to the 
discrepancy of expression of the protein complex, because the bulk of AzF could be converted 
to AmF (Figure 4.3A) under UV induction, which is structurally close to AzF but without 
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photo-crosslinking property (Shao et al., 2015). Thus, less reactive AzF was present to form 
protein complex leading to lower expression being detected.  
 
 
Figure 4.8. HEK293 transfected with LAT3amb-HA mutants in the presence or absence of AzF 
or UV and probed with anti-Akt antibody to examine Akt protein expression level after 
immunoprecipitation with anti-HA antibody compared to input and unbound phase of IP. A, 
transfection with S262amb-HA. B, transfection with Q263amb-HA. 
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In addition, whether the orthogonality of tRNA and AzF-RS pair remains intact after repeated 
expansion of the plasmid via bacterial culture and DNA purification needs to be validated. We 
transfected the HEK293 cells with either S267amb, tRNA (Yam), or AzF-RS, or different 
combinations. Wild type LAT3-HA was used as positive control. Immunoblotting showed 
strong LAT3 expression in positive control (wild type LAT3-HA), and showed no LAT3 
expression in negative control (no Yam, AzF-RS, or AzF) (Figure 4.9). However, in the 
presence of Yam, AzF-RS and AzF, there was no expression of LAT3, whereas Yam alone or 
with Yam and AzF-RS without AzF showed LAT3 expression (Figure 4.9). This result was 
unexpected and problematic, as the expression of amber mutant requires the orthogonal pair of 
tRNA and aaRS, and the presence of the Uaa. It raised the concern that the plasmid of either 
Yam and/or AzF-RS might be mutated during repeated bacterial amplifications, leading to the 
expression of LAT3 in the absence of AzF-RS or AzF. This comprises the Uaa expression 
system of LAT3, and may cause confusion in data interpretation, and the identification of 
crosslinking. 
 
 
Figure 4.9. Western blot of co-transfection with different combination of tRNA (Yam) and 
AzF-RS in the presence or absence of AzF in HEK293 cells, to validate the orthogonality. 
Wild type LAT3-HA was used as control. 
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Given the inconsistency of protein expression with the orthogonal pair and AzF, we decided to 
use a plasmid that contains both tRNA Yam and AzF-RS (from Dr Shixin Ye) instead of the 
orthogonal pair, to increase the co-transfection efficiency and reduce cytotoxicity.  
Since S267 is one of the reported phosphorylation sites, we transfected HA-tagged LAT3-
S267amb plasmid into HEK293 cells, and cultured in the presence or absence of AzF as well 
as UV. Lysates were purified by IP using anti-HA tag antibody so that HA-tagged expressed 
LAT3 proteins were enriched. After enrichment, anti-HA tag antibodies were used to probe the 
expression of LAT3 after SDS-PAGE. In the presence of AzF, LAT3-S267amb was detected 
in cell lysates (Figure 4.10A). Although there were some proteins being detected in the absence 
of AzF, it may be due to the read-through of tyrosine. The bands at higher molecular weight 
indicated the formation of a protein complex by UV induced crosslinking. We probed blots 
with anti-Akt after HA enrichment (Figure 4.10B). Akt was detected in the input samples at its 
regular molecular weight (60 kDa), however, in the IP samples, a band was observed around 
100 kDa, which represented crosslinked protein complex including Akt and HA-tagged LAT3. 
As AzF was incorporated into LAT3amb mutant to successfully express LAT3, its azido 
moiety could couple with neighbouring protein upon UV excitation. It’s also worth noting that 
in the IP samples of LAT3-S267amb treated with AzF but not UV radiation, there is a faint 
band around 100 kDa. It implies a background crosslinking has been formed. It is most likely 
due to the exposure to the ambient room light, which has been observed in previous studies 
(Grunbeck et al., 2011, Rust et al., 2014).   
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Figure 4.10. UV excitation (10 min) induced crosslinking in LAT3-S267amb transfected 
HEK293 in the presence of AzF. A, LAT3 amber mutant was successfully expressed, probed 
by anti-HA tag antibody; B, a strong band of potential cross-linked complex around 100 kDa 
was probed by anti-Akt antibody; the bands around 50 kDa of IP samples are of IgG heavy 
chain. 
  
128 
 
We also examined amber mutants at P266 and L268. Interestingly, they exhibit distinct photo-
crosslinking capability to S267 (Figure 4.11). Under UV excitation, only S267amb mutant 
showed bands at higher molecular weight, indicating the formation of protein complex from 
this residue. Since serine 267 is a potential phosphorylation site of LAT3, the crosslinking from 
this residue suggested that S267 could potentially be the binding and/or interacting site with its 
substrate that affects the function of LAT3. 
 
  
Figure 4.11. Western blot of UV excitation induced crosslinking in LAT3-P266amb, S267amb, 
and L268amb transfected HEK293 cells supplemented with AzF. After immunoprecipitation 
with anti-HA tag antibody, LAT3 was probed to examine the expression level of each site. A 
strong band presented around 100 kDa in S267, but not in P266 or L268.  
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4.3.2 Using RIME to explore LAT3 interactor 
4.3.2.1. RIME of UV induced photo-crosslinking with QTOF 
Since we have observed the upshifted band on western blot, it is possible to be the complex 
formed by LAT3 and Akt via covalent bond with AzF under UV excitation. In order to identify 
this photo-crosslinked complex, we attempted to use mass spectrometry to explore the 
composition of photo-crosslinked complex. HA-tagged wild type LAT3, S267amb and 
L268amb mutants were transfected into HEK293 cells and were cultured in the presence of 
AzF, where wild type LAT3-HA were used as a positive control. All cell lysates were 
immunoprecipitated with either anti-HA tag or with normal rabbit IgG antibody as negative 
control. All samples were prepared according to RIME protocols (section 4.2.2.1), and were 
run on QTOF instruments (section 4.2.2.3). The data from MS were collected and searched in 
SwissProt database through Proteome Discoverer and Mascot.  
The corresponding proteins from matched peptides were ranked by the score given by Mascot 
search. LAT3 with the highest score among WT LAT3-HA, and S267amb-HA, and the second 
highest score in the data of L268amb-HA samples indicating LAT3 proteins were successfully 
expressed with amber mutant in the presence of AzF, and immunoprecipitated by anti-HA tag 
antibody. The identified peptides also match virtual digestion by trypsin (Supplementary Table 
1). In comparison, there were few peptides of LAT3 being detected in the IgG controls. Besides 
LAT3, we noticed a few peptides that have been detected in the list repeatedly in different 
samples (Table 4.3), which may be worth of further study to elucidate the role they play. 
RS27A encodes a fusion protein consisting of ubiquitin at the N terminus and ribosomal protein 
S27a at the C terminus. As a ubiquitin, it targets cellular proteins for degradation (Ye and 
Zhang, 2007); BCAR1, human homologue of p130 Crk-associated substrate (p130Cas), is a 
ubiquitously expressed adaptor protein, acting as a docking protein for several signalling 
partners (Defilippi et al., 2006). It decreases in S267amb sample but increased in L268amb 
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sample compared to LAT3-HA sample, suggesting that S267 might be required for BCAR1 
interaction. The results indicated that the interaction between Akt and LAT3 may be indirect, 
and there may be some other proteins functioning as the Akt substrate that could also bind with 
LAT3. 
Table 4.3. List of peptides that are of interest from RIME. emPAI represents Exponentially 
Modified Protein Abundance Index, indicating an approximate, relative quantitation of protein 
in a mixture based on protein coverage by peptide matches (Ishihama et al., 2005). 
Accession Description emPAI in samples 
  LAT3-HA LAT3-S267amb LAT3-L268amb 
LAT3 
Large neutral amino acids 
transporter small subunit 3 
1.99 2.15 0.69 
RS27A 
Ubiquitin-40S ribosomal 
protein S27a 
3.7 3.7 1.36 
BCAR1 
Breast cancer anti-estrogen 
resistance protein 1 
0.51 0.15 0.99 
 
 
We also grouped all samples into HA (IP with anti-HA tag) or IgG (IP with anti-IgG) according 
to the antibody used in IP for comparison. The unique proteins identified in all HA samples are 
listed in Table 4.4. This list may include substrates that were photo-crosslinked by Uaa AzF, 
but not immunoprecipitated through non-specific binding of IgG antibody. These five unique 
proteins contain 33 peptides that are identified in common among WT LAT3-HA, S267-HA 
and L268-HA as shown in the middle of the Venn diagram from Scaffold analysis (Figure 4.12). 
There are 6 peptides identified that are in common in S267-HA and L268-HA but not in WT 
LAT3-HA, and they belong to two proteins: PARP1 (Poly [ADP-ribose] polymerase 1) and 
GRP78 (78 kDa glucose-regulated protein).  
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Table 4.4. Unique protein identified in HA samples (WT LAT3, S267, L268) compared to 
IgG samples (WT LAT3, S267, L268). 
Accession  Protein Name 
BCAR1_HUMAN Breast cancer anti-estrogen resistance 
protein 1 
TBB4B_HUMAN Tubulin beta-4b chain 
HSP7C_HUMAN Cluster of heat shock cognate 71 kDa 
protein 
HS90B_HUMAN Cluster of heat shock protein HSP 90-
beta 
KPYM_HUMAN Pyruvate kinase PKM 
IF4A1_HUMAN Eukaryotic initiation factor 4A-I 
 
 
Figure 4.12. Venn diagram showing the overlap of peptides identified among samples of WT 
LAT3-HA, S267-HA, and L268-HA from UV-RIME experiments. 
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Given the high score and function description of BCAR1, we performed co-
immunoprecipitation to validate the interaction of BCAR1 and LAT3 in LNCaP cells (Figure 
4.13). Unfortunately, immunoprecipitation with either anti-LAT3 or BCAR1 antibody and 
probe for the other protein yield no bands from western blot. It suggests that there is no direct 
interaction between LAT3 and BCAR1 detectable by co-IP. BCAR1 showed protein 
expression in IgG pull-down sample, indicating BCAR1 may be degraded and bind to IgG, 
since the molecular weight of BCAR1 is 130 kDa.  
 
 
Figure 4.13. Validation of BCAR1 and LAT3 interaction in LNCaP cells by co-IP and western 
blot. IP with either anti-BCAR1 or LAT3 followed by probing the other protein did not show 
any bands, indicating there was no direct interaction between LAT3 and BCAR1. IB with 
LAT3 shows only IgG heavy chain, but BCAR1 showed protein expression in IgG pull-down. 
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We have repeated this UV-RIME experiments for 3 times, and we have attempted with 
different columns for the mass spectrometer, including cleaning and calibrating the columns 
with standard BSA before samples; and have optimised the acquisition method (acquisition 
time varies from 30 min, 60 min to 90 min), detection threshold, dynamic exclusion time and 
etc. The protocol in sample preparation required stringent washes with RIPA buffer, which 
may have caused loss of magnetic beads for IP. However, we were unable to determine the 
interactor(s) with LAT3. We decided to use Q ExactiveTM mass spectrometer to increase the 
sensitivity of peptides identification, and to employ formaldehyde as crosslinking agent, which 
has been widely used in the study of protein-protein interactions. Sample preparation was 
identical except crosslinking with formaldehyde instead of UV excitation.   
4.3.2.2. Formaldehyde induced crosslinking coupled with MS with Q 
ExactiveTM 
In order to compare with the method of UV-induced crosslinking and subsequent MS 
identifications of matched peptides, we utilised formaldehyde to crosslink proteins in HEK293 
cells transfected with WT LAT-HA, S262-HA and S267-HA in the presence of AzF after 48 h 
of transfection (section 4.2.1.3) followed by RIME preparation (section 4.2.2.1), and MS run 
was performed with Q ExactiveTM mass spectrometer (section 4.2.2.3). 
From Q ExactiveTM mass spectrometer, the number of identified peptides increased 
significantly as a result of higher sensitivity of the instrument. All peptides could be classified 
based on their involvement of molecular functions (Figure 4.14A) or biological process, or 
cellular component. A large portion of identified proteins were involved in molecular function, 
binding and catalytic activity (Figure 4.14A). The overlapping of peptides between different 
samples were evaluated. One example of comparison is shown in Figure 4.14B, as it displays 
the number of the unique peptides in individual sample as well as peptides that are in common 
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between two or three samples. WT LAT3-HA and S267-HA have 187 peptides in common 
(highlighted area), compared to 754 peptides that are present in all three samples.  
 
 
 
Figure 4.14. Result from formaldehyde crosslinking coupled with RIME. A, classification of 
identified proteins based on their molecular function. B, Venn diagram showing the overlap of 
peptides identified among samples of WT LAT3-HA, S267-HA, and WT LAT3-IgG. The 
highlighted portion represents the number of protein that are in common of both WT LAT-HA 
and S267-HA. 
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The peptides of LAT3 that have been matched are listed (partially) in Table 4.5. In the example 
of first peptide in the list APSEDGSDAFMSPQDVR, it was further ionized into a mixture of 
b ions and y ions (Figure 4.15A and B) by energy collision during MS/MS. The b ions are 
fragmented from the N-terminal of the peptides, and the y ions are fragmented from the C-
terminal (Roepstorff and Fohlman, 1984). The subscript number of the ion corresponds to the 
number of residues it contains from N-terminal for b ions and from C-terminal for y ions 
(Johnson et al., 2002). Thus, these ions are consisted of certain amino acid sequence from each 
terminal that can be used for de novo sequencing (Papayannopoulos, 1995). The highlighted 
ions in Figure 4.15A matched the peaks in Figure 4.15B, where b ions and y ion started from 
opposite direction of the peptides.  
Table 4.5. List of peptides of LAT3 being identified in WT LAT3-HA sample generated with 
Scaffold. It contains the sequence of matched peptide and the probability of the matching. 
Index Peptide Prob Exclusive To 
1 APSLEDGSDAFMSPQDVR 100% 
Large neutral amino acids 
transporter small subunit 3 
2 APSLEDGSDAFMSPQDVRGTSENLPER 99% 
Large neutral amino acids 
transporter small subunit 3 
3 APTLQQAYR 100% 
Large neutral amino acids 
transporter small subunit 3 
4 APTLQQAYRR 20% 
Large neutral amino acids 
transporter small subunit 3 
5 ARLQQEYAANGMGPLK 100% 
Large neutral amino acids 
transporter small subunit 3 
6 FGPRPVR 27% 
Large neutral amino acids 
transporter small subunit 3 
7 GTSENLPER 100% 
Large neutral amino acids 
transporter small subunit 3 
8 IIFYMAAVNK 100% 
Large neutral amino acids 
transporter small subunit 3 
9 IKDCVDAPTQGTVLGDAR 98% 
Large neutral amino acids 
transporter small subunit 3 
10 IKLSGLALDHK 100% 
Large neutral amino acids 
transporter small subunit 3 
11 IKLSGLALDHKVTGDLFYTHVTTMGQR 100% 
Large neutral amino acids 
transporter small subunit 3 
12 KSLCSPTFLWSLLTMGMTQLR 5% 
Large neutral amino acids 
transporter small subunit 3 
13 LQQEYAANGMGPLK 100% 
Large neutral amino acids 
transporter small subunit 3 
14 LSGLALDHK 100% 
Large neutral amino acids 
transporter small subunit 3 
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15 LSGLALDHKVTGDLFYTHVTTMGQR 100% 
Large neutral amino acids 
transporter small subunit 3 
16 LSQKAPSLEDGSDAFMSPQDVR 100% 
Large neutral amino acids 
transporter small subunit 3 
17 
LSQKAPSLEDGSDAFMSPQDVRGTSENLPE
R 
95% 
Large neutral amino acids 
transporter small subunit 3 
18 MAPTLQQAYR 100% 
Large neutral amino acids 
transporter small subunit 3 
19 MLEYLVTGGQEHETNEQQQK 100% 
Large neutral amino acids 
transporter small subunit 3 
20 SVPLRK 17% 
Large neutral amino acids 
transporter small subunit 3 
21 VTGDLFYTHVTTMGQR 100% 
Large neutral amino acids 
transporter small subunit 3 
 
 
Figure 4.15. MS/MS data of a peptide identified from WT LAT3-HA sample. A, the m/z value 
of b ions and y ions of peptide APSEDGSDAFMSPQDVR of LAT3 are identified; B, the 
spectrum of tandem MS/MS showing relative intensity of b and y ions, and it matches the 
highlighted ions in A. 
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We have compared the identified peptides between HA and IgG in S262, and have obtained 
177 proteins that are unique in S262-HA sample (Table 4.6). LAT3 is listed with highest score 
among the unique proteins and all peptides being identified of LAT3 account for 27% coverage 
of the LAT3 sequence.  
Table 4.6. List of proteins that are matched with unique peptides identified in S262-HA 
compared to S262-IgG. Top 20 out of 177 proteins ranked by score.  
Accession Protein Name 
LAT3_HUMAN Large neutral amino acids transporter small subunit 3 
MAP7_HUMAN Ensconsin 
MA7D1_HUMAN MAP7 domain-containing protein 1 
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 
HMMR_HUMAN Hyaluronan mediated motility receptor 
PKN2_HUMAN Serine/threonine-protein kinase N2 
MA7D3_HUMAN MAP7 domain-containing protein 3 
MDC1_HUMAN Mediator of DNA damage checkpoint protein 1 
TF3C5_HUMAN General transcription factor 3C polypeptide 5 
ANR17_HUMAN Ankyrin repeat domain-containing protein 17 
MAGD2_HUMAN Melanoma-associated antigen D2 
CCAR2_HUMAN Cell cycle and apoptosis regulator protein 2 
LRC40_HUMAN Leucine-rich repeat-containing protein 40 
KIF4A_HUMAN Chromosome-associated kinesin KIF4A 
RPC2_HUMAN DNA-directed RNA polymerase III subunit RPC2 
ECHA_HUMAN Trifunctional enzyme subunit alpha, mitochondrial 
UBC12_HUMAN NEDD8-conjugating enzyme Ubc12 
RPC1_HUMAN DNA-directed RNA polymerase III subunit RPC1 
EMAL4_HUMAN Echinoderm microtubule-associated protein-like 4 
 
We also grouped all samples into anti-HA tag (HA) or anti-IgG (IgG) according to the antibody 
used in IP for comparison, and filtered out unique peptides in all HA samples but not in all IgG 
samples (Table 4.7). This list may include substrates that were crosslinked by formaldehyde 
via lysine side chains, but not immunoprecipitated through non-specific binding of IgG 
antibody. Additionally, we classified the proteins based on their molecular function, such as 
protein kinase, ubiquitin related enzymes, and membrane related proteins (Table 4.8). 
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Table 4.7. List of unique peptides identified in HA samples (WT LAT3, S262, S267) compared 
to IgG samples (WT LAT3, S262, S267). Top 20 out of 151 proteins ranked by score. 
Accession Protein Name 
TF3C5_HUMAN General transcription factor 3C polypeptide 5  
RPC1_HUMAN DNA-directed RNA polymerase III subunit RPC1 
PUR9_HUMAN Bifunctional purine biosynthesis protein PURH 
4F2_HUMAN 4F2 cell-surface antigen heavy chain 
NCKP1_HUMAN Nck-associated protein 1  
RIR1_HUMAN Ribonucleoside-diphosphate reductase large subunit 
GNL3_HUMAN Guanine nucleotide-binding protein-like 3 
NOP58_HUMAN Nucleolar protein 58  
SRPRA_HUMAN Signal recognition particle receptor subunit alpha 
CCD47_HUMAN Coiled-coil domain-containing protein 47 
LS14B_HUMAN Protein LSM14 homolog B  
DHX36_HUMAN ATP-dependent RNA helicase DHX36 
SPTC1_HUMAN Serine palmitoyltransferase 1  
RPN2_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2  
MCTS1_HUMAN Malignant T-cell-amplified sequence 1 
MA7D2_HUMAN MAP7 domain-containing protein 2 
STX5_HUMAN Syntaxin-5 
VATA_HUMAN V-type proton ATPase catalytic subunit A 
FR1OP_HUMAN FGFR1 oncogene partner 
 
Table 4.8. List of protein identified in all HA samples. Classified into kinases, ubiquitin related 
enzymes, and membrane related proteins. 
Accession Protein Name 
GALK1_HUMAN Galactokinase  
PFKAL_HUMAN ATP-dependent 6-phosphofructokinase, liver type  
AURKB_HUMAN Aurora kinase B  
DCAKD_HUMAN Dephospho-CoA kinase domain-containing protein 
AMFR_HUMAN E3 ubiquitin-protein ligase AMFR  
TRI18_HUMAN E3 ubiquitin-protein ligase Midline-1  
TIM50_HUMAN Mitochondrial import inner membrane translocase subunit TIM50  
TMM33_HUMAN Transmembrane protein 33 
CLPT1_HUMAN Cleft lip and palate transmembrane protein 1 
EMC2_HUMAN ER membrane protein complex subunit 2 
SCAM3_HUMAN Secretory carrier-associated membrane protein 3 
TMX1_HUMAN Thioredoxin-related transmembrane protein 1 
TMED9_HUMAN Transmembrane emp24 domain-containing protein 9 
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LMAN2_HUMAN Vesicular integral-membrane protein VIP36 
GP180_HUMAN Integral membrane protein GPR180 
TMUB1_HUMAN Transmembrane and ubiquitin-like domain-containing protein 1 
APMAP_HUMAN Adipocyte plasma membrane-associated protein 
TM237_HUMAN Transmembrane protein 237 
SCAM2_HUMAN Secretory carrier-associated membrane protein 2 
BCAR1_HUMAN Breast cancer anti-estrogen resistance protein 1 
 
In comparison to photo-crosslinking via Uaa AzF, the crosslinking via formaldehyde yielded 
more peptide fragments, leading to more proteins being identified. However, crosslinking by 
formaldehyde depends on multiple aspects, such as the reaction condition (pH, temperature), 
accessibility of reactive group (N-terminal amino group, lysine side chains) due to the tertiary 
structure of native proteins, the concentration and incubation time of formaldehyde (Hoffman 
et al., 2015). Thus, it is difficult to fully control the efficiency and accuracy of crosslinking, 
which would introduce noises. In RIME protocol, washing with different lysis buffer and RIPA 
buffer multiple times introduced many contaminants into MS samples, as these buffers contain 
detergents. Even with C18 ZipTip clean-up, there were residues of detergent that may affect 
the ionisation process, thus affecting the detection of accurate m/z and retention time. As a 
result, we attempted to perform in-gel enzymatic digestion to explore the interactors of LAT3. 
4.3.3 Using in-gel digestion-mass spectrometry to explore LAT3 interactors 
Since we have been able to observe the upshifted band in western blots (Figure 4.10) when 
transfected with S267amb-HA, we are interested in exploring what composes the potential 
complex by performing in-gel enzymatic digestion followed by MS analysis. Briefly, HEK293 
cells were transfected with S267amber-HA in the presence or absence of AzF or UV, thus 
providing four different conditions as: (1) -AzF -UV, (2) +AzF -UV, (3) -AzF +UV, and (4) 
+AzF +UV. For condition (1) and (2), 5 g of protein was used for SDS-PAGE, while 3 g of 
protein was used for condition (3) and (4). After being resolved by SDS-PAGE, and the gel 
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was stained with Coomassie Blue overnight. After de-staining and rinsing the gel, the bands 
became visible and were subsequently excised into 1 mm3 cube for further process (section 
4.2.2.2). Three bands in each condition were excised for enzymatic digestion as indicated by 
the black rectangles (Figure 4.16). The top rectangle was between 75 kDa and 100 kDa, referred 
as 100 kDa sample; the middle rectangle was between 50 kDa and 75 kDa, referred as 60 kDa 
sample; the bottom rectangle was at 50 kDa, referred as 50 kDa sample (Figure 4.16, in red). 
Since the proteins in each sample have been separated by bis-Tris gel, protein complexes within 
each band were semi-purified thus containing less irrelevant proteins and detergents used for 
in-solution digestion and concentrating the target proteins.  
 
Figure 4.16. SDS-PAGE gel stained with Coomassie blue with marked bands for excision 
followed by in-gel enzymatic digestion. HEK293 cells were transfected with S267amb-HA in 
the presence or absence of AzF, and treated with or without UV excitation for photo-
crosslinking before lyse 48 h post-transfection, thus generating four different conditions: (1) -
AzF -UV, (2) +AzF -UV, (3) -AzF +UV, and (4) +AzF +UV. All lysates were 
immunoprecipitated with anti-HA tag antibody and resolved by SDS-PAGE. Protein bands in 
the black rectangles were excised in each condition, where the top rectangle is referred as 100 
kDa sample, the middle rectangle is 60 kDa sample, and lower rectangle is 50 kDa sample, for 
subsequent in-gel digestion. 
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From the first attempt, MS results showed good coverage of LAT3 sequence in all conditions 
(Table 4.9). In Condition 1 (-AzF -UV), three samples contained LAT3 peptides and had 8% 
to 14% of coverage of LAT3 sequence. In Condition 2 (+AzF -UV), LAT3 coverage were from 
9% to 15%. Condition 3 (-AzF +UV) and Condition 4 (+AzF +UV) showed low coverage at 
1%. The low coverage of LAT3 is likely due to less amount of total protein loaded for SDS-
PAGE. The expression of LAT3 in the absence of AzF may be due to read-through of tyrosine, 
leading to the protein expression. We also identified peptides that belong to Akt1 from MS 
(Table 4.9), and the coverage of Akt1 was 4%-10% (Condition 2), 4% (Condition 3), and 5% 
to 15% (Condition 4). The detection of Akt1 in the absence of UV (Condition 2) may be 
induced by ambient light crosslinking or non-specific immunoprecipitation. Since the 
molecular weight of Akt is 60 kDa, the detection of Akt in the 50 kDa samples may be due to 
the cleavage or post-translational modification of Akt.  
Condition 4 (+AzF +UV) is the one that we are mostly interested in, as it suffices the conditions 
for photo-crosslinking to occur. We found that both Akt1 and LAT3 were identified in 100 kDa 
band, indicating the possibility of forming a complex between Akt1 and LAT3. We observed 
the spectra of relative abundance of ions derived from LAT3 (Figure 4.17A) and Akt1 from 
Condition 4 (Figure 4.17B), and also compared 3 samples within Condition 4 (Figure 4. 17C). 
Bands at different molecular weight 50 kDa, 60 kDa, and 100 kDa had 15 proteins in common 
(Table 4.10), including Akt1, cytoskeletal proteins (keratin, actin), and other common proteins 
like IgG, and histone. The cytoskeletal proteins, IgGs and histones are usually considered as 
background noise. There were 13 unique proteins in 100 kDa, including LAT3 (Table 4.11). 
In addition, there were other proteins that were unique in Condition 4 and may be of importance 
in the context, such as EF1G (elongation factor 1-gamma) and CCPG1 (Cell cycle progression 
protein 1).  
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Table 4.9. Protein coverage of LAT3 and Akt for in-gel enzymatic digestion samples. Coverage 
of Akt1 is in red; LAT3 is in blue; - indicates no peptides detected. 
Percentage of 
Akt1 and LAT3 
coverage 
1: -AzF -UV 2: +AzF -UV 3: -AzF +UV 4: +AzF +UV 
Akt1 LAT3 Akt1 LAT3 Akt1 LAT3 Akt1 LAT3 
100 kDa - 10% - 9% - 1% 5% 1% 
60 kDa - 8% 4% - - 1% 6% - 
50 kDa - 8% 10% 15% 4% - 15% - 
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Figure 4.17. Spectra of relative abundance of ions derived from peptides in condition (4) +AzF 
+UV. A, relative abundance of ions produced from LAT3 peptide with m/z=501.74673; B, 
relative abundance of ions produced from Akt1 peptide with m/z= 647.99298; C, Venn diagram 
of protein identified from bands at 50 kDa, 60 kDa and 100 kDa. 15 proteins are in common 
including Akt1, and 13 proteins are unique in 100 kDa including LAT3.  
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Table 4.10. List of proteins identified in common among 50 kDa, 60 kDa, and 100 kDa in 
condition 4 (+AzF +UV). 
Accession Protein Name 
K2C1_HUMAN Keratin, type II cytoskeletal 1  
K1C10_HUMAN Keratin, type I cytoskeletal 10  
ACTB_HUMAN Actin, cytoplasmic 1  
ALBU_HUMAN Serum albumin  
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal  
IGHG1_HUMAN Ig gamma-1 chain C region  
SPTB2_HUMAN Spectrin beta chain, non-erythrocytic 1  
K1C9_HUMAN Keratin, type I cytoskeletal 9  
HS90A_HUMAN Heat shock protein HSP 90-alpha  
SPTN1_HUMAN Spectrin alpha chain, non-erythrocytic 1  
AKT1_HUMAN RAC-alpha serine/threonine-protein kinase  
ACTN4_HUMAN Alpha-actinin-4  
H2B1A_HUMAN Histone H2B type 1-A  
K1C14_HUMAN Keratin, type I cytoskeletal 14  
ACTBL_HUMAN Beta-actin-like protein 2  
 
Table 4.11. List of unique proteins identified in 100 kDa in condition 4 (+AzF +UV) compared 
to 50 and 60 kDa. 
Accession Protein Name 
SPA12_HUMAN Serpin A12  
EF1G_HUMAN Elongation factor 1-gamma  
VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog  
SPTN2_HUMAN Spectrin beta chain, non-erythrocytic 2  
CH60_HUMAN 60 kDa heat shock protein, mitochondrial  
H11_HUMAN Histone H1.1  
LAT3_HUMAN Large neutral amino acids transporter small subunit 3  
VIME_HUMAN Vimentin  
H4_HUMAN Histone H4  
CCPG1_HUMAN Cell cycle progression protein 1  
LRIQ1_HUMAN Leucine-rich repeat and IQ domain-containing protein 1  
GMFB_HUMAN Glia maturation factor beta  
LMO7_HUMAN LIM domain only protein 7  
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In the second and third attempts of in-gel enzymatic digestion coupled with MS, the amount of 
total protein input was less than the first time. However, there was no peptides of Akt1 being 
detected in any of the conditions, even though LAT3 peptides were identified with good 
coverage. Thus, it raised several concerns regarding the interpretation of results. First, the 
abundance of potential crosslinked complex may be too low for detection, as the antibody-
based affinity purification relies greatly on the specificity of antibody used. So the quality of 
the antibody would affect the affinity binding and the efficiency of purification, and may 
decrease the abundance of target protein and introduce non-specific binding. So it is doubtful 
whether the identification of Akt1 in the first attempt is false positive or false negative in the 
latter attempts. Second, using non-specific antibody IgG as experiment control may recognise 
irrelevant proteins and causing inaccurate representation of background binding (Dunham et 
al., 2012). Third, we have seen carry-overs from previous sample to the next sample during 
MS run, leading to contamination of sample and misrepresentation of result.  Thus, it is difficult 
to draw any solid conclusions from these data. Future work will be needed to address these 
issues and overcome the difficulties. 
4.4. Discussion 
Since we have observed that LAT3 function and expression correlates with Akt activation in 
Chapter 3, and residues S262 and S267 within TM6 and TM7 of LAT3 have been reported as 
phosphorylation sites, which may contribute to the regulation of LAT3 function, we attempted 
to explore the potential interaction between LAT3 and Akt via genetic code expansion (LAT3 
amber mutant), co-transfection, crosslinking (UV or formaldehyde), affinity purification 
(RIME and in-gel digestion), and mass spectrometric study.  
Wild type LAT3 and site-specific amber mutant constructs were successfully generated, and 
were able to be expressed after transient transfection into HEK293 cells in the presence of 
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photo-crosslinker AzF. We have observed migration of protein bands on western blot with 
LAT3-S267amb transfection in the presence of AzF and UV excitation (Figure 4.10), 
indicating the formation of a complex induced by photo-crosslinking. The migrated band was 
probed with anti-Akt antibody after HA-tag immunoprecipitation, however, the identity of 
complex needs to be confirmed with more definitive techniques like mass spectrometry.  
To purify the complex for MS, we used RIME and in-gel digestion for sample preparation. 
Both methods are based on the affinity of antibody of epitope tag (HA-tag), where RIME 
includes stringent wash with detergent containing buffer and in-gel digestion undergoes 
alkylation and reduction processes. The abundance of the protein complex is relatively low, 
and it may be lost during stringent purification process, thus reducing the probability of being 
identified from MS/MS.  
Phosphorylation is the main way by which Akt regulates its downstream targets, acting like a 
“molecular switch” for many proteins, turning the protein on or off (Manning and Cantley, 
2007). The minimal sequence motif of Akt is highly conserved as R-X-R-X-X-(S/T)-B, where 
X represents any amino acid and B represents bulky hydrophobic residue (Alessi et al., 1996). 
R residue at -3 and -5 position (3 and 5 residues from N-terminal to phosphorylation site) is 
critical in ensuring substrate specificity (Manning and Cantley, 2007). However, in vitro 
experiments have found Akt is able to phosphorylate substrates with sequence motif R-X-X-
(S/T) given enough time and substrate (Manning and Cantley, 2007). A broader AGC kinase 
family recognises and phosphorylates this R-X-X-(S/T) motif, and Akt belongs to this kinase 
family (Alessi et al., 1996, Peterson and Schreiber, 1999). LAT3 contains a sequence RGTS 
from 282 to 285, which matches this motif. Thus, it is possible that Akt could phosphorylate 
LAT3 within this motif. However, we were not able to see it and there has been no evidence 
showing S285 could be phosphorylated. The reported phosphorylation site S262 and S267 
(257-285: MGQRLSQKAPSLEDGSDAFMSPQDVRGTS) do not fit the motif, thus LAT3 
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might be the substrate of other kinases. Furthermore, LAT3 structure has not yet been solved, 
making it difficult to predict the binding/phosphorylation site without tertiary structure.  
The affinity purification with antibody of epitope tagged proteins is widely used in detection 
of protein-protein interactions. Epitope tagging is achieved by fusing DNA sequences to an 
Open Reading Frame (ORF) of a target gene to express a peptide or protein tag that allows 
high-affinity antibody recognition and binding, leading to purification of the target protein 
(Dunham et al., 2012). A main advantage of epitope tagging is that it allows different proteins 
to be tagged with the same epitope, thus to be purified in the same way, rather than relying on 
each individual antibody (with varying affinities) recognising the native protein. Therefore, the 
background contaminants would be consistent across all purification (Dunham et al., 2012). 
However, the disadvantage of epitope tagging is the expression level of the tag and the 
recombinant protein. Because overexpressed or problematically tagged proteins may induce 
protein misfolding, mislocalisation, or misregulation, resulting in both false-positives and 
false-negatives identifications and increasing background contaminants (Goel et al., 2000, 
Hofemeister et al., 2011, Rumlova et al., 2001). In this study, the overexpression of HA-tagged 
LAT3 may have undergone misfolding or mislocalisation, thus affecting the protein expression 
and localisation, as well as its interactions with potential interactor(s). 
Unnatural amino acids possess unique physical and chemical properties that can extend the 
means of studying protein structure and function (Liu and Schultz, 2010, Young and Schultz, 
2010). The Uaa AzF in this study is photo-crosslinkable with UV induction. It has been 
incorporated into N-methyl-D-aspartate receptors (NMDARs), which are major excitatory 
neurotransmitters in the brain that regulates fast synaptic transmission activated by glutamate, 
to study the interface of allosteric inhibition of N-terminal domain (NTD) of NMDAR (Tian 
and Ye, 2016). Also, AzF has been incorporated into the second extracellular loop (ECL2) of 
calcitonin receptor-like receptor (CLR) to reveal the sites of interaction between calcitonin 
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gene-related peptide (CGRP) and the receptor (Simms et al., 2018). Another example of AzF 
application is coupled with infrared spectroscopy of the azido stretching vibration. AzF 
incorporated at different position of Calmodulin (CaM) was sensitive to the chemical 
environment in CaM/CaM-binding domain complexes, thus exhibiting distinct spectral pattern 
based on different binding motifs (Creon et al., 2018). In this study, we were able to incorporate 
AzF into LAT3 amber mutants and to form protein complexes with UV induced crosslinking. 
It may be possible to apply similar methods to further investigate the interaction of LAT3 and 
its interactors. 
In summary, the investigation of LAT3 interactor and phosphorylation sites may require other 
experimental techniques, such as phosphoproteomics. The enrichment of phospho-peptides by 
TiO2 increases the abundance significantly (Humphrey et al., 2015a), thus increasing the 
chance of identification. In addition, stable isotope labelling by amino acid in cell culture 
(SILAC) may provide quantitative insight into cell signalling, post-translational modification, 
and protein-protein interactions (Ong et al., 2002, Ibarrola et al., 2003, Ibarrola et al., 2004). 
These techniques may provide accurate and quantitative insight into the identification of LAT3 
interactor/binding partner in future work. 
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Chapter 5. 14C-labelled leucine tracing reveals metabolic alteration in prostate cancer 
cells 
5.1 Introduction 
Cancer metabolism has been an old yet new topic in cancer research. The history of cancer 
metabolism studies dates back nearly 100 years (Warburg et al., 1927), however, the research 
in this area has advanced substantially in the past decade. The fundamental idea of cancer 
metabolism is based on the observation that metabolic activities are altered in cancer cells 
compared to normal cells, and these alterations enable cancer cells to survive and proliferate 
under unfavourable conditions to maintain their malignancy (DeBerardinis and Chandel, 2016). 
The underlying mechanisms, biological interactions and the consequences related to metabolic 
reprogramming in cancer models have been explored and many important findings have been 
reported. Emerging evidence has indicated that metabolic reprogramming is critical for cancer 
cells to produce energy, synthesise macromolecules, and maintain the balance of redox 
(DeBerardinis and Chandel, 2016, Cantor and Sabatini, 2012). On one hand, this 
reprogramming results from the mutation or amplification/deletion of oncogenes and/or tumour 
suppressors which activate oncogenic signalling pathways and downstream transcription 
factors (DeBerardinis and Chandel, 2016, Vander Heiden and DeBerardinis, 2017). For 
example, PI3K/Akt/mTORC1 signalling pathway, a highly conserved but frequently 
dysregulated signalling network involved in many cancer types, when activated by growth 
factor, PI3K/Akt activates transcription factors hypoxia-inducible factor-1 (HIF-1) to promote 
glycolytic flux , and stimulates sterol regulatory element-binding protein 1 (SREBP1) to 
promote fatty acid biosynthesis (Dibble and Manning, 2013). On the other hand, 
unconventional metabolic reprogramming affects many aspects of cells, including cellular 
signalling, gene expression through post-translational modifications, and epigenetics 
(DeBerardinis and Chandel, 2016). Therefore, cancer metabolism is integrated with all aspects 
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of cellular activities, and has become an important strategic target for the development of 
cancer treatments. 
In this chapter, we used a TRIzolTM phase separation method coupled with scintillation counter 
to measure the incorporation of radio-labelled leucine in prostate cancer cells in the presence 
of inhibitors. We collected 6 different phases, including CO2, polar (soluble macromolecules), 
RNA, DNA, protein, and organic (lipids), which cover all possible metabolic channels of 
leucine, thus reflecting how prostate cancer cells utilise leucine under signalling pathway 
inhibition or transporter inhibition, and examining whether prostate cancer cells are able to 
adapt to limited leucine supply and to maintain their survival and growth.  
5.1.1 Metabolic reprogramming 
Cell proliferation is the foundation to embryogenesis, cell growth, tissue function and 
tumourigenesis in mammalian cells (DeBerardinis et al., 2008). It requires large amounts of 
nutrients to fulfil its demand in bioenergy and biosynthesis, and it is closely associated with 
cell metabolism (Pavlova and Thompson, 2016). Metabolism is one of the most critical cellular 
activities and it is associated with virtually every other cellular process (DeBerardinis and 
Thompson, 2012). It involves three major aspects: anabolism, where simple molecules are 
synthesised or polymerised into macromolecules with more complexity by consuming energy; 
catabolism, where macromolecules are degraded to small molecules while releasing energy; 
and the elimination of the surplus or toxic metabolic wastes produced by anabolic or catabolic 
processes (DeBerardinis and Thompson, 2012). Metabolic process provides large quantity of 
nutrients including carbohydrate, amino acids, fatty acids, nucleotides and generates essential 
energy for various biosynthetic activities that are involved in cell proliferation and mass 
accumulation (DeBerardinis and Thompson, 2012, DeBerardinis and Chandel, 2016, Vander 
Heiden et al., 2009).  
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Aberrant metabolism has been identified as one of the emerging cancer hallmarks (Hanahan 
and Weinberg, 2011, Pavlova and Thompson, 2016), along with evading immune suppression, 
in addition to the well-established hallmarks: sustaining proliferative signalling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis (Pavlova and Thompson, 2016, Hanahan and 
Weinberg, 2011). Cancer cells are able to reprogram metabolic pathways to bypass the scarcity 
of nutrients and to adapt the signalling pathway to utilise limited nutrients to support tumour 
initiation and progress. This reprogramming overcomes the dependency of extrinsic stimuli 
such as growth factors, and often couples with mutations that enable signalling pathways to 
constitutively utilise the available nutrients (DeBerardinis and Chandel, 2016, Hsu and Sabatini, 
2008).  
Many cancer cells exhibit apparent signature of metabolism reprogramming. The most 
prominent reprogramming is known as the Warburg effect, where tumour slices and ascites 
cancer cells constitutively uptake glucose and metabolise it into lactate even in the presence of 
ample oxygen supply (Warburg, 1925, Warburg, 1956). This process is termed as ‘aerobic 
glycolysis’, which has been observed in many types of cancer cells and tumours (Koppenol et 
al., 2011, DeBerardinis and Chandel, 2016). The conventional pathway of glucose metabolism 
is through oxidation in mitochondria and conversion into glycolytic pyruvate to produce 36 
adenosine triphosphate (ATP) per glucose molecule (DeBerardinis et al., 2008), whereas the 
aerobic glycolysis only generates 2 ATP per glucose molecule (Feng and Levine, 2010, Vander 
Heiden et al., 2009). Therefore, highly proliferative cancer cells need to consume glucose at a 
much higher rate and generate ATP at a higher rate to compensate for the lower efficiency 
(Pfeiffer et al., 2001). This feature does not only apply to malignant cells; however, it reflects 
the status of proliferation-related metabolism alteration in proliferating cells (Vander Heiden 
and DeBerardinis, 2017). Furthermore, proliferating cells often overexpress glucose 
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transporters and enzymes for glycolytic degradation compared to the regular amount required 
for aerobic respiration (Curi et al., 1988, Barthel et al., 1999, Wieman et al., 2007). Positron 
emission tomography (PET) imaging system has been successfully used in imaging glucose 
uptake in tumours and adjacent normal tissue by using a radioactive glucose analogue, 18F-
fluorodeoxyglucose (18F-FDG), and it has been introduced in the clinical diagnosis and staging 
analysis (Almuhaideb et al., 2011).   
Glucose is the best-known metabolic nutrient source that contributes to various downstream 
biosynthetic processes. Enzymatic degradation of glucose through tricarboxylic acid (TCA) 
cycle in mitochondrial could provide various metabolic intermediates as precursors for 
biological synthesis, including ribose sugars for nucleotides; glycerol and citrate for lipids; 
nonessential amino acids for protein; and NADPH (reduced nicotinamide adenine dinucleotide 
phosphate) for fatty acid synthesis, through the oxidative pentose phosphate pathway 
(DeBerardinis et al., 2008) 
Warburg effect is a representative phenomenon in cancer metabolism, and it reflects the 
interplay between the glucose, metabolic enzymes and the microenvironment of the cells. The 
reprogramming of metabolism shapes the way of how proliferative cells utilise nutrients and 
explains why cancer cells are addicted to certain nutrients for growth. With further 
understanding of cancer metabolism, many signalling pathways and other nutrients are found 
to have distinct functions and features in regulating or participating in cellular metabolism. 
5.1.2 Signalling pathways in metabolism 
Not only the availability of nutrient is import for cancer growth, but the regulatory signalling 
pathways are also critical in transducing signals and orchestrate the metabolic process. A 
master complex mTORC1 converges external signals cascades and regulates cellular 
biosynthesis of proteins, lipids, and nucleic acids (Laplante and Sabatini, 2012, Dibble and 
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Cantley, 2015), as well as sensing the availability of intracellular nutrients, especially amino 
acids leucine, arginine, glutamine and serine (Hara et al., 1998, Beugnet et al., 2003, Wang et 
al., 2015b, Jewell et al., 2015, Fan et al., 2016). In many cancer cells, mTORC1 is constitutively 
active due to the mutation of oncogenes, or deletion of tumour suppressors within its upstream 
signalling pathways (Song et al., 2012).  
PI3K/Akt signalling pathway is the most frequently dysregulated pathway upstream of 
mTORC1 (DeBerardinis and Chandel, 2016). PI3K/Akt signalling is activated by extracellular 
growth factors and is constitutively active in many cancer cells due to PTEN loss (Thorpe et 
al., 2015, Song et al., 2012). Its activation enables cells to increase the surface expression of 
the nutrient transporters, leading to increased nutrients including glucose, amino acids and 
other nutrients (Edinger and Thompson, 2002, Roos et al., 2007). Active PI3K/Akt promotes 
the expression of glucose transporter GLUT1 mRNA, as well as the translocation of GLUT1 
protein from the endo-membranes to the cell surface (Barthel et al., 1999, Wieman et al., 2007). 
Furthermore, Akt stimulates the glycolytic process, driving the degradation of glucose into 
glucose 6-phosphate by phosphorylating hexokinase (Gottlob et al., 2001). Glucose 6-
phosphate can be converted into glycogen and then stored by muscle and liver, or catabolised 
to produce cellular energy (Smith et al., 2014).  Akt mediates the glycogen synthase kinase 3 
(GSK3) by phosphorylation, leading to the inhibition of the kinase in order to promote 
glycogen synthesis (Manning and Cantley, 2007). In addition, Akt activation enhances the rate 
of glycolysis (Elstrom et al., 2004), which is the key feature of tumour cells in glucose 
metabolism. mTORC1 signalling increases the expression of hypoxia inducible factor-1 (HIF-
1), leading to the overexpression of glycolytic enzymes that promotes glycolysis rather than 
mitochondria oxidative respiration (Zundel et al., 2000, Zhong et al., 2000, Blancher et al., 
2001). PI3K/Akt enhances glycolysis and lactate production, which reflects the nature of 
oncogenic signalling pathway. 
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5.1.3 Glutamine metabolism 
Other than glucose, glutamine is another main nutrient source served as carbon and nitrogen 
donor through various intermediates. Circulating glutamine is the most abundant amino acid 
(Mayers and Vander Heiden, 2015), accounting for over 20% of the total free amino acids in 
blood and 40% in muscle (Bergstrom et al., 1974). After entering the cells, glutamine is 
converted by glutaminase into glutamate plus an ammonium ion within mitochondria (Altman 
et al., 2016). Glutamate is then converted into α-ketoglutarate (α-KG) by glutamate 
dehydrogenase (GLUD) that releases ammonia from glutamate, or by a number of non-
ammonia-producing aminotransferases to produce other amino acids (Moreadith and 
Lehninger, 1984). Then, α-KG enters the TCA cycle to generate a series of metabolites that are 
precursors for lipids and nucleotides synthesis, and eventually produces ATP (Altman et al., 
2016). In addition to the main stream of metabolic process, glutamine can directly contribute 
to nucleotide biosynthesis and uridine diphosphate N‑acetylglucosamine (UDP‑GlcNAc) 
synthesis to support protein folding and trafficking (Wellen et al., 2010) before entering 
mitochondria; glutamate generated within mitochondria can be converted into glutathione 
(Welbourne, 1979). Glutamine derived malate generated from TCA cycle could exit and 
produce pyruvate and NADPH (DeBerardinis et al., 2007), and oxaloacetate (OAA) could be 
converted into aspartate to support nucleotide synthesis (Son et al., 2013).  
Glutamine metabolism produce large amount of ATP as cellular energy, and also contribute to 
many other aspects. Glutamine provide carbon and nitrogen for the synthesis of other amino 
acids, for example, proline can be produced from glutamine-derived nitrogen and carbon, and 
it is important in generating extracellular matrix protein collagen (Phang et al., 2015); and 
aspartate, whose biosynthesis is dependent on the glutamine flux through the TCA cycle and 
glutamate transamination, is critical in mediating purine and pyrimidine biosynthesis for cell 
division (Sullivan et al., 2015, Birsoy et al., 2015, Patel et al., 2016). The majority of amino 
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acids used for protein synthesis can be derived from the α-nitrogen of glutamine (Wise and 
Thompson, 2010, Alberghina and Gaglio, 2014). Glutamine can also donate carbon to the TCA 
cycle to fuel fatty acid synthesis through reductive carboxylation (Altman et al., 2016). 
Reductive carboxylation is a process where α-ketoglutarate derived from glutamine is reduced 
by isocitrate dehydrogenases (IDHs) in the reverse direction of TCA cycle to form citrate, 
followed by conversion to acetyl-CoA and then into lipid synthesis (Ward et al., 2010).   
5.1.4 Branched-chain amino acid (BCAA) metabolism 
There are nine essential amino acids (EAAs), including histidine, isoleucine, leucine, lysine, 
methionine, phenylalanine, threonine, tryptophan, and valine. Among them, leucine, isoleucine 
and valine are proteinogenic branched-chain amino acids (BCAAs), which account for 40% of 
free EAAs in blood serum (Hutson et al., 2005). All essential amino acids cannot be synthesised 
de novo, thus the only source is from diet. When they come into cells, BCAAs either participate 
protein biosynthesis directly as building blocks, or they are catabolised by metabolic enzymes 
(Harper et al., 1984). BCAAs are important carbon source for the replenish of tricarboxylic 
acids (TCA) cycle and energy production, and nitrogen source for nonessential amino acid and 
nucleotide biosynthesis as it provides metabolic intermediates during metabolism (Ananieva 
and Wilkinson, 2018). As shown in Figure 5.1, the catabolism of BCAA is through branched-
chain aminotransferase 1 (BCAT1) in cytosol or through BCAT2 in mitochondria, where the 
amino group of BCAA is transferred to α-ketoglutarate (α-KG) to produce a corresponding 
branched chain α-keto acid (BCKA) and to generate glutamate at the same time (Ananieva et 
al., 2016). BCKAs can be subsequently converted back to BCAAs, or oxidised by a number of 
additional enzymes to produce acetyl-CoA and succinyl-CoA which enter the TCA cycle and 
contribute to energy conversion (Selwan and Edinger, 2017, Ananieva and Wilkinson, 2018, 
Adeva-Andany et al., 2017, Sperringer et al., 2017).  
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BCAA metabolism plays an important role in cellular homeostasis in nutrient and energy 
production, but appear to have distinct driving mechanisms (Mayers and Vander Heiden, 2017, 
Dey et al., 2017, Mayers et al., 2016). The conversion of BCAAs into BCKA is accompanied 
by the formation of glutamate as a result of transamination, and glutamate can subsequently 
participate in biosynthesis of other nonessential amino acids (NEAAs) such as glutamine via 
glutamine synthetase (GLUL), and alanine, arginine, aspartate, glycine and serine via 
corresponding aminotransferases(Ananieva and Wilkinson, 2018), or can be converted to α-
KG (Cluntun et al., 2017, Altman et al., 2016). In non-small cell lung cancer (NSCLC) tumours, 
elevated expression level of BCAT1 and high rate of BCAA uptake have been observed along 
with high concentration of glutamate and glutamine (Mayers et al., 2016). In glioblastoma cells, 
knockdown of BCAT1 expression or molecular inhibition of BCAT1 resulted in decreased the 
level of glutamate (Tonjes et al., 2013). On the contrary, in chronic myeloid leukaemia (CML) 
blast crisis, overexpression of BCAT1 is associated with lower concentration of BCKAs and 
glutamate (Hattori et al., 2017), indicating that the correlation between BCAT1 and glutamate 
is diverse and is cancer type dependent.  
BCAT1 is the main isoform that has been associated with cancer growth. In healthy humans, 
BCAT1 expression is largely limited in nervous system and gonadal tissue (Sweatt et al., 2004). 
However, BCAT1 shows high levels of expression in activated T lymphocytes (Ananieva et 
al., 2016), and in activated macrophages in inflammatory diseases (Papathanassiu et al., 2017), 
as well as in many cancer cells (Dey et al., 2017, Mayers et al., 2016, Tonjes et al., 2013), thus 
it has been proposed as a prognostic marker for cancer and is a promising therapeutic target 
(Ananieva, 2015, Panosyan et al., 2017, Wang et al., 2015c, Zhang and Han, 2017, Zheng et 
al., 2016, Hattori et al., 2017, Ananieva et al., 2014, Zhou et al., 2013b).  
In glioblastoma, BCAT1 expression is associated with wild-type isocitrate dehydrogenase 1 
and 2 (IDH1 and IDH2), and the knockdown of IDH1 significantly downregulate BCAT1 
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through DNA methylation of the BCAT1 promoter and the corresponding epigenetic silencing 
of BCAT1 (Tonjes et al., 2013). In acute myeloid leukaemia (AML), where IDH1 and IDH2 
are commonly mutated, the expression of BCAT1 is upregulated and promotes tumour growth 
(Hattori et al., 2017). Interestedly, in epithelial ovarian cancer (EOC), the silencing of BCAT1 
suppresses IDH1 and IDH2 expression, indicating an inverse relationship between IDH1/2 and 
BCAT1 (Wang et al., 2015c). Since the wild-type IDH1/2 could catalyse isocitrate into α-KG 
which is required for BCAA transamination via BCAT1, it indicates that IDH1/2 and BCAT1 
are all involved in BCAA metabolism.  
Suppression of BCAT1 expression has been shown to reduce tumour growth in animal models, 
including glioblastoma and NSCLC (Mayers et al., 2016). However, mice injected with 
SKOV3 ovarian cancer cells with suppressed BCAT1 expression did not show reduction in 
tumour growth (Wang et al., 2015c). Similarly, suppression of BCAT1 in pancreatic ductal 
adenocarcinoma (PDAC) could not reduce tumour burden (Mayers et al., 2016). Therefore, the 
expression of BCAT1 and tumour growth does not correlate, rather, it is highly dependent on 
the tissue of origin (Ananieva and Wilkinson, 2018).  
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Figure 5.1. Schematic description of branched chain amino acids metabolism. When BCAAs 
are transported into cells, the amino groups of BCAAs are transferred to α-KG (transamination) 
to produce corresponding BCKAs and producing glutamate at the same time by BCAT1 in 
cytosol and BCAT2 in mitochondria. BCKAs can be converted back to BCAAs. In 
mitochondria, BCKAs can be oxidised by BCKDH to produce corresponding branched-chain 
acyl-CoA, which can be further catalysed into acetyl-CoA and succinyl-CoA (not shown). 
They can readily enter the TCA cycle and contribute to energy production. One TCA 
intermediate OAA can exit TCA cycle and be converted into aspartate to support de novo 
nucleotide synthesis. In cytosol, BCAAs regulate mTORC1 signalling which controls protein 
synthesis, and BCAAs also participate in protein synthesis directly. Glutamate derived from 
BCAAs can be converted into glutamine via GLUL, and contributes to biosynthesis of NEAAs, 
including alanine, aspartate, serine, glycine, and asparagine. mTORC1: mechanistic target of 
rapamycin complex 1; BCAT1/2: branched-chain aminotransferase 1/2; α-KG: α-ketoglutarate; 
BCKDH: branched-chain keto acid dehydrogenase; BC-acyl-CoAs, branched-chain acyl-CoAs; 
TCA: tricarboxylic acid cycle; OAA: Oxaloacetate; GLUL: glutamine synthetase; NEAA: non-
essential amino acid. Adapted from (Ananieva and Wilkinson, 2018). 
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5.1.5 Leucine metabolism 
Intracellular leucine participates in protein synthesis and provides metabolic intermediates that 
serves as nitrogen donors for subsequent de novo synthesis of glutamine and alanine (Garber 
et al., 1976, Sweatt et al., 2004). Also, leucine regulates the activity of mTORC1 signalling 
which is critical in cell growth and development as discussed before (Nicklin et al., 2009). In 
prostate cancer, leucine has been demonstrated to contribute to cell cycle, cell growth in 
prostate cancer, as deprivation of leucine by inhibition LAT3 suppressed M-phase cell cycle 
genes through regulatory transcription factors (Wang et al., 2013). As shown in Figure 5.2, the 
first stage of leucine degradation is through transamination to α-ketoglutarate (α-KG) by 
BCAT1/2 which mainly happens in skeletal muscle and liver (Sweatt et al., 2004, Ananieva et 
al., 2016). The transfer of the α-amino group of leucine to α-KG to form α-ketoisocaproate 
(KIC) and glutamate is reversible (Ananieva et al., 2016). Glutamate subsequently undergoes 
amidation to produce glutamine, or transamination to α-KG to generate alanine in diverse 
tissues (Duan et al., 2016, Wu et al., 1989). As mentioned in section 5.1.3, glutamate and 
glutamine are involved in many aspects of metabolic processes, including nucleotide 
biosynthesis, lipid biosynthesis, NEAAs conversion, and cell energy production, thus linking 
leucine with all these processes as well.   
Most of leucine is used for protein synthesis, resulting in only ~ 20% being converted into KIC 
(Duan et al., 2016). When leucine is converted into KIC by BCATs, the majority of KIC is 
released into bloodstream and further catalysed by branched-chain α-keto acid dehydrogenase 
complex (BCKDC) in the liver into isovaleryl-CoA (isovaleryl coenzyme A). BCKDC is 
comprised of multiple enzymes: a branched-chain -keto acid decarboxylase (E1), a 
dihydrolipoyl transacylase (E2), and a dihydrolipoyl dehydrogenase (E3), which mediates the 
oxidative decarboxylation of leucine (Sweatt et al., 2004). The oxidative decarboxylation 
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regulates the supply of leucine for protein synthesis and is important to control the 
accumulation of toxic metabolites or excessive leucine concentrations (Ananieva et al., 2016). 
There is another important metabolite that is derived from KIC by cytosolic KIC dioxygenase, 
β-hydroxy-β-methylbutyrate (HMB) (Zanchi et al., 2011), accounting for 5% of leucine and 
this conversion is irreversible (Duan et al., 2016). However, HMB can also be converted from 
isovaleryl-CoA, as isovaleryl-CoA is metabolised into methylcrotonyl-CoA (MC-CoA) and 
HMB-CoA by isovaleryl-CoA dehydrogenase and enoyl hydratase, respectively (Ananieva and 
Wilkinson, 2018). HMB can enhance protein synthesis (Wheatley et al., 2014) and attenuate 
protein degradation (Noh et al., 2014) in a relatively small dosage compared to leucine (Duan 
et al., 2016). HMB-CoA can be further metabolised into mevalonate for cholesterol, and 
acetoacetate and acetyl-CoA for energy production through TCA cycle (Ananieva et al., 2016). 
Thus, leucine metabolism is regulated by multiple enzymes in a multiple-step way, and its 
intracellular concentration and supply is controlled for protein synthesis and other cellular 
functions. 
Dysregulation of leucine metabolism has been associated with many diseases, as the 
accumulation of toxic metabolites and excessive leucine concentration could be harmful. For 
example, maple syrup urine disease (MSUD) is associated with increased leucine concentration 
in plasma and presence of BCKAs in urine (Burrage et al., 2014); KIC derived from leucine 
has also been found to accumulate in patients with MSUD, and it can disrupt the balance of 
energy in brain (Amaral et al., 2010); excessive concentration of leucine is toxic and could 
perturb the energy metabolism of the brain by inhibiting pyruvate dehydrogenase and α-KG 
dehydrogenase (Patel et al., 1973, Patel, 1974). Moreover, it has been found that leucine 
supplementation could enhance the tumour growth in both lean and overweight mice with 
pancreatic cancer (Liu et al., 2014a). For cancer patients with cachexia, leucine 
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supplementation enhanced tumour progression, even though the purpose was to prevent from 
cancer-induced cachexia (Ananieva et al., 2016).  
Since leucine is involved in several aspects of cell metabolism and is associated with many 
diseases, we are interested in investigating leucine metabolism in prostate cancer. In addition, 
the PI3K/Akt signalling pathway is highly involved with metabolic reprogramming in cancer, 
and our previous results have demonstrated the regulatory effect of PI3K/Akt over leucine 
uptake. Therefore, we set out to examine leucine metabolism in the context of PI3K/Akt, and 
to investigate the effect of inhibition of either signalling pathway or leucine transporters.  
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Figure 5.2. Schematic description of leucine metabolism. Leucine is firstly converted into KIC 
by BCATs through transamination reaction, producing α-KG and glutamate. Approximate 90% 
KIC is catalysed by BCKDC into isovalery-CoA in mitochondria, and only 5% KIC is oxidised 
into HMB by KIC dioxygenase (KICD) in cytosol. HMB is further catalysed to mevalonate for 
cholesterol, and acetyl-CoA and acetoacetate for energy production through TCA cycle. 
Isovalery-CoA is converted to MC-CoA by isovaleryl-CoA dehydrogenase, and MC-CoA is 
further converted into HMB by enoyl hydratase. MC-CoA can be converted to acetyl-CoA and 
acetoacetate for energy production. Intermediates of TCA cycle contribute to multiple 
biosynthesis. Malate can be converted into pyruvate and produce lactate and NADPH; Citrate 
is used for lipid synthesis; OAA is converted into aspartate and is used for nucleotide synthesis. 
Leucine regulates mTORC1 signalling, leading to activation of S6K and inhibition of 4E-BP1, 
and converged to protein synthesis. BCAT1/2: branched chain aminotransferase 1/2; α-KG: α-
ketoglutarate; KIC: α-ketoisocaproate; BCKDC: α-keto acid dehydrogenase complex; HMB: 
β-hydroxy-β-methylbutyrate; MC-CoA: methylcrotonyl-CoA; TCA: tricarboxylic acid; 
NADPH: reduced nicotinamide adenine dinucleotide phosphate; OAA: Oxaloacetate; 
mTORC1: mechanistic target of rapamycin complex 1; S6K: p70 ribosomal S6 kinase; 4E-
BP1: eukaryotic initiation factor 4E (eIF4E)-binding protein 1. Adapted from (Ananieva et al., 
2016, Duan et al., 2016) 
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5.2 Method 
5.2.1 U-14C6-leucine labelling 
Prostate cancer cells, LNCaP or PC-3, were seeded in duplicates at the density of 7×105 per 
well in 6-well plate and allow to adhere overnight at 37℃. Warm up 10 mL leucine free RPMI 
media (containing 10% dialysed FBS) in water bath, and prepare 5 g/L L-leucine solution (50 
mg L-leucine powder in 10 mL of TC grade H2O), and dilute 10 mM MK2206 stock into 100 
µM. Add 100 µL L-leucine (5 g/L stock) and 50 µL of U-14C6-leucine (uniformly labelled, 100 
µCi/mL stock) into 10 mL of leucine free media, mix well by inverting the tube. The 14C-
leucine is uniformly labelled. Then aliquot this media into three tubes representing three 
different conditions: Control, MK2206, BCH with 3 mL each. Remove 300 µL of the media 
and add 300 µL PBS, 300 µL 100 µM MK2206 (final concentration = 10 µM), and 300 µL 
100 mM BCH (final concentration = 10 mM) respectively. Remove the media in 6-well plate 
and add 1 mL of conditioned media in duplicate and incubate at 37℃ for 6 h or 24 h. Keep 100 
µL of each conditioned media for specific activity analysis.  
5.2.2 Cell fractionation with TRIzolTM reagent 
At the end of the incubation, collect the media from each condition into tubes and wash the 
monolayer of cells with PBS once with care. Lyse the cells in 1 mL of TRIzolTM reagent 
(Thermo Fisher Scientific, 15596018) per well in fume cupboard, and collect lysates into 
labelled tubes and freeze down at -80℃ to fully lyse the cells.  
CO2, RNA, DNA, protein, polar and organic phases are extracted from cell lysate (Figure 5.3) 
and the incorporation of 14C labelled leucine is measured by liquid scintillation counting. Media 
collected from each condition were used to measure the 14C incorporation of CO2 phase. 
Prepare glass jar and place a tube in it without lid. Add perchloric acid with equal volume as 
collected media into the glass jar but outside the tube. Add 500 µL 1Nsodium hydroxide inside 
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the tube, and then transfer the media into the jar to mix with acid, and seal the glass jar 
immediately. Shake at RT for at least one hour before collecting the sodium hydroxide into 
scintillation vial and mix with 3 mL scintillation liquid. The samples can be stored at RT for a 
few days until analysis with other phase extracts. 
The next day, thaw cell lysates on ice and add 200 µL chloroform (Sigma, C2432) into each 
tube (guanidium thiocyanate-phenol-chloroform extraction). Then incubate at RT for 15 min 
before centrifuge at 12,000 ×g at 4℃ for 20 min. Label fresh tubes for RNA phase. Transfer 
the top transparent aqueous phase into labelled tubes (do not touch the middle phase), and add 
800 µL isopropanol to precipitate the RNA. Store the RNA tubes at -30℃ overnight.  
Add 300 µL 100% ethanol (Sigma, E7023) and 2 µL glycogen (molecular biology grade, Astral 
Scientific, BIOGB0301) into interphase and organic phase to precipitate DNA. Mix by 
inverting the tube and incubate at RT for 3 min. Store the tubes at -30℃ overnight. 
The next day, thaw RNA and DNA tubes on ice and centrifuge at max speed at 4℃ for 20 min 
to pellet nucleic acid. Collect the supernatant of RNA to a new tube and label as polar phase, 
and store at -30℃ till analysis. Wash the RNA pellets briefly with 1 mL 75% ethanol once. 
RNA pellets turned from transparent to white in the presence of ethanol. Centrifuge at 7,500 
×g for 5 min and remove ethanol carefully, then air dry the RNA pellet. Resuspend the pellet 
well with 100 µL sterile nuclease free water, and use Nanodrop to measure RNA concentration. 
Collect the supernatant of DNA to a new 15 mL falcon tube and label as Organic phase, and 
store at -30℃ till analysis. Wash DNA pellets with 1 mL 75% ethanol twice, and incubate 10 
min at RT with gentle mix. Remove ethanol carefully and air dry the pellet. Resuspend DNA 
pellet with 100 µL sterile nuclease free water, and heat up at 65℃ to better dissolve DNA. 
Then treat the DNA with 0.5 µL of 10 mg/mL RNAse at 37℃ for 30 min to reduce RNA 
contamination. Use Nanodrop to measure DNA concentration. Store all samples at -30℃.  
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The next day, thaw the tubes labelled Organic and add 3 volume of acetone (approximately 
2700 µL). Mix by inverting the tubes for 15 sec to homogenise the solution, and incubate at 
RT for 20 min. Centrifuge at 12,000 ×g at 4℃ for 10 min to pellet protein, and transfer the 
supernatant to new tubes labelled as Organic and store at -30℃. Protein pellets were washed 3 
times by vigorously dispersing in 4 mL of protein wash buffer (95% ethanol, 2.5% glycerol 
and 0.3M guanidine hydrochloride), and incubate at RT for at least 30 min. Centrifuge at 3,200 
×g at 4℃ for 20 min and remove the supernatant. Protein pellets were stored in protein wash 
buffer at 4℃ overnight.  
The next day, remove the buffer from protein pellets and wash the pellet in 97.5% ethanol with 
2.5% glycerol. Centrifuge at 3,200 ×g at 4℃ for 20 min and remove supernatant. Air dry the 
pellet briefly before add 100 µL cell lysis buffer to solubilise the protein pellet at RT for 20 
min with intermittent mixing. Heat the samples at 98℃ for 3 min to enhance solubility and 
centrifuge at 3,200 ×g at 4℃ for 20 min. Transfer the supernatant into new tubes labelled as 
Protein phase and store at -30℃ till analysis. 
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Figure 5.3. Schematic workflow of cellular fractionation with TRIzolTM reagent, adapted from 
(Hosios et al., 2016). Media for cell culture is collected for CO2 phase separation. After lysing 
the cells with TRIzolTM reagent, guanidium thiocyanate-phenol-chloroform extraction is 
performed by adding chloroform. The aqueous phase is further separated by adding isopropanol, 
where the soluble phase is termed polar phase that mainly contains small metabolites, and the 
insoluble phase is RNA. The organic phase is further separated by adding ethanol, where the 
insoluble phase is DNA. The soluble phase can be further separated again by adding acetone, 
where the soluble phase is organic phase that mainly contains lipids and the insoluble phase is 
protein.  
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For analysis, add 100 µL of each sample from each phase extraction into the scintillation vial 
and add 3 mL Ultima GoldTM scintillation fluid (PerkinElmer) into each vial. 14C activity was 
measured by liquid scintillation counter in a Tri Carb® Liquid Scintillation Analyser 
(PerkinElmer). Use Flag 2 or 4 for 14C measurement. The “organic” fraction was divided into 
two 1.4 mL aliquots and each was transferred into separate scintillation vials to ensure that the 
scintillation reaction was not quenched by the residual phenol present in this fraction. 
Each tube was then counted for 5 min and the average counts per minute (CPM) from each 
tube was used for subsequent analysis. To calculate the specific activity of the 14C-leucine, 100 
uL of unused labelled medium from each experiment was transferred into duplicate scintillation 
vials and scintillation was measured as described above. The CPM values for these duplicate 
vials were averaged and used to extrapolate the specific activity of the 14C-leucine in decays 
per minute per picomole (dpm/pmol). This specific activity value was then used to calculate 
the 14C activity of each phase in equivalent pmol of 14C-leucine. All samples from the same 
experiment were counted and analysed at the same time to minimise any variability in counting 
efficiency. 
5.3 Results 
From previous results, we have demonstrated that prostate cancer cell lines LNCaP and PC-3 
have different sensitivity to growth factor mediated PI3K/Akt signalling pathway, and distinct 
patterns in leucine uptake due to the expression level of LAT1 and LAT3 in the context of 
PI3K/Akt signalling pathway. In this chapter, we applied Akt inhibitor MK2206, and LATs 
inhibitor BCH, for 6 h or 24 h, and measured the incorporation of radio-labelled carbon into 
different phases of cells to explore the metabolism of leucine under such conditions.  
We successfully extracted 6 phases of cells, including CO2, DNA, RNA, protein, polar and 
organic phases and measured the radioactivity of each phase, and compared between different 
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time frames as well as different cell lines. CO2 phase is to measure how much radio-labelled 
leucine has entered the TCA cycle for energy production. DNA and RNA phases indicate the 
contribution to nucleotide synthesis from radio-labelled leucine. Protein would be the major 
destination of leucine, as leucine is one of the most abundant amino acids for protein synthesis. 
Polar phase contains soluble macromolecules, and organic phase contains non-polar materials, 
like lipids (Hosios et al., 2016).  
5.3.1 24 h U-14C6-leucine tracing 
The total uptake of 14C-labelled leucine is indicated by the sum of radioactivity (in pmols) from 
each individual phase (Figure 5.4A and 5.5A). We calculated the percentage of the 
radioactivity of each phase, and stacked them together to compare the changes between 
different condition (Figure 5.4B and 5.5B).  In LNCaP cells, the total leucine uptake was 
decreased significantly with MK2206 treatment, whereas PC-3 showed more reduction with 
BCH inhibition (Figure 5.4A and 5.5A). The percentage of protein phase in LNCaP cells under 
different condition were similar to one another, however the percentage of protein phase in PC-
3 cells showed distinct difference between MK2206 and BCH treatment (Figure 5.4B and 5.5B). 
The radioactivity was low in CO2 and nucleic acid (RNA and DNA) phases, and accounted for 
small portion of the total 14C incorporation (Figure 5.4C and 5.5C). Thus, the signal-to-noise 
ratio would be low and may cause fluctuation and generate big error bar. The organic phase 
was the largest portion among all (Figure 5.4C and 5.5C). 
In LNCaP cells, after 24 h treatment with MK2206, the total uptake of 14C-leucine was reduced 
significantly to 33% of Control, whereas BCH treatment inhibited 14C-leucine uptake to 87% 
of Control (Figure 5.4A). This significant decrease in leucine uptake by MK2206 would be 
because of the suppression of the Akt signalling pathway which regulates dominant leucine 
transporter LAT3 in LNCaP cells, leading to the decrease of total leucine uptake. More 
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importantly, 24 h treatment with MK2206 would effectively inhibit the enzymatic activity of 
Akt towards various substrates in regulating multiple aspects of cellular metabolic processes, 
including glucose protein synthesis, glycogen synthesis, lipogenesis, nucleotide biosynthesis 
(Whiteman et al., 2002, Hers et al., 2011), resulting in reduced requirement of leucine as the 
source of carbon and nitrogen. In comparison, BCH exhibited less inhibitory effect in leucine 
uptake (Figure 5.4A) and this may be due to BCH being a competitive inhibitor. BCH is a 
leucine analogue that competes with leucine in occupying transporters, so that its competitive 
inhibitory effect is reversible. After 24 h incubation, cells would reach an equilibrium status, 
thus diminishing the inhibitory effect of BCH. However, the percentage of each phase didn’t 
change much between conditions, other than CO2 phase accounted for 7.3% in MK2206 
compared to 2.3% in Control and 2.6% in BCH; and DNA phase accounted for 2.5% in BCH 
compared to 0.5% in Control and 1.0% in MK2206 (Figure 5.4B). It indicated that LNCaP 
utilises leucine in the same fashion regardless of the total amount of intracellular leucine. 
In terms of the amount (pmol) of 14C incorporation in each phase, there were no significant 
changes in CO2, nucleic acid and polar phases, and it became significant in the incorporation 
of protein fraction and organic fraction (Figure 5.4C). The inhibitors barely affected the 14C 
incorporation of CO2 phase, indicating that the amount of intermediates derived from leucine 
that enter TCA cycle were fairly constant despite the inhibition. BCH could suppress cell cycle  
and render cells arrested at G0-G1 phase (Wang et al., 2014b), however, MK2206 inhibited 
Akt and downstream nucleotide biosynthesis. Thus 14C-leucine showed a significant increase 
in RNA and DNA incorporation (Figure 5.4 D) in BCH-treated LNCaP cells compared to 
MK2206 treatment. This  suggested that more leucine was metabolised to support nucleic acid 
synthesis with inhibition of the transporter. However, the absolute amount of RNA and DNA 
are very small (Figure 5.4C), therefore the fluctuation might be exaggerated by systematic 
noise. Protein phases were the second biggest fraction in all three conditions, suggesting that 
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the major destination of leucine was protein synthesis regardless of the available level of 
intracellular leucine. Most phases showed a similar decrease with each treatment, indicating 
that LNCaP cells metabolised leucine in similar fashion in 24 h time frame. 
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Figure 5.4. 14C-leucine incorporation after 24 h treatment with MK2206 and BCH in LNCaP 
cells. A, each colour represents one fraction and the height of each bar represents the amount 
of 14C incorporation in that phase measured in pmols. The sum of each bar in each condition 
represents the total amount of 14C-leucine incorporation. It shows apparent decrease of total 
14C-leucine incorporation in MK2206-treated cells; B, the height of each bar represents the 
percentage of a phase. C, pmol of each phase in each condition; D, percentage of each phase 
normalised to Control. It indicates the change of each phase in the presence of inhibitors. Data 
are shown as mean ± SEM, n=4. Two-way ANOVA was performed. Comparisons that are not 
significant are not labelled, and only significant differences are labelled with asterisk (*). 
*p<0.05, **p<0.01, ****p<0.0001 
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In PC-3 cells, 24 h treatment with MK2206 reduced total leucine uptake to 86% of Control, 
and BCH reduced it to 68% (Figure 5.5A). As discussed in previous chapter, the leucine uptake 
in PC-3 cells was mediated by LAT1, and LAT3 only contributed to a small percentage (Figure 
3.1A and B). Additionally, LAT1 expression was not regulated by PI3K/Akt signalling 
pathway, resulting in less inhibition of leucine uptake by MK2206 but more inhibition by BCH. 
However, due to the nature of BCH being a competitive inhibitor, leucine uptake would reach 
equilibrium status after 24 h treatment. Thus it showed less potent inhibitory effect compared 
to short-term (30 min) treatment in Figure 3.1. The percentage of each fraction remains largely 
the same among three samples, other than the protein fraction in BCH treatment. It accounted 
for 39% of total 14C incorporation, whereas protein phase accounted for 25% in Control, and 
21% in MK2206. In spite of intracellular leucine was reduced by BCH treatment, the amount 
of protein phase was more than that in Control and in MK2206 (Figure 5.5 C and D). It 
indicated that PC-3 cells prioritised protein synthesis over other macromolecules when leucine 
availability was limited.  
In comparison of LNCaP and PC-3 cells treated with inhibitors for 24 h, the inhibition of Akt 
signalling pathway and inhibition of leucine transporter showed distinct patterns of leucine 
uptake as well as incorporation into all fractions. The dominance of transporters is different in 
these two cells lines, resulting in the different responses to the inhibition of Akt signalling 
pathway by MK2206. There were no significant changes in the percentage of each fraction in 
LNCaP cells when treated with either inhibitors, whereas the protein phase increased in PC-3 
cells when treated with BCH. The polar phase was reduced in the same manner as the total 
leucine incorporation, suggesting the incorporation of leucine into soluble molecules was not 
affected much by inhibitors. The extent of reduction of 14C incorporation of organic fractions 
in BCH-treated LNCaP and PC-3 cells was similar to the total uptake. However, MK2206-
treated PC-3 cells showed no decrease of incorporation in organic phase, which was 
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contradictory to the inhibitory effect of Akt by MK2206. It may imply the occurrence of certain 
metabolic reprogramming events that needs further investigation. 
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Figure 5.5. 14C-leucine incorporation after 24 h treatment with MK2206 and BCH in PC-3 cells. 
A, each colour represents one fraction and the height of each bar represents the amount of 14C 
incorporation in that phase measured in pmols. The sum of each bar in each condition 
represents the total amount of 14C-leucine incorporation. It shows apparent decrease of total 
14C-leucine incorporation in MK2206- and BCH-treated cells; B, the height of each bar 
represents the percentage of a phase. C, pmol of each phase in each condition; D, percentage 
of each phase normalised to Control. It indicates the change of each phase in the presence of 
inhibitors. Data are shown as mean ± SEM, n=3. Two-way ANOVA was performed. 
Comparisons that are not significant are not labelled, and only significant differences are 
labelled with asterisk (*). *p<0.05. 
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5.3.2 6 h U-14C6-leucine tracing 
The 24 h treatment of inhibitors would affect not only the leucine uptake via transporter but 
also affect various effectors downstream of Akt signalling. Akt is a master controller of various 
aspects of cell metabolism, including the synthesis of protein, lipid, glycogen, and nucleic acids. 
The cells would have adapted to the reduced level of intracellular leucine and adjusted the use 
of leucine in 24 h. In comparison, 6 h pulse treatment triggered acute response of cells to the 
inhibitors. It would affect the signalling pathway, but may not be able to further affect the 
downstream reactions such as protein expression or other metabolic events. 
In LNCaP cells, after 6 h treatment with inhibitors, the uptake of 14C-leucine was reduced 
significantly to 58% of the Control by MK2206, and 64% of the Control by BCH (Figure 5.6A). 
The percentage of each phase in LNCaP cells under three conditions were similar, with minor 
changes in CO2 and polar phase in MK2206 treatment and RNA phase in BCH treatment 
(Figure 5.6B). The inhibition of both Akt signalling and transporter exhibited similar effects in 
total leucine uptake, but differently on fractions (Figure 5.6C and D). MK2206 inhibition 
reduced 14C incorporation in all fractions other than CO2, which was similar to 24 h treatment, 
indicating the portion of leucine that entered TCA cycle remained fairly constant. Furthermore, 
BCH treatment reduced 14C incorporation in most fractions proportionally as the total leucine 
uptake except CO2 and protein phase (Figure 5.6C and D). Incorporation of 
14C into protein 
phase remained very close to the level of Control, suggesting that protein synthesis was not 
affected in BCH-treated LNCaP cells. In Figure 5.6C, only the amount of 14C incorporation in 
the organic phase showed significant decrease with inhibitor treatment, indicating the 
conversion from leucine to lipid was decreased. The percentage of RNA showed a significant 
decrease in MK2206 treatment and DNA also decreased (Figure 5.6D), suggesting the 
conversion of leucine into glutamine and subsequent nucleic acid biosynthesis were blocked. 
In comparison to 24 h treatment of BCH, the 14C-leucine incorporation of nucleic acids 
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accounted for very small amount and did not show any increase. This may be because of 
relatively short treatment of BCH, where the cells haven’t reached an equilibrium status as 24 
h treatment, and less leucine was available for metabolic conversion to glutamine and 
subsequent conversion to nucleic acid.  
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Figure 5.6. 14C-leucine incorporation after 6 h treatment with MK2206 and BCH in LNCaP 
cells. A, each colour represents one fraction and the height of each bar represents the amount 
of 14C incorporation in that phase measured in pmols. The sum of each bar in each condition 
represents the total amount of 14C-leucine incorporation. It shows apparent decrease of total 
14C-leucine incorporation in MK2206- and BCH- treated cells; B, the height of each bar 
represents the percentage of a phase. C, pmol of each phase in each condition; D, percentage 
of each phase normalised to Control. It indicates the change of each phase in the presence of 
inhibitors. Data are shown as mean ± SEM, n=3. Two-way ANOVA was performed. 
Comparisons that are not significant are not labelled, and only significant differences are 
labelled with asterisk (*). ***p<0.001, ****p<0.0001 
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In PC-3 cells, the total 14C-leucine incorporation was reduced to 85% by MK2206, and further 
to 55% by BCH (Figure 5.7A). The percentage of 14C incorporation of protein fraction was 
reduced slightly from 18% in Control to 15% with MK2206 treatment, and it was increased to 
26% with BCH treatment (Figure 5.7B). The percentage of CO2 fraction increased slightly with 
both inhibitors (Figure 5.7B). Even though the absolute amount of polar phase was reduced 
compared to Control, the percentage increased slightly with MK2206 treatment (Figure 5.7B 
and C). Organic phase showed a significant decrease in the amount of 14C incorporation with 
inhibitor treatment (Figure 5.7C). In comparison to 24 h treatment of BCH, the increase of 
percentage of protein fraction was not significant in 6 h, but was consistent with 24 h, as PC-3 
cells exhibited the ability of proritising protein synthesis over other macromolecule synthesis 
to maintain the protein production. 
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Figure 5.7. 14C-leucine incorporation after 6 h treatment with MK2206 and BCH in PC-3 cells. 
A, each colour represents one fraction and the height of each bar represents the amount of 14C 
incorporation in that phase measured in pmols. The sum of each bar in each condition 
represents the total amount of 14C-leucine incorporation. It shows apparent decrease of total 
14C-leucine incorporation in MK2206- and BCH-treated cells; B, the height of each bar 
represents the percentage of a phase. C, pmol of each phase in each condition; D, percentage 
of each phase normalised to Control. It indicates the change of each phase in the presence of 
inhibitors. Data are shown as mean ± SEM, n=3. Two-way ANOVA was performed. 
Comparisons that are not significant are not labelled, and only significant differences are 
labelled with asterisk (*). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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In addition, we conducted leucine uptake with [3H]-leucine in the presence of MK2206 and 
BCH for 6 h and 24 h to validate the uptake with 14C-leucine (Figure 5.8). The uptake patterns 
were very similar between these two radio-labelled leucines, indicating the measurement of 
14C incorporation was reliable and was capable of reflecting the changes in different fraction.  
Furthermore, we performed an MTT assay to evaluate the cell viability of both LNCaP and 
PC-3 cells in the presence of MK2206, BCH, or their combination. For LNCaP cells, cell 
growth was blocked in the presence of inhibitors (Figure 5.9A). BCH inhibited cell growth 
after 24 h treatment, and cells showed limited growth after 72 h. In the presence of MK2206, 
cells growth was decreased from 24 h onwards. In the combination of BCH and MK2206, it 
showed similar effect as MK2206 alone on cell growth, indicating inhibition of Akt signalling 
pathway was capable to suppress LNCaP cell growth.  
In comparison to LNCaP cells, PC-3 cells showed a different growth pattern in the presence of 
MK2206 and BCH. Cell growth with MK2206 treatment increased by 15% and 50%, at 48 h 
and 72 h, respectively, compared to Control at Day 0, and cell growth with BCH treatment 
shows similar extent of decreasing to control (Figure 5.9B). However, cell growth is decreased 
in the presence of the combination of MK2206 and BCH since Day 1, and reduces the cell 
growth by 25% compared to Day 0 (Figure 5.9B). It indicated that inhibition of both Akt 
signalling pathway and uptake of leucine could lead to cell death. As observed previously, 
LAT3 plays a dominant role in leucine transport in LNCaP cells and is mediated by Akt 
signalling pathway, while LAT1 is the major transporter in PC-3 cells but insensitive to 
upstream signalling pathway. Thus, it requires dual inhibition to suppress the growth of PC-3 
cells.  
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Figure 5.8. 3H-leucine uptake in the presence of MK2206 and BCH for required time for both 
LNCaP and PC-3 cells. A, MK2206 and BCH treatment for 24 h for LNCaP cells, n=3; B, 
MK2206 and BCH treatment for 24 h for PC-3 cells, n=3; C MK2206 and BCH treatment for 
6 h for LNCaP cells, n=4; D, MK2206 and BCH treatment for 6 h for PC-3 cells, n=3. One-
way ANOVA was performed. Data are shown as mean ± SEM. 
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Figure 5.9. MTT assay with Akt inhibitor MK2206, LATs inhibitor BCH, and the combination 
of MK2206 and BCH. Data acquired at 0, 24 h, 48 h and 72 h respectively. A, in LNCaP cells, 
inhibitors blocked cell growth significantly. The combination of MK2206 and BCH showed 
similar effect as MK2206 by itself. B, in PC-3 cells, MK2206 and BCH slowed down cell 
growth individually, however, the combination of MK2206 and BCH caused cell death. Two-
way ANOVA was performed. Data are shown as mean ± SEM, n=4 for LNCaP, n=3 for PC-3. 
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5.4 Discussion 
BCAAs, especially leucine metabolism, play an important role in cell metabolism as essential 
amino acids. Leucine participates in multiple metabolic pathways and derives many critical 
intermediates for various macromolecule biosynthesis (Garber et al., 1976, Sweatt et al., 2004). 
From our 14C tracing experiments, we attempted to evaluate the impact of inhibition of 
upstream regulatory signalling pathway as well as competitive inhibition of transporters on 
leucine metabolism in prostate cancer cells. MK2206 is a non ATP-competitive allosteric 
inhibitor of Akt, and is effective in inhibiting the Akt signalling pathway in vivo and in vitro 
(Yap et al., 2011, Cheng et al., 2012, Hirai et al., 2010). BCH is a Na+-independent system L 
specific substrate, used as an inhibitor of LAT family transporters (Christensen, 1990). 
The incorporation of 14C-derived from uniformly labelled leucine has demonstrated the fate of 
leucine in cell metabolism. In all phases, organic phase takes up the biggest portion in both 
LNCaP and PC-3 cells. It mainly contains lipids synthesised from leucine and may contain 
some proteins that was unable to be extracted. As mentioned previously, leucine is catabolised 
through a transamination reaction to convert into α-ketoglutarate (α-KG) by BCATs, producing 
α-ketoisocaproate (KIC) and glutamate (Ananieva et al., 2016). Glutamate and α-KG 
subsequently participate in TCA cycle and generate intermediates like citrate, which exits 
mitochondria and supports lipid synthesis (Altman et al., 2016, Ward et al., 2010). As a result, 
the carbon incorporated in lipids that are donated by leucine is through the conversion into 
glutamate and through intermediates from TCA cycle. This would represent a major aspect of 
leucine metabolism as it accounts for the largest portion. Since Akt is known to positively 
regulate lipid biosynthesis by phosphorylating and inhibiting its downstream effector glycogen 
synthase kinase 3 (GSK3), which induces the degradation of its substrate sterol regulatory 
element-binding proteins (SREBPs) that controls cholesterol and lipid metabolism (Cross et 
al., 1995, Sundqvist et al., 2005, Hers et al., 2011). Thus, inhibition of Akt by MK2206 would 
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reduce the lipid synthesis. In addition, inhibition of Akt by MK2206 affects glucose uptake by 
blocking glucose transporter GLUT4 (Kohn et al., 1996) and GLUT1 (Chen et al., 2015), 
leading to slow glycolysis and inhibition of lipid biosynthesis (Leto and Saltiel, 2012, Manning 
and Toker, 2017, Chen et al., 2015). We observed an apparent reduction in most experiments 
other than PC-3 cells with 24 h MK2206 treatment. This aberrant phenomenon may indicate 
certain metabolic reprogramming events have occurred, which warrants further investigation.  
The second biggest portion of all fractions is protein, and this is also a major destination of 
leucine. Leucine does not only participate in protein synthesis, but also regulates mTORC1 
signalling (Bar-Peled and Sabatini, 2014). The intracellular level of free amino acids is very 
important for mTORC1 activity, as mTORC1 integrates upstream signals as well as available 
nutrients to regulate translation initiation and protein synthesis (Dibble and Manning, 2013). 
We have observed that the percentage of protein phase remains largely constant with inhibitors 
in LNCaP cells, suggesting LNCaP cells are able to maintain the production of protein even 
with a limited source of leucine. PC-3 cells even increase the percentage of the protein phase 
under inhibition, indicating its dependence of protein synthesis and its adaptation when the 
supply is limited. 
The polar fraction, which includes soluble metabolites like nucleotides, amino acid and organic 
acids (Fei et al., 2014), shows a reduction in the presence of inhibitors. As discussed previously, 
leucine is converted into α-KG and glutamate, and glutamate contributes to various 
biosynthetic processes including de novo synthesis of non-essential amino acids (NEAAs), 
such as alanine, aspartate, arginine, glycine and serine, as well as nucleotide biosynthesis 
(Ananieva and Wilkinson, 2018, Ananieva et al., 2016). Thus, radiolabelled carbon can be 
detected in the polar phase. In LNCaP cells, MK2206 treatment reduces the incorporation of 
14C into polar metabolites after 6 h and shows further reduction with 24 h treatment (Figure 
5.4A and 5.6A), whereas BCH treatment does have a substantial effect. However, in PC-3 cells, 
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BCH treatment shows a larger decrease in the incorporation into polar phase than MK2206 
treatment. This indicates that LNCaP and PC-3 cells have distinct patterns in utilising limited 
leucine concentrations in de novo synthesis of NEAAs and nucleotides. The inhibition of Akt 
affects these processes in LNCaP cells more than that of PC-3 cells, whereas blocking leucine 
uptake by BCH suppresses more in PC-3 cells.  
The transamination of leucine by BCAT2 in mitochondria produces KIC, which is 
subsequently catalysed by multiple enzymes to form isovaleryl-CoA, MC-CoA, and eventually 
acetyl-CoA (Duan et al., 2016). Acetyl-CoA starts the TCA cycle by transferring its two-carbon 
acetyl groups to oxaloacetate (OAA, a four-carbon acceptor complex) to form citrate 
(containing six carbons) (Wolfe and Jahoor, 1990). Then, citrate undergoes several enzymatic 
steps, and loses two carboxyl group in the form of CO2. However, the carbon in CO2 is not 
directly from leucine-derived acetyl-CoA, rather it is from oxaloacetate. The carbons from the 
acetyl group become part of the oxaloacetate backbone after one TCA cycle, and it takes several 
turns of TCA cycle for leucine-derived carbon to be transformed into CO2 (Nelson, 2005). As 
a result, despite some fluctuations, the CO2 phase remains at similar levels with inhibitor 
treatment in both cell lines and accounts for a relatively small portion. Since the major source 
of acetyl-CoA is glucose-derived pyruvate by glycolysis (Kahn and Flier, 2000), leucine is not 
a major source of CO2, and its contribution for CO2 production is minimal and largely constant.  
The nucleic acids account for a very small proportion of the total 14C incorporation from leucine. 
It requires the transamination reaction of leucine to produce α-KG and glutamate for TCA cycle. 
The intermediate OAA is converted into aspartate, which is used for nucleotide synthesis and 
for RNA and DNA synthesis. mTORC1 has been reported to promote nucleotides synthesis for 
DNA replication and ribosome biogenesis to support cell growth and proliferation. mTORC1 
could enhance the expression level of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), 
which is critical in mitochondrial tetrahydrofolate cycle that supplies purine synthesis (Ben-
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Sahra et al., 2016). S6K1, downstream of mTORC1, could phosphorylate and activates 
carbamoyl-phosphate synthetase (CAD) for de novo pyrimidine biosynthesis (Ben-Sahra et al., 
2013, Robitaille et al., 2013). As a downstream effector of Akt, inhibition of Akt would 
inactivate mTORC1 activity, leading to the suppression of nucleotide biosynthesis. 
The inhibition of Akt signalling pathway shows apparent decrease in total leucine uptake and 
each fraction. 14C-tracing experiments provide information limited to the detection of 
radioactive signalling based on fractionation, but it couldn’t provide any further details as 
which metabolites carry the radiolabelled carbon derived from leucine and through which 
metabolic pathway the metabolites are generated. Further investigation is needed to elucidate 
this process by using 13C-and/or 15N-labelled leucine combined with targeted LC-MS/MS 
metabolomics analysis to identify and map the metabolites generated from leucine and how 
these intermediates contribute to biosynthesis of various macromolecules. In addition, the 
expression patterns of related metabolic enzymes, like BCATs and BCKDC, need to be 
examined to reveal the regulation with inhibition of upstream signalling pathway, and to 
identify the metabolic vulnerability for potential therapeutic strategy and to develop drug target 
for prostate cancer treatment.  
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Chapter 6. Discussion 
This thesis focuses on L-type amino acid transporter LAT3 in prostate cancer. As an androgen 
receptor regulated leucine transporter , LAT3 had been found to be upregulated in prostate 
cancer cells (Babu et al., 2003, Cole et al., 1998). We have demonstrated that with EGF 
stimulation, Akt phosphorylation/activation was associated with the increase of leucine uptake 
as well as LAT3 expression (Chapter 3).  The inhibition of PI3K/Akt signalling blocked leucine 
uptake as well as suppressed LAT3 expression levels. In addition, when LAT3 was knocked 
down by shRNA, EGF depletion with serum free media or further inhibition with Akt inhibitor 
wouldn’t affect the decrease of leucine uptake. These all indicated that the signalling pathway 
exerted its impact on the function and expression of LAT3 via Akt. Subsequently, we showed 
that Akt and LAT3 co-located at the plasma membrane and the surface expression of LAT3 
was significantly increased with EGF stimulation, suggesting that the translocation of LAT3 
onto plasma membrane were likely to be regulated by Akt. The ubiquitin mediated degradation 
of LAT3 by the proteasome also showed a decrease with EGF stimulation, indicating that 
activation of the signalling pathway contributed to the stabilisation of LAT3 and prevented it 
from being degraded.  
It is worth noting that LAT1 is another leucine transporter in prostate cancer cells. In the cell 
lines that we used in this thesis, PC-3 cells have higher expression level of LAT1 compared to 
LAT3, while LNCaP cells are the opposite, largely due to transcriptional regulation by the 
androgen receptor (Wang et al., 2011a). In prostate cancer cells, LAT3 is responsive to the 
activation or inhibition of this signalling pathway, while LAT1 is not responsive. Thus, in this 
context, the leucine uptake affected by activation or inhibition of the signalling pathway is 
through LAT3.  
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The mTORC1 signalling node is a master controller over multiple cellular activities. It 
integrates many signalling cascades and acts by regulating downstream substrates in mediating 
protein translation, cell growth, and cell metabolism (Laplante and Sabatini, 2009). Other than 
upstream signalling pathways, the availability of amino acids, especially leucine, can control 
mTORC1 activation via Rag GTPases (Sancak et al., 2008). Therefore, LAT3 can potentially 
affect mTORC1 signalling as the main transporter of leucine. We applied the mTORC1 
inhibitor rapamycin in our experiments, but didn’t observe any inhibitory effect on leucine 
uptake, suggesting LAT3 resides upstream of mTORC1 in signalling pathway. 
mTOR also forms another multi-protein complex mTORC2, which is also a serine/threonine 
kinase that plays a critical role in altered growth factor receptor signalling in many cancer types 
(Masui et al., 2014). mTORC2 is required for the full activation of Akt at S473 and is involved 
in several essential metabolic pathways in cancer, including glycolysis, glutaminolysis, 
lipogenesis, and nucleotide and ROS metabolism (Aramburu et al., 2014, Dang, 2012, 
Lamming and Sabatini, 2013). A recent study has reported that mTORC2 could phosphorylate 
cystine-glutamate antiporter xCT (SLC7A11) at serine 26 and inhibit its activity (Gu et al., 
2017). The co-immunoprecipitation, proteomic, and in vitro kinase assays showed that xCT 
physically interacts with mTORC2, and serine 26 was identified as a phosphorylation site. In 
the sequence of xCT, serine 26 is preceded with arginine at -3 position, thus xCT contains a 
motif of R-X-X-S/T, and mTORC2 recognised this motif and phosphorylated xCT at serine 26. 
LAT3 contains a sequence (282-285: RGTS) that matches this motif. Future studies should 
investigate this motif in a similar way to examine the involvement of mTORC2.  
Growth factors can activate multiple downstream signalling pathways via RTKs, including 
PI3K/Akt/mTORC1, ERK1/2 (extracellular signal-regulated kinase) and MAPK (mitogen-
activated protein kinase) pathways (Mendoza et al., 2011). This ERK/MAPK signalling 
pathway, including several effectors, such as Ras, Raf, MEK1/2, ERK1/2, and RSK, also plays 
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a very important role in regulating cell survival, differentiation, proliferation, metabolism, and 
motility in response to extracellular stimulations (Dhillon et al., 2007). Many studies have 
shown the crosstalk between PI3K/Akt/mTORC1 and ERK1/2-MAPK pathways, including 
cross-inhibition and cross-activation (Mendoza et al., 2011). For example, inhibition of 
MEK1/2 activates EGF-induced Akt signalling (Yu et al., 2002, Hoeflich et al., 2009). 
Similarly, Akt could phosphorylate the inhibitory sites in the N-terminal of Raf, thus inhibiting 
the activation of ERK1/2 (Zimmermann and Moelling, 1999, Dhillon et al., 2002, Guan et al., 
2000, Cheung et al., 2008). In contrast, the Ras/ERK-MAPK pathway cross-activates 
PI3K/Akt/mTORC1 signalling by positively regulating key components. Ras-GTP can bind to 
PI3K directly and allosterically activate PI3K (Kodaki et al., 1994, Rodriguez-Viciana et al., 
1994, Suire et al., 2002). ERK1/2 and RSK can phosphorylate TSC1/2 complex with EGF 
stimulation, leading to the inhibition of GTPase activating function of TSC1/2 complex, and 
subsequently activation of mTORC1 signalling (Zoncu et al., 2011b, Roux et al., 2004). 
Moreover, the key components in these two signalling pathways, such as ERK1/2, RSK, and 
Akt, often act on the same substrates when activated, to promote several cellular activities 
(Mendoza et al., 2011). In addition, RSKs and Akt belong to the broader AGC kinase family, 
and shares similar kinase activities towards their substrates (Pearce et al., 2010). As a result, 
PI3K/Akt and ERK/MAPK signalling pathways are closely connected within the signalling 
network. It is likely that with EGF stimulation the crosstalk between them affects leucine 
transport and metabolism, as well as LAT3 expression. And, it is possible that the activity of 
LAT3 is regulated co-ordinately by both signalling pathways at the same time. The underlying 
mechanism needs future work to elucidate.  
 
Mass spectrometry data has shown that serine 262 and serine 267 of LAT3 have been 
phosphorylated in several different cells (Zhou et al., 2013a, Wilson-Grady et al., 2013, 
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Phanstiel et al., 2011). Given the fact that the phosphorylation of glucose transporter Glut1 at 
S226 has been reported to have enhanced membrane localisation of transporters leading to 
increased glucose transport (Lee et al., 2015), we hypothesise that this may apply to LAT3 as 
well. Thus, we explored whether these phosphorylation sites are critical in LAT3 function, and 
investigated how LAT3 transport capability and expression are affected by PI3K/Akt signalling, 
and through which node it exerts the impact on LAT3. We successfully set up the genetic code 
expansion (GCE) method to incorporate unnatural amino acid (Uaa) AzF into LAT3 sequence 
in a site-specific manner, and utilised the photo-crosslinking property of AzF to explore the 
effector or binding partner of LAT3 with LC-MS/MS.  
Unnatural amino acid mutagenesis and incorporation into the protein of interest can effectively 
facilitate structural and dynamic studies. AzF has been used to map the ligand binding site in 
G protein-coupled receptors (Ye et al., 2010, Naganathan et al., 2013b, Naganathan et al., 
2013a, Grunbeck et al., 2011). In this study, the incorporation of AzF by amber codon 
suppression system enabled the site-specific LAT3 mutant to be expressed in live cells. UV 
light (365nm) induced the azido moiety of AzF to react with neighbouring amines or aliphatic 
hydrogens to form a cross-linking complex (Grunbeck et al., 2012, Koole et al., 2017). 
Therefore, it may potentially trap the transient protein-protein interactions that provide clues 
leading to identify the binding partners of LAT3. 
We have observed migrating Akt bands in western blot (Figure 4.8B), which indicates the 
formation of photo-crosslinked Akt-LAT3 complex. Then, we utilised different methods to 
purify this complex and digested it into peptides for mass spectrometry study. However, we 
were not able to confirm any interactors of LAT3, and there remains some concerns over the 
current experiments that need to be further optimised. In the constructs using LAT3 amber 
mutants, HA-tag is fused at C-terminal of LAT3. Therefore, anti-HA-tag antibody is used for 
purification of overexpressed LAT3. Although the short and linear recognition motif 
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(YPYDVPDYA) of HA-tag rarely affects the structure and properties of fusion protein, and it 
is generally specific to its primary antibody, the yield of purified protein by HA-tag is usually 
low; and the low pH elution may cause an irreversible effect on protein properties (Kimple et 
al., 2013). Furthermore, the LAT3 construct was transfected and overexpressed in HEK293 
cells before UV crosslinking and purification for mass spectrometry. The overexpression may 
lead to the accumulation of unfolded proteins in the cytoplasm. As several heat shock proteins 
and cytoskeletal proteins, including actin, keratin, tubulin were present in the mass 
spectrometry data with high abundance, we infer that the overexpressed LAT3 might interact 
with these proteins either for correct folding of the structure or for the translocation from the 
endoplasmic reticulum (ER) to the cytoplasm and membrane. These interactions may affect the 
regulatory interaction from signalling pathways or mask the detection of regulatory interactor(s) 
which are relatively low in abundance. 
Affinity purification, such as immunoprecipitation or co-immunoprecipitation, highly relies on 
the quality of antibody (Dunham et al., 2012). The affinity of the antibody to the protein of 
interest strongly affects the integrity of the pull-down complex. Non-specific binding would 
increase the complexity of the sample and lower the efficiency of pulling down protein of 
interest as much as it possibly can; it would introduce contaminants during sample preparation 
for the MS run, thus increasing noise, masking the peptides of interest, and reducing the 
accuracy of detection; it would also decrease the reproducibility between experimental repeats 
(Trinkle-Mulcahy et al., 2008).    
Although RIME method has been able to provide insights into protein complexes, it is highly 
dependent on high-affinity and high-specificity antibodies of the protein of interest. It is unable 
to characterise the complexes without purification with high quality antibodies. The sample for 
RIME consists of multiple protein complexes, and is analysed in a single experiment. Thus, 
the resolution of distinguishing subtle differences in complexes is compromised. For example, 
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a transcription factor may contain multiple genomic binding sites, and each of them could have 
its unique combination of regulatory proteins (Mohammed et al., 2016). Moreover, RIME is 
unable to provide details of protein-protein interaction within the complex, resulting in 
difficulties in distinguishing direct from indirect interactions. When comparing different 
samples, it is also uncertain to conclude whether the differences in complexes between two 
samples are due to the resolution of detection or actual differences in complex formation. Using 
negative IgG controls and increasing technical and biological replicates are able to reduce 
ambiguity and promote the reproducibility and reliability. But the specificity of a certain 
protein complex needs to be validated with other experiments including co-
immunoprecipitation and western blot. 
Other methods can be used to detect protein-protein interaction and post-translational 
modification (PTM), such as stable isotope labelling by amino acid in cell culture (SILAC), 
and phosphoproteomics. In SILAC, the isotope-labelled essential amino acids (such as 
deuterated-leucine, 13C-labelled lysine, 13C-labelled arginine) are provided in growth media, 
and they are subsequently synthesised into proteins by live cells (Ong et al., 2002, Blagoev et 
al., 2003, Ibarrola et al., 2003). After several times of doubling, all newly synthesised proteins 
contain isotope-labelled amino acids, and are subjected to particular treatment (stimulus or 
inhibitor) followed by protein extraction. Both labelled (heavy) and non-labelled (light) cell 
lysates are mixed with a certain ratio, and are immunoprecipitated with the antibody of protein 
of interest or epitope tag, followed by SDS-PAGE, in-gel tryptic digestion and LC/MS-MS 
analysis (Ong et al., 2002, Ibarrola et al., 2003). The resulting MS spectra display two sets of 
distributions of peptides pairs: one set being unmodified peptides that shows similar level of 
intensity, suggesting these protein expressions are not affected by treatment; other set 
representing peptides that are affected by the treatment and show differences in intensity 
(Ibarrola et al., 2003). The mass-to-charge (m/z) differences on the spectrum between light and 
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heavy peptides are determined by the mass of isotope used for labelling, and the observed 
relative ratio of intensity should be close to the ratio of protein mix. By comparing the 
intensities of labelled and non-labelled peptides mass spectra, one can confirm the status of 
PTM (Ibarrola et al., 2003) or identify protein-protein interaction (Blagoev et al., 2003). Using 
13C9-tyrosine coupled with the SILAC method, polymerase I and transcript release factor 
(PRTF) was identified as a novel substrates of insulin signalling pathway in 3T3-L1 adipocytes 
among other known substrates (Ibarrola et al., 2004). This was achieved by quantitatively 
filtering the ratio of intensities of the spectra of tyrosine-containing peptide pairs with a mass 
difference of 9 Da, and selecting the ratio over 1.5, which represented peptides derived from 
tyrosine kinase substrates that were enriched by immunoprecipitation stimulated by insulin 
(Ibarrola et al., 2004). SILAC can also be used to study the time course of phosphorylation and 
identify phosphorylation sites with double isotopic labels (Ibarrola et al., 2003).  Another study 
combined SILAC method with GFP (green fluorescent protein)-tagged fusion protein, where 
GFP tag was used for affinity purification as well as for fluorescent microscopy, to improve 
the recovery of low abundance interaction partner, to quantitatively identify specific interaction 
partners of well-characterised survival of motor neurons (SMN) complex, and to create a 
database of protein found to bind non-specifically to affinity matrices (Trinkle-Mulcahy et al., 
2008). 
Phosphoproteomics has been widely used in cancer research to study signalling pathways, and 
to identify aberrant kinase activities and its effect on downstream substrates. In combination 
with SILAC, quantitative phosphoproteomics is able to identify therapeutic targets of kinase 
inhibitors and off-target effects of kinase inhibitors (Harsha and Pandey, 2010). The 
development of high-throughput technologies has greatly expanded the number of 
phosphorylation sites being newly identified (Humphrey et al., 2015b).  Due to the low 
abundance and complex nature of the phosphoproteome, fractionation and enrichment 
194 
 
strategies are required to reduce the complexity for subsequent MS analysis. Anti-
phosphotyrosine antibodies are often used to enrich tyrosine phosphopeptides, while 
serine/threonine are often enriched with immobilised metal affinity chromatography (IMAC) 
or titanium dioxide, which allows unbiased selective enrichment of thousands of 
phosphorylation sites detectable by high resolution and high sensitivity mass spectrometers 
(Harsha and Pandey, 2010).  
Therefore, in the future work, SILAC and phosphoproteomics could be used to provide 
quantitative insight into the identification of LAT3 interactors/binders in the context of the 
PI3K/Akt signalling pathway in prostate cancer, and to validate the phosphorylation status of 
LAT3. Isotope labelled leucine, such as 13C-leucine, can be added into growth media and 
incorporated into proteins after several rounds of cell doubling. The cells can be treated with 
stimulation, such as EGF, or inhibition of PI3K/Akt signalling pathway, such as LY294002 or 
MK2206, or with the LAT family inhibitor BCH. These treatments would lead to distinct 
utilisation of leucine and differential regulation of LAT3. Samples will be further processed 
for MS study and analysed based on the MS/MS spectrum. The proteins that are altered by the 
treatments would exhibit a particular difference in mass (12 Da as per molecular weight of 
carbon with one charge), and the ratio of their intensities would reflect the extent to which the 
treatments have exerted. Identification of potential candidates can be further validated by 
biochemical methods, and can be tested for its functional correlation with LAT3. 
 
Aberrant cell metabolism has become a new hallmark of cancer (Hanahan and Weinberg, 2011). 
Cancer cells are able to adapt to unfavourable conditions and alter their metabolic behaviour 
to survive and maintain their malignancy (DeBerardinis and Chandel, 2016). Glucose and 
glutamine are the most frequently used nutrients in proliferating cells via glycolysis and 
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glutaminolysis (Wise and Thompson, 2010, Wise et al., 2008). They are the major donors of 
carbon and nitrogen that are critical for various biosynthesis. However, glucose and glutamine 
are not the sources of the majority of cell mass. Instead, amino acids other than glutamine 
contribute to the cell mass with greater proportion (Hosios et al., 2016). These non-glutamine 
amino acids include essential amino acids that could only be obtained from extracellular matrix, 
including branched-chain amino acids (BCAAs). BCAAs have been characterised as essential 
for regulation mTORC1 signalling pathway that controls cell growth; as indispensable for 
protein synthesis as building blocks; as important carbon sources for anaplerosis which is the 
replenish of TCA cycle, and for energy production; and as important nitrogen sources for 
NEAAs and nucleotide biosynthesis (Ananieva and Wilkinson, 2018). Leucine, being one of 
BCAAs, is therefore critical for cellular homeostasis in various nutrient biosynthesis and 
energy production. The conversion of leucine into glutamate and α-KG makes its metabolism 
closely related to glutamine metabolism, and is linked with NEAAs production, lipid synthesis, 
nucleotide synthesis, although this conversion accounts for a small portion. The destination of 
the majority of leucine is for protein synthesis (Duan et al., 2016), as amino acids are the main 
contributor to biomass (Hosios et al., 2016).  
From the 14C-labelled leucine tracing experiment, we have observed that LNCaP and PC-3 
cells exhibited different pattern of leucine metabolism when treated with Akt specific inhibitor 
and pan-LAT inhibitor. With 24 h treatment of Akt inhibitor MK2206, LNCaP cells showed 
more reduction in the total 14C incorporation, as well as in all fractions, whereas PC-3 cells 
showed less reduction in each fraction compared to Control. It implies that inhibition of Akt 
signalling pathway has stronger effect on LNCaP cells in leucine metabolism and incorporation 
into different cellular fractions. In contrast, BCH, as the pan-LAT inhibitor, reduced total 
incorporation more in PC-3 cells, and increased the proportion of protein fraction compared to 
Control. With 6 h treatment, inhibition of Akt and LATs showed similar reduction in total 14C 
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incorporation in LNCaP cells, whereas inhibition of LATs reduced more in PC-3 cells, with 
increased percentage of protein phase. The differences in 14C-leucine incorporation between 
these two cell lines are due to the different dominance of active transporter, and the sensitivity 
to the signalling pathway. As mentioned before, LAT3-dominant LNCaP cells are responsive 
to Akt signalling pathway, and LAT3 expression level is positively correlated with Akt 
activation. PC-3 is LAT1 dominant, but LAT1 expression does not show any changes with Akt 
activation or inhibition. Furthermore, 24 h inhibition is a long term treatment, and it allows 
enough time for cells to respond and adapt to the limited supply of intracellular leucine. During 
this time, inhibition of Akt signalling pathway could also affect the protein translation, 
expression and degradation, leading to the altered protein function (Elstrom et al., 2004, 
Bellacosa et al., 2005, Hers et al., 2011). Also, many metabolic enzymes associated with 
leucine degradation may be altered as well (Ananieva et al., 2016). For 6 h pulse treatment, 
inhibitors induced acute response of cells, reducing the total 14C-leucine incorporation. 
Although the absolute amount of 14C incorporation of protein phase was reduced in PC-3 cells 
with BCH treatment after 6 h, the percentage of protein phase increased apparently (Figure 
5.7B and C). It implies that PC-3 cells altered the leucine metabolism to meet their need for 
protein synthesis. In LNCaP cells, both inhibitors reduced total leucine incorporation but 
maintained similar level of incorporation in each phase. It indicates that Akt inhibition and 
transporter inhibition merely affect global uptake and incorporation of leucine into each 
fraction. 
The PI3K/Akt signalling pathway has been closely associated with many metabolic disorders. 
In prostate cancer, this signalling pathway is constitutively active due to PTEN loss (Thorpe et 
al., 2015, Song et al., 2012), leading to the activation of multiple substrates that regulates 
various biosynthetic processes. Moreover, other signalling pathways which have crosstalk with 
PI3K/Akt signalling pathway also contribute to metabolic regulation, such as Myc and RAS. 
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Myc is an oncogenic transcription factor that overexpresses in many cancer types (Hsieh et al., 
2015).  It is downstream of PI3K and its amplification could antagonise therapeutic inhibition 
of PI3K, thus promoting tumourigenesis (Dang, 2012). Many target genes of Myc are involved 
in glucose metabolism, as Myc upregulates glucose transporters and hexokinase, which 
mediates glucose uptake and catabolism (Osthus et al., 2000). In addition, many other genes 
related to glycolysis are upregulated by Myc, including phosphoglucose isomerase, 
phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, 
and enolase (Osthus et al., 2000). Furthermore, Myc mediates many genes that affect 
mitochondrial biogenesis and glutamine metabolism, and induces expression of genes that 
promote anabolic processes of fatty acid synthesis and serine metabolism (Stine et al., 2015). 
KRAS from the RAS family is considered as one of the most frequently mutated genes, and it 
has been found active in lung, colon and pancreatic cancer (Ryan et al., 2015, Yun et al., 2009). 
Mutated KRAS is able to drive tumour initiation, and is coordinated with PI3K and Myc 
pathways to promote cancer progression (DeBerardinis and Chandel, 2016, Mendoza et al., 
2011). 
Since LNCaP and PC-3 cells showed different pattern in utilising leucine under inhibition, 
more detailed work is needed to elucidate the detail in this process, such as using 13C/15N 
labelled leucine to quantitatively trace the isotopic incorporation into metabolic intermediates 
derived from leucine under various conditions. Also, targeted LC-MS/MS metabolomics study 
coupled with isotopic labelling will enable the identification and mapping of metabolites that 
derived from leucine. It will provide more insights in understanding the metabolic regulation 
of leucine in prostate cancer, and reveal the signalling pathways. In addition, it will be 
beneficial to examine the expression and function of the metabolic enzymes that are involved 
in leucine metabolism to identify new potential therapeutic targets.  
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In conclusion, this study has improved our understanding of leucine transporter LAT3 in 
PI3K/Akt signalling pathway in prostate cancer. LAT3 responds to extracellular stimulation 
like growth factors and mediates the homeostasis of intracellular leucine, thus contributing to 
the activation of mTORC1 signalling which regulates protein synthesis and cell growth. 
Furthermore, leucine, as an essential amino acid, is an important source of carbon and nitrogen 
for various cellular metabolic processes. Inhibition of PI3K/Akt signalling pathway and leucine 
transporter caused perturbation of leucine metabolism in prostate cancer cells. In addition, the 
genetic code expansion method for site-specific incorporation of unnatural amino acid has been 
established. It provides with extra tools to trap protein-protein interactions and can readily 
couple with mass spectrometry analysis to identify potential interactors. As a result, LAT3 
could be considered as a potential therapeutic target in prostate cancer. The combination of 
therapeutics targeting signalling pathway and LAT3 may provide benefits for prostate cancer 
patients.  
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Supplementary data 
Supplementary Figure 1 
 
Supplementary Figure 1. A, LAT1 expression after EGF treatment in PC-3 cells. GAPDH was 
used as loading control. B, leucine uptake in PC-3 cells after JPH203 treatment in the absence 
or presence of EGF for 30 min. Two tailed Student’s t-test was performed. Data are the mean 
± SEM, n=4. C, GAPDH is examined in cell surface fraction in LNCaP cells. Cell lysates of 
LNCaP cells are used as positive control. D and E, Ubiquitin and LAT3 were examined after 
immunoprecipitation with anti-LAT3 in the presence or absence of EGF in LNCaP (D) and 
PC-3 (E) cells. Ratio of IB: ubiquitin expression level is shown relative to Input: LAT3. F, 
LAT3 expression levels were examined in the absence or presence of MG132 in EGF treated 
LNCaP or PC-3 cells. GAPDH was used as loading control. Protein expression levels were 
normalised to loading control.  
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Supplementary Table 1. Virtual digestion of LAT3 by trypsin. 
Mass Position Modification  Sequence 
1969.51 348-382   VAETVGFYSSVFGAMQLLCL LTCPLIGYIMDWRIK 
1919.946 66-100   WPGCDQQDEMLNLGFTIGSF VLSATTLPLGILMDR 
1848.92 348-380   VAETVGFYSSVFGAMQLLCL LTCPLIGYIMDWR 
1782.976 507-536   GEPFWVNLGLLLFSLLGFLL PSYLFYYRAR 
1756.863 318-347   IIFYMAAVNKMLEYLVTGGQ EHETNEQQQK 
1725.945 12-41   RWWMACTAVLENLFFSAVLL GWGSLLIILK 
1718.389 298-327   SLCSPTFLWSLLTMGMTQLR IIFYMAAVNK 
1669.407 507-534   GEPFWVNLGLLLFSLLGFLL PSYLFYYR 
1647.895 13-41   WWMACTAVLENLFFSAVLLG WGSLLIILK 
1453.167 265-291 PHOS: 267 1493.1502 APSLEDGSDAFMSPQDVRGT SENLPER 
1380.711 236-260 PHOS: 237 1420.6937 LSGLALDHKVTGDLFYTHVT TMGQR 
1356.201 101-126   FGPRPVRLVGSACFTASCTL MALASR 
1354.578 42-65   NEGFYSSTCPAESSTNTTQD EQRR 
1276.528 42-64   NEGFYSSTCPAESSTNTTQD EQR 
1207.126 297-317   KSLCSPTFLWSLLTMGMTQL R 
1189.568 261-282 PHOS: 262, 
267 
1269.5346 LSQKAPSLEDGSDAFMSPQD VR 
1182.099 537-559   LQQEYAANGMGPLKVLSGSE VTA 
1181.553 328-347   MLEYLVTGGQEHETNEQQQK 
1143.078 298-317   SLCSPTFLWSLLTMGMTQLR 
1141.584 245-264 PHOS: 262 1181.5667 VTGDLFYTHVTTMGQRLSQK 
1130.092 165-186   STLMALMIGSYASSAITFPG IK 
1095.029 383-404   DCVDAPTQGTVLGDARDGVA TK 
961.4334 265-282 PHOS: 267 1001.4166 APSLEDGSDAFMSPQDVR 
951.4677 108-126   LVGSACFTASCTLMALASR 
929.97 381-398   IKDCVDAPTQGTVLGDAR 
913.4487 245-260   VTGDLFYTHVTTMGQR 
873.9514 535-550   ARLQQEYAANGMGPLK 
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809.3805 383-398   DCVDAPTQGTVLGDAR 
777.9153 283-296   GTSENLPERSVPLR 
760.3823 537-550   LQQEYAANGMGPLK 
667.8535 1-11   MAPTLQQAYRR 
600.3464 399-409   DGVATKSIRPR 
597.8639 234-244 PHOS: 237 637.847 IKLSGLALDHK 
589.803 1-10   MAPTLQQAYR 
585.323 318-327   IIFYMAAVNK 
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